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     ABSTRACT 
Non Cystic Fibrosis bronchiectasis is characterised by perpetual neutrophilic inflammation in 
the lungs.  The ongoing vicious cycle of bronchiectasis leads to further damage to already 
damaged airways and is a culmination of repeated infection, inflammation and failure of the 
host response to maintain sterility of the airway, despite a sophisticated innate and adaptive 
immune system.   
Pseudomonas aeruginosa commonly colonises the lungs of patients with bronchiectasis.  I 
hypothesised that the concept of inhibitory antibodies in the serum may be a feature of 
Pseudomonas colonisation through a specific interaction between the host adaptive immune 
system and strain specific features.   
Here I have identified a mechanism where some patients colonised with Pseudomonas
aeruginosa produce IgG2 antibodies specifically against the O antigen of bacterial LPS, 
which rather than promote complement-mediated killing actually inhibits it.   
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CHAPTER 1 INTRODUCTION 
 
1.1  Bronchiectasis 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
Non Cystic Fibrosis Bronchiectasis is defined as an abnormal and irreversible dilation with 
damage of bronchi and bronchioles due to recurrent episodes of airway infection and repeated 
cycles of inflammation (Reid 1950; O’Donnell 2000; Barker 2002).  This condition manifests 
in both adults and children with variable severity of symptoms. Classically, however, patients 
suffer from chronic production of sputum even in the stable clinical state.  This is frequently 
purulent or mucopurulent in appearance, with frequent exacerbations of the condition with 
superimposed lower respiratory tract infections, and associated dyspnoea also typical of this 
condition (Whitters and Stockley, 2012).  As a consequence there is significant morbidity and 
poorer quality of life in patients with bronchiectasis, ( ar  ne - ar  a et al., 2007), and in 
developing countries it continues to be a significant cause of childhood morbidity (Karadag et 
al., 2005). Allied to the daily symptoms experienced by patients, chronic bacterial 
colonisation with pathogenic organisms exacerbates these symptoms and provides clinicians 
with a major challenge in management of bronchiectasis.   The failure to maintain sterility of 
the airways implies a failure of host defences and there are a number of host and bacterial 
factors that contribute to bacterial colonisation and perpetuate the resulting on going 
inflammation characteristic of the lung in bronchiectasis. 
 
1.1.1  Incidence and Prevalence of Bronchiectasis 
 
Bronchiectasis increases in prevalence with age.  Data from the United States of America 
estimates that it affects 4.2 per 100,000 people aged 18 to 34 and increases to 271.8 per 
 2 
100,000 in those over the age of 75 (Weycker et al., 2005).  British data has similarly shown 
an increased prevalence with age and greater in females.  Somewhat surprisingly there has 
been an increased prevalence recorded year on year (Quint et al., 2015). This is contrary to 
the previously held belief that bronchiectasis was predominantly caused by childhood illness, 
and would become less common as a result of vaccination, antibiotic therapies and improved 
living standards.  It may be that the increasing use of high resolution computed tomography 
(HRCT) scanning is identifying more patients, and that in an aging population there are 
causes of adult onset bronchiectasis which were previously unidentified or lead to increased 
burden of symptoms as patients age, resulting in reporting/presentation to health care 
systems. Moreover, bronchiectasis is increasingly recognized as with a feature of Chronic 
Obstructive Pulmonary Disease (O’Brien et al.  2000; ar  ne - ar  a et al., 2007), which is 
diagnosed in one million people in the UK alone although thought to be an underestimation 
(National Clinical Guideline Centre 2010).  
 
1.1.2     Causes of Bronchiectasis 
 
Bronchiectasis is often classified as idiopathic as, despite detailed medical history and 
investigation, an underlying cause is not identified in up to 50% of patients (Pasteur et al., 
2000; Guan et al., 2015; Lonni et al., 2015; Dimakou et al., 2016; Gao et al., 2016).  
Identifying an underlying cause (if possible) is considered important in the management of 
bronchiectasis as it can, in some cases, alter treatment.  For example screening suitable 
patients for Cystic Fibrosis (CF) variants as recommended by British Thoracic Society 
guidelines 2010 (Pasteur, Bilton and Hill, 2010), and identifying these patients affected can 
significantly alter their treatment, with opportunities for more specialist care and therapies. 
Similarly identifying an underlying immunoglobulin deficiency may lead to effective 
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treatment with immunoglobulin replacement.   The causes and associations of bronchiectasis 
are shown in table 1.1 (King et al., 2006; Godoy et al., 2008; Rosenzweig 2008; Kilpatrick et 
al., 2009; MacFarlane et al., 2012; Whitters and Stockley, 2012; Chalmers et al., 2013; 
Araujo and Sucena, 2015; Parikh et al., 2015).  Many of these conditions are rare and the 
broad category of post infective causes are the most commonly identified and hence assumed 
to be a causative factor, and this seems to be irrespective of geography and the patient 
population studied (Pasteur et al., 2000; Guan et al., 2015; Lonni et al., 2015; Gao et al., 
2016).  
 
1.1.3    Clinical Features 
 
The characteristic feature of bronchiectasis is a chronic cough productive of sputum ranging 
from a mucoid appearance to mucopurulent/ purulent (Stockley et al., 1984). Many patients 
seen in secondary or tertiary care will describe daily symptoms whilst those with milder 
disease may only experience these symptoms during exacerbations.  The increased purulence 
of sputum is due to release of myeloperoxidase (MPO) contained within the azurophilic 
granules of airway neutrophils.  The green pigmentation of this protein infers that increasing 
sputum purulence relates to increased numbers of inflammatory cells in the sputum as a result 
of increased neutrophil recruitment reflecting host response (Stockley et al., 2001).  
Patients frequently recognise that exacerbations of their chronic disease is associated with 
increasing sputum purulence or volume - essentially with a worsening of their symptoms 
from  heir per eived “normal” baseline s a e.  The isola ion of a pa hogeni  organism is no  
necessarily diagnostic of an exacerbation as patients will often be chronically colonised with 
organisms and thus these will often be isolated on standard bacterial culture when the patient
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 Table 1.1.  C
auses and A
ssociation of N
on C
ystic Fibrosis B
ronchiectasis
Post infective causes 
Host immune defects 
Impaired mucociliary 
clearance 
Inflammatory disease 
associations 
Others 
Post viral (measles) 
 P
ertussis (‘w
hooping cough’) 
 Post tuberculosis 
 Bacterial pneumonia 
Primary Antibody Deficiency 
- 
Common variable 
immune deficiency 
(CVID) 
- 
X linked 
agammaglobulinaemia 
- 
IgG subclass deficiency 
- 
Selective IgA 
deficiency 
- 
X linked hyper IgM
 
syndrome. 
 Complement deficiency 
- 
M
annose Binding 
Lectin deficiency. 
- 
L- Ficolin deficiency 
 Inate immune defects 
- 
Chronic 
granulomatous disease 
- 
Defective oxidative 
burst 
 Acquired immune deficiency 
- 
Chronic lymphocytic 
leukaemia. 
- 
M
ultiple myeloma 
- 
Protein losing states. 
 
Primary ciliary dyskinesia 
 Kartageners syndrome 
Youngs syndrome 
 
Chronic obstructive 
pulmonary disease (COPD) 
 Rheumatoid arthritis 
 Inflammatory bowel disease. 
 - Ulcerative colitis 
 - C
rohn’s disease. 
 
Alpha-1-antitrypsin deficiency  
- 
ZZ phenotype 
associated with 
increased severity of 
bronchiectasis. 
 
M
iddle lobe syndrome 
 Foreign body inhalation 
 Gastro oesophageal reflux 
disease (GORD) 
 Yellow nail syndrome 
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 is in, what they believe to be, their stable state.  An increase in sputum purulence, indicative 
of increased neutrophil recruitment in response to worsening infection is therefore a useful 
clinical tool in identifying a clinical exacerbation.  For the purposes of this thesis, and 
recruitment of patients to this study, I have considered an exacerbation to be defined by an 
increase in purulence or volume of sputum in comparison to the pa ien s’ normal baseline 
level.  
 
The average frequency of exacerbations per year is reported to be between 2.1 and 6 (Smith 
et al.,1996; Wilson et al., 1997a; Wilson et al., 1998; Tsang et al., 1999).  It should be noted 
that a consensus is required in the definition of an exacerbation as this can vary.   Recognition 
and appropriate management of exacerbations are imperative in the treatment of 
bronchiectasis as more frequent and severe infections are associated with an accelerated ra e 
of de line in l ng f n  ion ( ar  ne - ar  a et al., 2007).  Repeated infections are thought to 
contribute to an ongoing inflammatory process in bronchiectasis and intuitively increased 
frequency of exacerbations would seem likely to be associated with poorer quality of life.   
The Bronchiectasis Severity Index (BSI) is a clinical predictive tool that identifies patients at 
risk of future mortality, hospital admissions and exacerbations.  It identifies three or more 
exacerbations as an independent risk factor for increased mortality in bronchiectasis.  
Furthermore increased severity of disease as defined by BSI and an increased number of 
exacerbations were associated with worsening quality of life as assessed by the St Georges 
Respiratory Questionnaire. (Chalmers et al., 2014) 
 
Other symptoms associated with bronchiectasis include haemoptysis that can be life 
threatening (though rarely) and most often occurs during an exacerbation.  Increased 
dyspnoea is often reported (Nicotra et al., 1995; Habesoglu, Ugurlu and Eyuboglu, 2011) 
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with impaired pulmonary function usually demonstrating mild to moderate airflow 
obstruction (King, 2011). There is some correlation between severity of dyspnoea and the 
extent of bronchiectasis measured by HRCT scanning and the degree of lung function 
impairment (Smith et al., 1996; Guan et al., 2014). Decline in lung function as measured by 
FEV1 has been demonstrated in patients with idiopathic bronchiectasis over time (King et al., 
2005). There are often additional other non specific symptoms such as chest pain and fatigue.  
  
1.1.4  Pathological Findings 
 
The basis for much of the knowledge regarding the macroscopic changes seen in the 
bronchiectatic bronchi is based on post mortem findings from the 1950s (Whitwell, 1952). 
These showed inflammatory changes of the thickened bronchial wall and dilated bronchi 
often containing pus.  Evidence of the destructive nature of bronchiectasis was demonstrated 
by the finding of loss of muscle and cartilage in cases of advanced disease with granulation 
tissue noted in areas of ulcerated epithelium indicative of healing tissue.  These findings 
identified bronchiectasis with three distinct pathological types, (cylindrical, cystic and 
varicose). These descriptions continue to provide the basis for radiological descriptions of 
bronchiectasis with features of thickened irregular bronchial walls, areas of bronchial 
dilatation, and mucus plugging often identifiable on HRCT.  Cylindrical bronchiectasis is 
 hara  erised radiologi ally by bron hi  ha  fail  o  aper normally wi h  he ‘ signe  ring’ sign 
characteristic of this.  This is most commonly seen and is often clinically associated with the 
least severe symptoms.  Varicose bronchiectasis is where the dilated bronchi can be seen to 
have areas of relative narrowing, or a beaded appearance on CT scan.  Cystic bronchiectasis 
is the most severe form with cyst like appearances of the bronchi, often extending to the 
pleural surface, relative destruction of the normal bronchial architecture, with visible air-fluid 
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levels also seen.  This can vary in severity with localisation of disease or can be diffuse 
throughout both lungs and is partially dependent on the underlying aetiology.  For example 
post tuberculous infection bronchiectasis may be confined to the previously affected area 
while bronchiectasis due to severe immunodeficiency may be more diffuse and that due to CF 
or ABPA may be more proximal.  
 
1.1.5  Pathogenesis of bronchiectasis.  
 
As described it is often difficult to attribute the development of bronchiectasis to a particular 
underlying disease or immune state.  Post infective related are the most common subgroup 
and it is believed that infective insults to the lung not only initiate the development of the 
features of bronchiectasis but that repeated infection maintains and increases it.  The vicious 
cycle hypothesis of bronchiectasis describes an initial breach in the lung host defence, usually 
due to infection, with subsequent neutrophilic inflammation, impaired mucociliary clearance 
facilitating bacterial survival and an ongoing inflammatory response with airway destruction, 
resulting chronic bacterial colonisation perpetuating the cycle (Cole and Wilson, 1989). 
There are other factors that may also impact on this cycle.  For example a genetic 
predisposition such as cystic fibrosis, or impaired innate or adaptive immune response will 
also facilitate bacterial survival and perpetuate the ongoing inflammatory response (Whitters 
and Stockley, 2012) as outlined in Fig 1.1. 
 
1.1.6  Bacterial Colonisation 
 
 
Bacterial Colonisation in lung disease is generally defined as at least two positive sputum 
cultures separated by at least 3 months in a year (Pasteur et al., 2000).   The prevalence of 
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Figure 1.1   The initial breach in the lung in bronchiectasis is usually thought to be caused by 
infection. Predisposing defects in innate immunity or primary lung defence mechanisms may 
predispose to this initiation including genetic predisposition as in cystic fibrosis.  This 
establishes a chain of events culminating in bacterial colonisation and perpetuated by tissue 
damage as a consequence of the subsequent inflammatory response.  In addition other 
inherited conditions such as primary ciliary dyskinesia will impair clearance of secretions, 
and immune deficiencies impair innate and adaptive immune responses (Cole and 
Wilson,1989; Whitters and Stockley,2012). 
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bacterial colonisation varies in the literature and many published studies are based on 
pathogen isolation on only one occasion rather than repeated growth over time.  Colonisation 
is reported to be high amongst patients with bronchiectasis.  Studies defining colonisation as 
positive sputum at different time points report rates of colonisation amongst patients of 
between 35.5% up to 66% (Angrill et al., 2002; Pasteur et al., 2000; King et al., 2007; 
Borekci et al., 2016). Haemophilus  influenzae (H. influenzae) and Pseudomonas aeruginosa 
(P. aeruginosa) are reported to be the most common colonising organisms isolated.  P. 
aeruginosa colonisation is reported in 9-24 % of patients with bronchiectasis with 
H.influenzae reported in 11 -35% in these same studies.  Other potentially pathogenic 
colonising organisms include Staphylococcus aureus, Streptococcus pneumoniae, 
Escherichia coli, Klebsiella pneumonia, acinetobacter sp  and Moraxella cattarhalis (Pasteur 
et al,. 2000; King et al., 2007).   Non-tuberculous mycobacteria (NTM) are also significant 
pathogens found in patients with bronchiectasis with meta-analysis showing a prevalence of 
NTM of just over 9% in patients with bronchiectasis (Chu et al, 2014).  
 
1.1.7    Pseudomonas aeruginosa Colonisation 
 
The mechanisms influencing colonisation with P. aeruginosa will be discussed in detail as 
this forms the basis of the studies reported in this thesis.  Not only is this one of the two most 
common pathogenic organisms that colonise patients with bronchiectasis but it is resistant to 
many of the commonly used antibiotics.  Resistance patterns of P. aeruginosa in cystic 
fibrosis have been studied in detail (Doring et al., 2000; Oliver et al., 2000; Pitt et al., 2003;) 
but less is known about resistance of strains isolated in non-CF bronchiectasis.  It is perceived 
to be less common, perhaps because in comparison to CF patients, those with bronchiectasis 
are less likely to be on long term antibiotics.   
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Chronic colonisation with P. aeruginosa has been identified as an independent risk factor for 
an accelerated rate of decline in l ng f n  ion in bron hie  asis ( ar  ne - ar  a et al., 
2007).  Other studies have identified it in association with more severe impairment of lung 
function though whether this is cause or effect is unclear (Davies et al., 2006; McDonnell et 
al., 2015).   
 
Hospital admissions have been shown to be higher than with other colonising organisms 
(McDonnell et al., 2015) and it is associated with increased numbers of exacerbations and 
poorer quality of life (Wilson et al 199 ;  ar  ne - ar  a et al., 2007; Goeminne et al., 
2012; Rogers et al., 2013; Guan et al., 2014; Rogers et al., 2014; McDonnell et al., 2015).  
BSI has also shown that P. aeruginosa colonisation is an independent predictor of hospital 
admission (Chalmers et al, 2014.  Further meta analysis has also shown P. aeruginosa to be 
associated with a higher risk of death, hospital admission and exacerbations (Finch et al, 
2015).   
 
1.1.8   Diagnosis and Management 
 
In clinical practice the diagnosis of bronchiectasis is usually made by identification of 
classical symptoms confirmed by radiological features of bronchiectasis on HRCT.    
Investigations are then aimed to try and establish an underlying cause and identify any 
pathogenic organisms in the sputum.  Measurements of serum immunoglobulin are taken 
(IgA, IgM and IgG) to establish any adaptive immune deficiency.  The usefulness of 
checking IgG subgroup levels are uncertain and not routinely recommended.  No significant 
association with IgG subclass deficiency and bronchiectasis has been identified (Hill et al., 
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1998; Stead et al., 2002; King et al., 2006).    
 
Baseline specific antibody levels against tetanus toxoid, and the capsular polysaccharides of 
H. influenzae and S. pneumoniae are measured although the colonising species of H.  
influenzae is not capsulated.  If these antibody levels are low, vaccination is undertaken with 
the relevant antigen followed by repeat measurement at least three weeks later. If levels 
remain low it may indicate a failure of the adaptive immune response. Both tests of the 
immune system are recommended (Vendrell et al., 2005) and indeed are considered routine 
clinical practice in a specialist bronchiectasis clinic.  Pulmonary function testing is usually 
undertaken particularly in cases where a concurrent diagnosis of COPD or asthma is 
suspected. In addition to these standard tests, specialist investigation such as nasal nitric 
oxide (nNO) can be undertaken where primary ciliary dyskinesia is suspected.  
Measurements of nNO are lower in patients with PCD in comparison to healthy patient and 
those with idiopathic bronchiectasis (Wodehouse et al, 2003).  Ciliary biopsy would be 
undertaken where primary ciliary dyskinesia is suspected and younger patients should be 
screened for cystic fibrosis variants as recommended by the British Thoracic Society 
Bronchiectasis Guideline (2010) (Pasteur, Bilton and Hill, 2010), particularly when other 
features suggestive of CF are present. 
The management of bronchiectasis includes treatment of the underlying cause where 
identified and where a suitable treatment exists.  Irrespective of the underlying cause patients 
are taught airway clearance techniques and encouraged to perform these exercises daily as 
sputum clearance thought imperative to the management of this condition.  A Cochrane 
systematic review deemed airway clearance techniques safe although requiring further study 
and evaluation of short and long term benefits (Lee et al., 2015). Evidence to support the use 
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of inhaled bronchodilators, inhaled steroids and mucolytics in bronchiectasis is lacking.  
Inhaled therapies only have a role where there is coexistant airway obstruction in line with 
their utilisation in COPD (Whitters and Stockley, 2013).  Antibiotics form the mainstay of 
current management of bronchiectasis and courses of between 10-14 days of a suitable 
antibiotic targeted to the organism found in the patients sputum is recommended during 
exacerbations (Pasteur, Bilton and Hill, 2010).  Where patients exacerbate frequently, are 
colonised with a pathogenic organism or chronically produce purulent sputum to suggest a 
high bacterial load, long term antibiotic therapy, either nebulised or oral may be initiated in 
an attempt to lower the bacterial load. This has largely not been subjected to placebo-
controlled trials although sequential studies indicate clear benefit to sputum purulence and 
patient well being (Stockley, Hill and Burnett, 1985).   More recently confirmation of benefit 
has been shown with inhaled gentamicin in patients colonised with Pseudomonas aeruginosa 
(Murray et al., 2011). 
 
1.2 The Host Immune System  
 
The vicious cycle of bronchiectasis implies failure of host defences leading to ongoing 
inflammation and damage.  The innate immune system responds immediately to inhaled 
pathogens and is the first barrier to infection.  It comprises the physical epithelial barriers and 
mucociliary clearance in addition to secreted anti inflammatory proteins and polypeptides, 
with subsequent recruitment of phagocytes to the site of inflammation and specific antibody 
production.  Locally produced IgA and IgG in addition to diffusion of IgA and IgG from 
plasma form the basis of this immediate response.  
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The adaptive immune response has two main pathways.  The humoral response mediated by 
B-lymphocytes and their production of antibody.  Cell mediated immunity is mediated by T 
lymphocytes.  The role of cell mediated immunity in bronchiectasis is not fully understood 
although increased CD4 lymphocytes have been identified in the airways of bronchiectasis 
patients (Gaga et al., 1998), whilst bronchial biopsy specimens have shown a marked 
inflammatory infiltrate with a CD8+ and CD4+ T cells indicating that cell mediated 
inflammation is activated and may play a role in bronchiectasis pathogenesis (Silva et al 
1989). The humoral response and its relevance to the development and perpetuation of 
bronchiectasis is better established and relevant to the central hypothesis of this thesis. 
 
1.2.1    The Innate Immune System of the Lung 
 
The innate immune defence of the lung is the immediate defence against inspired pathogens.  
This comprises physical barriers with the mucociliary escalator the initial barrier to infection, 
and airway secretions containing anti infective proteins and polypeptides forming a local 
response to invading pathogens.  Immunoglobulins form part of this initial response with 
secretary IgA the main local antibody found in the respiratory tract contributing to the initial 
immune response.   
 
1.2.2     Mucociliary Escalator 
 
This physical barrier consists of ciliated epithelium that lines the airway from larynx to the 
terminal bronchioles.  It consists of goblet cells that secrete mucus and ciliated columnar cells 
(Clarke and Pavia, 1980). Particles greater than 2-3μm are  rapped on  he m   s layer  ha  
covers these cells and are then removed by mucociliary clearance and cough (Nicod 1999; 
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Loebinger, Bilton and Wilson, 2009).   It is failure of mucociliary clearance that affects 
patients with conditions such as primary ciliary dyskinesia predisposing to bronchiectasis.  
For pathogens that evade this initial barrier in the lung there are further local immune 
responses to aid clearance and modulate the local inflammatory response. 
 
1.2.3    Immune Proteins  
 
Epithelial lining fluid  (ELF) forms a thin fluid level lining the airways (Rogan et al., 2006; 
Rodvold, George and Yoo, 2011). This consists of airway secretions containing anti infective 
proteins and polypeptides including lysozyme, lactoferrin and Secretory Leucoprotease 
Inhibitor (SLPI) amongst others (Travis, Singh and Welsh, 2001; Rogan et al., 2006). When 
pathogens invade the lung sub mucosal gland epithelial cells and resident macrophages 
respond by making and secreting these antimicrobial proteins.  The most abundant are 
lysozyme, lactoferrin and SLPI.  
 
Lysozyme is stored in both primary and secondary neutrophil granules.  It has bactericidal 
and bacteriostatic effects and acts by lysis of the bacterial cell wall (Rogan et al., 2006).  
 
 Lactoferrin is released from neutrophil secondary granules and has both antimicrobial and 
anti-inflammatory effects. It also has bactericidal and bacteriostatic effects with additional 
antifungal and antiviral properties (Rogan et al., 2006).  Lactoferrin effects antibacterial 
activity in several ways. Firstly, it limits the amount of free iron available (which is essential 
for growth of microorganisms) by binding to iron and has been shown to enhance the 
antibacterial effects of some antibiotics (Leitch and Willcox, 1999).   Furthermore, it may 
inhibit biofilm formation by bacteria – a defence mechanism employed by bacterial 
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populations, including P. aeruginosa whereby bacteria are embedded within an extracellular 
polymeric substance (EPS), increasing resistance to antibiotics and host killing (Singh et al., 
2002). It has also been shown to have key anti-inflammatory actions by inhibition of 
production of interleukin-8 (IL-8), in human endothelial cells (Elass et al., 2002).   
Lactoferrin acts in synergy with lysozyme and SLPI in bacterial killing – each acting to 
enhance the effect of the others (Singh et al., 2000).  Increased levels of lactoferrin and 
lysozyme in bronchoalveolar lavage of patients with chronic bronchitis have been reported, in 
comparison to that seen in healthy smokers and healthy controls suggesting that both 
contribute to the inflammatory response.  However they did not correlate with neutrophil 
levels suggesting that recruited neutrophils were not the main source (Thompson et al., 
1990). This instead suggests that the majority of production of these proteins are from other 
airway cells including sub epithelial glands. Whether a similar process plays a role in 
bronchiectasis is unclear though it may be overwhelmed by the exaggerated neutrophilic 
response associated with bronchiectasis.    
 
SLPI is produced by the mucous glands, macrophages. neutrophils and airway epithelial cells  
and has antifungal, antiviral and antibacterial properties (Rogan et al 2006). It has anti 
bacterial effects against both gram negative and gram-positive organisms (Heimstra et al., 
1996). The Anti protease activity of SLPI acts to inhibit neutrophil elastase activity thereby 
opposing its damaging elastolytic activity as it is released from neutrophils in areas of 
inflammation and infection.  It is reduced by the presence of elastase activity (Sullivan et al., 
2008) and is subject to cleavage and inactivation in areas of lung affected by pneumonia, 
leaving neutrophil elastase less likely to be inactivated and hence exacerbating further 
inflammation and damage (Greene et al., 2003). It has also been shown to be reduced in the 
lungs of patients with chronic bronchitis during the time of an exacerbation, improving to 
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baseline level, following treatment of the exacerbation. (Hill et al., 1999; White et al., 2003).  
Whether similar mechanisms exist in bronchiectasis with chronic inflammatory changes is 
unknown although it may be relevant that it has been shown to be lowest in patients with the 
greatest degree of neutrophilic inflammation in the stable state. (Hill, Bayley and Stockley, 
1999) 
 
The secretion of lysozyme, lactoferrin and SLPI by neutrophils is modulated by the 
inflammatory response in the lungs.  In response to chemoattractants, neutrophils are 
recruited to areas of inflammation with the release of their immune proteins from preformed 
granules, during phagocytosis and production of reactive oxygen species (ROS) at the site of 
inflammation.  (Stockley, 2002; Cowburn et al., 2008; Whitters and Stockley, 2012).  
 
Bronchiectasis is characterised by neutrophilic inflammation irrespective of the underlying 
causes of the disease.  Neutrophil counts measured in bronchoalveolar lavage or sputum have 
repeatedly been demonstrated to be elevated (Angrill, Agusti and Torres, 2001; Watt et al., 
2004; Guran et al., 2007), with a further increase noted in association with isolation of 
potentially pathogenic organisms (Angrill, Agusti and Torres, 2001). Increased neutrophils 
have also been noted in the airway tissue of bronchiectasis patients to further support the role 
of a predominantly neutrophilic inflammatory response (Zheng et al., 2001). It is this 
continual inflammatory response by neutrophils which perpetuates the vicious cycle as 
previously described.  Although other inflammatory cells including B and T cells, natural 
killer cells and mast cells are also implicated in the inflammatory response, (Eller et al.,1994; 
O’Sha ghnessy et al., 1997; Gaga et al.,1998; Sepper et al.,1998 Zheng et al.,2001) in 
bronchiectasis neutrophils are the most abundant cells and mediator of damage and hence  are  
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discussed in more detail below. 
 
 
1.2.4    The Role of Neutrophils and Neutrophilic Inflammation in Bronchiectasis 
 
As previously noted, neutrophils have three main roles –phagocytosis, the production of 
reactive oxygen species (ROS) and the release of immune proteins from preformed granules.  
The chemoattractants IL-8, leukotriene B4 (LTB4)    mo r ne rosis fa  or α (TNFα)  and 
interleukin 1beta (IL-1β) are all drivers of neutrophil recruitment. IL8 in particular has been 
shown to have a crucial role during exacerbations (Gaga et al., 1998; Mikami et al., 1998; 
Watt et al., 2004). An increase in IL-8 is seen in increasingly purulent sputum with a higher 
chemotactic activity which may perpetuate the cycle of damage with continued neutrophil 
recruitment.  (Mikami et al., 1998).  Targeting therapies to this exaggerated response may be 
detrimental as at the time of an acute infection neutrophil chemotaxis is required. The 
immune proteins are released on activation of the neutrophil, through a hierarchical process 
of degranulation (Borregaard et al., 2001; Xu and Hakansson, 2002).  
Azurophilic granules (primary granules) release (amongst others) myeloperoxidase, 
bactericidal/permeability increasing protein (BPI), defensins, neutrophil elastase, proteinase 3 
and cathepsin G.  Specific granules (secondary granules) release other key antibacterial 
proteins such as lactoferrin and cathelicidin and tertiary (gelatinase) granules contain, and 
release, gelatinase acetyltransferase and lysozyme (Rogan et al., 2006).  It may be that the 
release of all these pro inflammatory mediators has a role to play in the development of 
bronchiectasis.  However, in particular the activity of proteases released by neutrophil 
activation are thought to have a major role in the pathogenesis of bronchiectasis. The 
protease/antiprotease imbalance has been crucial to the understanding of the destructive 
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processes in other inflammatory lung conditions such as COPD (Stockley 1999), and it may 
be that unregulated activation of proteases has a similar role in bronchiectasis.  Proteases 
have been said to cause bronchial dilatation – a diagnostic finding of bronchiectasis and thus 
unopposed protease activity may be relevant in the development of bronchiectasis (Khair et 
al., 1996; Zheng et al., 2000).  Neutrophil elastase perpetuates the neutrophilic inflammation 
seen in the airways by upregulating the production of Interleukin 8 (IL-8) from epithelial 
cells (Devaney et al., 2003).   It has also been shown to reduce ciliary beat frequency, and 
therefore inhibit mucous clearance, at high concentrations with epithelial damage evident at 
lower concentrations without slowing ciliary beat frequency (Amitani et al., 1991).    
The respiratory burst, or oxidative burst, results in the release of ROS to facilitate bacterial 
killing.  During phagocytosis, phagocytes including neutrophils increase oxygen consumption 
through the activity of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) oxidase that 
generates oxygen metabolites and formation of antimicrobial ROS (Dahlgren and Karlsson,  
1999; Tung et al., 2009). 
 
The release of uncontrolled ROS by neutrophils, and oxidative stress, may however be 
deleterious with a damaging effect on tissues (Tung et al., 2009).  In the case of 
bronchiectasis this would exacerbate the existing process. It was previously believed that 
ROS exert a direct toxic effect on ingested pathogens but has been suggested by Reeves et al 
that respiratory burst sets in motion events which enhance the activity of proteases to digest 
the contents within the phagocytic vacuole (Reeves et al., 2002).   
 
Chronic granoulomatous disease is a disease associated with bronchiectasis as shown in table 
1.1.  Patients have a defective gene for one of the subunits of NADPH oxidase and therefore 
are not able to produce ROS (Rosenzweig 2008).   Patients with this condition frequently 
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develop infections and granuloma formation and inflammatory complications (Godoy et al., 
2008).   
 
It has been shown by King et al 2006, that phagocytosis was normal in bronchiectasis 
compared to control subjects, but that oxidative burst was lower (King et al., 2006), however, 
there was failure to identify any significant difference in respiratory burst in a detailed 
analysis of causative factors in bronchiectasis (Pasteur et al., 2000).  Therefore, the role of 
ROS in neutrophilic inflammation and its significance or otherwise in the pathogenesis of 
bronchiectasis remains uncertain.  
 
Finally neutrophils act by phagocytosis whereby they engulf and internalise the bacterial 
pathogen forming a phagosome. King et al have previously shown phagocytosis to be normal 
in patients with bronchiectasis (King et al., 2006).  The pathogen is subject to opsonisation by 
binding of IgG via its Fab portion.  The Fc portion binds to Fc receptors on the cell surface of 
the neutrophil facilitating the formation of a phagosome and destruction of the pathogen.  The 
composition of immunoglobulins in the airways is discussed below.   
 
1.2.5   Secreted Immunoglobulin 
 
Secretary Immunoglobulin A (IgA) is the major antibody isotype found in mucosal secretions 
in the respiratory tract contributing to initial defence mechanisms whilst Immunoglobulin G 
(IgG)  predominates in plasma (Pilette et al., 2006). Most lung IgA is produced locally within 
the pulmonary tissues by sub epithelial plasma cells.  IgA in the airway is thought to inhibit 
adherence of antigens to the lung epithelium and behave as an immune barrier (Pilette et al., 
2001). It is reported to bind to lectin-like bacterial adhesions, blocking epithelial colonisation 
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and operating as an immune barrier.  Moreover, similar to IgG it is able to promote 
phagocytosis at least by airway macrophages.  IgA enables delivery of antigens across the 
epithelium into luminal secretions, thereby removing locally formed immune complexes and 
limiting systemic access (Burnett et al., 1987).   The structure and composition of IgA found 
in airway secretions is different to that in serum. In humans there are two subtypes of IgA 
(IgA1 and IgA2).  Lung secretions have around 30% IgA2 compared to only 10-20% in 
blood.  The majority of IgA in the airways is produced locally in epithelial cells although a 
proportion is still derived from blood. (Burnett 1986; Burnett, Crocker and Stockley, 1987; 
Pilette et al., 2001) In the presence of infection stability of IgA2 is maintained better than 
IgA1 as it is less susceptible to destruction by bacterial IgA proteases (Burnett, Crocker and 
Stockley, 1987; Pilette et al., 2001). In the presence of infection, an increase in the proportion 
of IgA2 has been demonstrated (Burnett et al., 1990).  There does appear to be a local IgA 
response to pathogens with post mortem examination of the lungs of patients with bronchitis 
or bronchiectasis demonstrating and increased number of IgA positive cells compared with 
controls (Burnett, Crocker and Stockley, 1987). 
 IgG is the predominant antibody found in human serum.  A more detailed discussion of its  
function is discussed later. Four subclasses of IgG exist in human sera and all have been 
detected in bronchoalveolar sampling from healthy subjects (Merrill et al., 1985).  The 
majority of airway IgG is present due to diffusion from plasma (Reynolds 1988). Plasma cells 
producing IgG are however found in bronchial mucosa (Soutar 1977; Burnett 1986) and are 
the source of the locally produced IgG.  The biological effect of IgG in the lung is poorly 
understood.  In the knowledge that the majority of IgG in the airways is due to diffusion from 
plasma it seems intuitive that levels of IgG in the lung would be similarly affected by 
conditions such as hypogammaglobulinaemia with low serum immunoglobulin levels – 
perhaps contributing in part to the tendency to infection and bronchiectasis.  Hill et al have 
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demonstrated increased levels of IgG in the sputum of patients with bronchiectasis. Local 
production was thought to account for some of this increased IgG. (Hill et al.,1998). 
IgG antibody to P. aeruginosa and complement components are readily detectable in the  
sputum of patients with cystic fibrosis bronchiectasis where these antibodies are shown to 
opsonise colonising P. aeruginosa in the lung (Hann and Holsclaw 1976). Thus it seems 
likely that IgG found in the lung is involved in antibody mediated killing as a component of 
the local immune response.  Similarly Hann et al demonstrated the presence of complement 
proteins in the sputum specimens recovered from the lung, suggesting local complement 
activation.  This would imply that, it is highly likely that antibody-mediated killing is 
involved in the host defence against bacterial lung infection. 
 
 
1.2.6   The Complement System 
 
The complement system is a crucial component of host defence consisting of a highly 
regulated cascade of multiple plasma proteins which compliment the killing of bacteria by 
serum antibodies.   Initially thought to have a primary role in innate immunity it has been 
shown to compliment bacterial killing by both innate and adaptive immune systems.  It 
compliments killing by antibodies by opsonisation with activated complement proteins 
binding to pathogens and facilitating phagocytosis. C3b is the most potent of these proteins.  
Fragments of some complement proteins (C3a, C5a), are products of the sequential enzymatic 
cleavage and have a critical role.  C3a and C5a are chemoattractants to phagocytes such as 
neutrophils attracting them to the site of inflammation or infection (Sarma and Ward, 2010). 
Finally there is the formation of the membrane attack complex C5b-9 (MAC), as the final 
product of the terminal components of the cascade.  This can destroy certain pathogens by 
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disruption of the bacterial cell membrane. (Sahu and Lambris, 2001; Janeway et al., 2005; 
Sarma and Ward, 2010; Merle et al., 2015)  
It has a role in both the innate and adaptive immune systems.   There are three well defined 
pathways which constitute the complement system – the classical pathway, the mannose 
binding lectin (MBL) pathway and the alternative pathway. The stimulants to each of these 
three pathways is shown in figure 1.3.  Briefly the classical pathway is activated by antibody 
and antigen binding by IgG or IgM whereas IgA is a poor initiator of complement response.  
The resultant IgG or IgM immune complex is then bound at the Fc portion by the C1 
complex (consisting of C1q,C1r and C1s molecules) of the cascade, by C1q binding.  This 
activates C1s and C1r to cleave C4 and C2 to form C3 convertase (C4bC2a) where the three 
pathways converge (Sahu and Lambris, 2001; Janeway  et al., 2005; Sarma and Ward, 2011; 
Merle et al., 2015).  
The mannose binding lectin (MBL) pathway is stimulated by carbohydrate on microbial 
surfaces binding to lectins (carbohydrate binding proteins) such as MBL or ficolin.  Both 
lectins circulate normally in the serum as complexes with MBL – associated proteins. 
(MASPs) (Sørensen, Thiel and Jensenius, 2005; Wallis, 2007) Activation of this pathway 
again leads to formation of the C3 convertase C4bC2a via cleavage of first C4 to C4a and 
C4b and C2 to C2a and C2b (Sahu and Lambris, 2001; Janeway et al., 2005). 
Finally, the alternative pathway is activated by lipids, carbohydrates and proteins found on 
cell surfaces.  It also terminates in the formation of a C3 convertase (C3 (H2O)Bb) (Sarma 
and Ward, 2011).  During normal healthy condition it is the most relevant of the three 
pathways maintaining a low level of activity monitoring for pathogen invasion in a process 
referred  o as “ i k over” ( erle et al., 2015).  This is essentially the constant hydrolysis of 
C3 found in plasma, to form C3 (H2O).  The change in configuration allows Factor B to then 
  23 
bind to the reconfigured C3 where it is cleaved by factor D, then cleaved to Ba and Bb.   Bb 
remains bound to C3 (H2O) to form a C3 convertase (C3 (H2O)Bb. (Sarma and Ward, 
2011;Merle et al.,2015).  
Following formation of C3 convertase the three pathways converge.  This ultimately results 
in cleavage of C3 forming C3a and C3b.  As stated previously C3b acts as an opsonin to 
facilitate phagocytosis and also binds C3 convertase to form C5 convertase which 
subsequently cleaves C5 to C5a and C5b.  C5b is then able to bind to C6, C7, C8 and C9 
resulting in the formation of activation products C3a, C3b, C5a and the membrane attack 
complex C5b-9 (MAC) and destroy pathogens by disrupting membrane integrity. 
A summary of the major components of the three pathways is provided in figure 1.2. The 
broad functions of each complement protein is shown in table 1.2.*   
1.2.7   Complement Deficiency and Bronchiectasis. 
 
Inherited complement deficiencies are rare.  They are reported to account for between 1-10% 
of primary immune deficiencies (Grumach and Kirschfink, 2014). As such their role in 
bronchiectasis is undetermined. Complement deficiency does however seem to increase the 
tendency to particular infections likely as a consequence of inadequate opsonisation and 
defects in cell lysis but the implications of deficiency of complement depend on which part of 
the pathway is affected.  C3 is the most abundant complement protein and is cleaved by C3 
convertase at the point of convergence of the three pathways.  Case numbers are small but a 
review of reported cases by Skattum et al reports that deficiency of C3 seems to be associated 
with increased tendency to encapsulated bacteria, likely at least partly as a consequence of 
impaired opsonisation. 
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Table 1.2 shows functional protein classes in the complement system.  *Regulatory proteins 
and complement receptors are not included (Janeway et al., 2005). 
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Figure 1.2 shows the major components and pathways of the three major complement 
cascade pathways – the classical, mannose binding lectin pathway and the alternative 
pathway. The stimulus to each pathway is depicted in the grey shaded boxes.   The three 
pathways converge with the cleavage of C3 to C3a and C3b.  The binding of C3b to C3 
convertase forms C5 convertase whch subsequently cleaves C5 to C5a and C5b which is then 
able to bind to C6, C7, C8 and C9 resulting ultimately in the formation of the membrane 
attack complex C5b-9 (MAC).    
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Respiratory tract infections and meningeal infections are the most common seen in C3 
deficiency.  Respiratory tract infections are associated with defects of the classical pathway   
(C1q,C1r,C1s,C2,C3 and C4 deficiencies), due primarily to Streptococcus Pneumoniae while 
defects of the alternative pathway predispose to infection with Neisseria. (Skattum et 
al.,2011). Whether the prevalence of bronchiectasis is increased in these patients with a 
greater tendency to infection is not known.  
Deficiencies of the mannose binding lectin pathway have been associated with an increased 
tendency to respiratory infection, particularly in childhood. (Koch et al., 2001;Cedzynski et 
al., 2004; Gomi et al., 2004).   
Low or deficient serum Mannose-binding lectin (MBL) has also been associated with 
worsening severity of disease in cystic fibrosis with worse lung function, earlier acquisition 
of P. aeruginosa and increased rate of death (Chalmers et al., 2011). Results are conflicting 
in bronchiectasis with Chalmers et al reporting increased severity of bronchiectasis, including 
increased exacerbations, hospital stays and increased bacterial colonisation rates with a 
higher rate of P. aeruginosa colonisation compared to controls.  The rate of MBL deficiency 
was not noted to be higher in patients with bronchiectasis compared with controls however. 
(Chalmers et al., 2013).  
A similar study failed to demonstrate any worsening severity of disease symptoms in 
bronchiectasis patients.  The incidence of MBL deficiency was again similar to the general 
population (MacFarlane et al., 2012). The conflicting results of these studies do seem to 
indicate similar rates of MBL deficiency in patients with bronchiectasis as in the general 
population which suggests it is not associated with a higher risk of developing bronchiectasis 
but whether it influences the severity and outcomes in the disease requires further study.  
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Perhaps of significance, measurement of serum L-ficolin and MBL in patients with stable 
bronchiectasis again found no difference in average MBL values between patients with stable 
bronchiectasis, healthy blood donors and patients admitted to hospital with pneumonia.  L-
ficolin deficiency however, was found more frequently in the bronchiectasis group suggesting 
a possible causative role due to a decreased capacity to activate the mannose binding lectin 
pathway of the complement cascade (Kilpatrick et al., 2009).  
 
1.2.8 Adaptive Immune System 
 
The adaptive immune system is a highly specific system required to protect the lungs from 
organisms which evade phagocytosis by the inate immune system. Where the inate immune 
system is effective in recognising pathogens, it mainly relies on recognition of surface 
molecules common to a variety of pathogens.  Bacterial evolution dictates that mechanisms 
have evolved to protect the recognition of the bacterial surface by the inate immune system, 
for example encapsulation, thereby limiting phagocytosis by resident macrophages.  The 
adaptive immune sytem can overcome this limitation on the innate immue system by 
recognising and developing memory for an infinite array of antigens. As stated previously 
cell mediated immunity by T cells forms a vital part of the adaptive response but its role in 
bronchiectasis is less well defined. There are however well recognised associations between 
B cell antibody formation, infection and bronchiectasis.  
 
Briefly, the adaptive immue response is typically triggered in response to infection with 
antigen initially presented to immature T. lymphocytes by macrophages or dendritic cells.  T 
– helper cells activate B cells which produce antibody specific to the antigen whilst cytotoxic 
T cells destroy the pathogen presented to it.  Immature circulating lymphocytes have antigen 
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receptors of a single specificity with different specificity of each lymphocyte.  When an 
antigen is bound to the specific receptor on the lymphocyte, it is activated to form a 
lymphoblast and subsequent clonal expansion takes place whereby clone cells differentiate to 
effector cells which secrete antibody with the same specificity as the surface receptor that 
was first activated.  Antibodies are then secreted from the B cell antigen receptor (Janeway et 
al., 2001). This process takes a number of days to complete.  Some effector cells persist after 
the antigen has been eliminated which forms the basis of immunological memory, whereby at 
the time of the second exposure to the same antigen the response is more rapid.  This 
secondary immune response produces higher amounts of more specific antibody to antigen to 
prevent reinfection and forms the basic principle of vaccination therapies.   
 
Three classes of B lymphocytes exist in humans.  B-1 lymphocytes and B-2 lymphocytes 
which are further differentiated to marginal zone (MZ) and follicular (FO) lineages  
(Hoffman et al, 2016). B-1 cells are part of the innate immune system, producing 
immunoglobulins , recognising self antigens and epitopes such as carbohydrate.  B-2 cells are 
present in secondary lymphoid organs and generally are considered mediators of adaptive 
immunity (Montecino-Rodriguez and Dorshkind, 2012).  All lineages arise initially from 
progenitor cells derived from haemopoietic stem cells (HCS).  B1 progenitor cells in the fetal 
liver and B-cell progenitor cells found in bone marrow further develop to B1 cells residing in 
pleural and peritoneal cavities and transitional 2 (T2 B) cells in the spleen which further 
differentiate to MZ lymphocytes found in the marginal zone of the spleen and FO 
lymphocytes found in spleen and lymph nodes.  B lymphocytes of each lineage have roles in 
antigen recognition through T dependent and independent pathways, rapid production of IgM 
antibodies, and the production of IgG forming the basis of immunological memory.  Distinct 
functions of B1 lymphocytes include the production of IgA, which has a role in mucosal 
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defence, and is discussed in more detail later.  MZ B-lymphocytes, in addition to the 
overlapping roles as described above, transport complement bound opsonins on to FO 
dendritic cells.  In addition to B1 cells, MZ B cells mediate rapid IgM response.  IgG 
antibodies, are derived from FO B cells forming the basis of immunological memory.  They 
are the most abundant of all B cells with its primary role the generation of high-affinity long-
lasting IgG antibodies in a T cell dependant role. FO B cells also have overlapping functions 
with MZ B cells and B1 lympocytes with the production of all immunoglobulin subtypes, 
including IgM, in a T cell-independent response (Hoffman et al, 2016). 
 
 
Three main antibody groups are found in human serum – immunoglobulin A, M and G.  IgD 
and IgE are also found but constitute a small percentage of total immunoglobulin with a role 
in allergic response/parasite clearance for E rather than infection and the role for D remains 
uncertain.  The main functions of antibody are to activate the classical and alternative 
pathways of the complement system.  The classical pathway is activated predominantly by 
IgM followed by IgG with the alternative pathway activated by IgG and IgA (Janeway et 
al.,2001).  Opsonisation is a function of IgG and IgM.  IgA as discussed previously has a role 
in mucosal protection.  The role of each antibody and subgroups are shown in table 1.3. 
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Immunoglobulin 
class 
Abundance in 
serum 
Complement 
fixation 
Opsonisation Function 
IgA 15% No No Local mucosal 
response 
IgM 10% yes yes Primary 
response. 
IgG 75%   Secondary 
response 
IgG1 67% Yes Yes Induced in 
response to 
protein and 
polypeptide 
antigens 
IgG2 22% Yes Yes Induced in 
response to 
Polysaccharide 
antigens 
IgG3 7% Yes Yes Induced in 
response to 
protein antigens 
IgG4 4% no No Role not fully 
established.  
Some response to 
polysaccharide 
antigens. 
 
Table 1.3 Immunoglobulin subclasses found in human serum with the proportion of each 
contributing to total immunoglobulin.  The ability to fix complement, function in 
opsonisation and  function is outlined for each subtype.  (Schroeder and Cavacini, 2010) 
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1.2.9   Immunoglobulin G Structure 
 
Immunoglobulin G is the most abundant antibody in human serum.  Its role in secondary 
immune response and subgroup response to particular antigens make it of particular interest 
in host, bacterial interactions.  Its structure is crucial in its binding to antigens and activating 
complement.  Ig  is formed of a 4 polypep ide  hain ba kbone. I   on ains  wo heavy  lass γ 
chains,(H) and two identical  light chains (L) connected by disulphide bonds (-s-s-).  These 
are arranged in a Y structure with two antigen binding sites.  The amino acid sequences 
which form the terminal ends of the peptide chains are referred to variable regions.  The light 
chains consist of one variable domain (VL) and one constant domain (CL).   There are two 
 ypes of ligh   hains referred  o as lambda (λ) and kappa (κ)  hains. The heavy chains have 
one variable domain (VH) with three constant domains (CH1, CH2 and CH3).   
 
The variable region binds to antigen whilst the constant domains are involved in complement 
binding and binding to the cell membrane.   Different subclasses of IgG are characterised by 
differen es in  he amino a id  on en  of  he heavy  hains and  he ra io of κ  o λ ligh   hains.    
The major structural difference between subgroups occurs in the hinge region.  The hinge 
forms a connection between the two heavy chains whilst providing some flexibility to the IgG 
enabling the fragment antigen binding portion (Fab) to interact with different sized epitopes 
(Vidarsson, Dekkers and Rispens, 2014).  The Fab region is the region of the antibody which 
binds to antigens.  The Fc region interacts with cell surface Fc receptors and proteins of the 
complement system thereby activating the immune system (Janeway et al 2001; Schroeder 
and Cavacini, 2010; Vidarsson, Dekkers and Rispens, 2014).  The structure is shown in figure 
1.3. 
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Figure 1.3 Structure of immunoglobulin G showing the 4 polypeptide chain backbone that 
forms IgG arranged in a Y structure.  There are  wo heavy  lass γ  hains (H) and  wo 
identical  light chains (L) connected by disulphide bonds (-s-s-) with two antigen binding 
sites (circled). The light chains consist of one variable domain (VL) and one constant domain 
(CL).   There are  wo  ypes of ligh   hains referred  o as lambda (λ) and kappa (κ)  hains. The 
heavy chains have one variable domain (VH) with three constant domains (CH1, CH2 and 
CH3). 
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1.2.10   Antibody Deficiency Syndromes 
 
Assessment for antibody deficiency is routine in the initial assessment of patients with 
bronchiectasis.  Primary antibody deficiency syndromes (PADS), where there is partial or 
complete deficiency in one or more immunoglobulin subclass have been associated with 
bronchiectasis (Verma, Grimbacher and Hurst, 2015). An inherited antibody deficiency may 
predispose to developing bronchiectasis and the impaired ability to mount and effective 
response is likely to be a factor in maintenance of the cycle of infection with impaired 
clearance and subsequent ongoing damage.  Up to 8% of adults with bronchiectasis are said 
to have a primary immune deficiency (Pasteur et al., 2000; Stead et al., 2002; Li et al., 2005; 
Shoemark, Ozerovitch and Wilson, 2007).  The major groups of primary antibody deficiency 
syndromes are listed in table 1.4.  
 
The effect of Common Variable Immune Deficiency (CVID) is an inability to mount an 
appropriate and competent antibody response to pathogen epitopes. PADs are rare conditions 
but there is a consistently high prevalence of bronchiectasis reported among those affected 
(Kainulainen et al., 1999; Quinti et al., 2007).  Selective IgA deficiency is said to be common 
in the normal population( >1/800 ), ( Holt, Tandy and Anstee, 1977) but usually  patients are 
symptom free.   Despite adequate immunoglobulin replacement Kainulainen et al reported 
progression of bronchiectasis in patients with either CVID or agammaglobulinaemia   
(Kainulainen et al., 1999) suggesting that despite optimal treatment with immunoglobulin, 
respiratory infections are still a problem in this group, perpetuating ongoing damage to the 
lung.  It may be that other strategies, for example with long term prophylactic antibiotic, 
enhancing chest clearance and ensuring these patients have dual care with a specialist 
respiratory team has a specific role here too in these patients. 
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Primary Antibody Deficiency Immunoglobulin deficiency 
Common Variable Immune Deficiency (CVID) Low IgG.  Low IgA. +/- low IgM.  Unable to 
mount secondary response to vaccine. 
Diagnosed in infants 
X linked aggammaglobulinaemia (XLA) Low IgA, IgM, IgG.  Diagnosed in male infants 
IgG subclass deficiencies Low IgG subgroup 1-4 
Specific antibody deficiency Normal levels of Ig but fail to respond to 
vaccination. 
Selective IgA deficiency Undetectable IgA in serum or secretions.  Often 
symptom free.   
X linked hyper IgM Syndrome Increased IgM.  Low IgG, IgA. 
 
Table 1.4.  Primary antibody deficiency syndromes are shown with the immunoglobulin 
deficiency that define, and are diagnostic of each of these (Whitters et al., 2012). 
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Acquired hypogammaglobulinaeamia asscociated with other medical conditions is also seen 
in protein losing states, B cell lymphoproliferative disease such as chronic lymphocytic 
leukaemia   (CLL) and multiple myeloma.  25% of newly diagnosed patients with CLL are 
said to have hypogammaglobulinaemia at the time of diagnosis with a further 25% 
developing this over the course of the disease (Parikh et al., 2015). The incidence of 
bronchiectasis in this group is not known but may form an important, under recognised group 
at this time. 
   
1.2.11   The significance of IgG Subclass Deficiencies in Bronchiectasis. 
 
IgG has four subclasses each with different antibody responses.  Low levels of isolated IgG 
subclasses have been identified, with undetectable levels of serum IgG4   present in up to 
10% of healthy adults (Buckley, 2002). Studies evaluating IgG subclass deficiency in 
bronchiectasis have provided conflicting results and as a consequence their role in causation 
and maintenance of the inflammatory response remains uncertain.  Hill et al concluded that 
IgG subclass deficiency was comparatively rare in patients with bronchiectasis compared to 
age matched healthy individuals (Hill et al., 1998). Similar findings have subsequently been 
reported elsewhere (Stead et al., 2002; King et al., 2006). Other groups have however found a 
small number of cases of severe IgG2 deficiency with defective antibody production in 
bronchiectasis suggesting that it may have a significant role in some individuals (Pasteur et 
al., 2000).  The significance of subgroup deficiency therefore remains undetermined.  On the 
other hand patients have been identified with normal levels of immunoglobulin but with a 
poor functional response to immunisation (Pasteur et al., 2000; Vendrell et al., 2005) hence 
the importance of evaluating functional response to immunisation rather than simple 
measurement of immunoglobulin levels.   
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Factors that facilitate bacterial colonisation are not confined to changes in host defence but 
also involve factors and behaviours inherent to bacteria themselves that can evolve to ensure 
its ability to invade and colonise the lung.  This is a particular problem in patients with 
bronchiectasis colonised by P. aeruginosa causing significant morbidity and its interactions 
with host defence are discussed.  
 
1.3 Pseudomonas aeruginosa  
 
P. aeruginosa is an opportunistic, environmental Gram-negative rod.  As previously stated it 
is one of the two most common colonising organisms in bronchiectasis.  It is the colonising 
organism in up to 80% of patients with bronchiectasis related to cystic fibrosis and is 
responsible for 10-20% of hospital acquired infections (El Solh et al., 2008). It is a cause of 
sepsis in immunosuppressed patients and its resistance to common antibiotics renders it a 
significant clinical pathogen with a need for alternative therapies.  Its sophisticated array of 
virulence factors have resulted in an organism able to counteract and subvert host defences 
culminating in a persistent inflammatory response.  Most of the studies evaluating chronic 
infection with P. aeruginosa have involved patients with cystic fibrosis and so much of what 
has been learned about its behaviour in the lung has been established in this group of patients.  
Although the clinical condition which affects the lungs of cystic fibrosis is bronchiectasis, 
there are a number of unique characteristics of the CF airway which may dictate bacterial 
behaviour in that environment is not necessarily replicated in the non CF lung.  However it 
remains likely that there are similarities in the factors governing P. aeruginosa colonisation 
in both conditions.  
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1.3.1   Virulence Factors 
There are multiple features associated with P. aeruginosa   that enable and enhance its ability 
to colonise a host.  It has several cell-associated and secreted virulence factors.  For example 
it expresses two proteases, Elastase and alkaline protease expressed in both environmental 
and clinical strains of P.aeruginosa (Nicas and Iglewski, 1986).  
Purified P. aeruginosa elastase has been shown in animal models to increase the permeability 
of epithelium and this method of tissue destruction could potentially contribute to the 
ongoing inflammatory response seen in patients chronically colonised with P. aeruginosa 
(Azghani, Bedinghaus, Klein, 2000).  It also inactivates Immunoglobulins, complement 
components and lysozyme by proteolytic cleavage thus reducing the host immune response 
(Pelletier et al., 1989).  Exotoxin A, induces apoptosis in host cells and inhibits protein 
synthesis amongst other actions (Michalska and Wolf, 2015), and phospholipase is reported 
to suppress neutrophil burst (Terada et al., 1999).  
Pyocyanin (PCN) is a secondary metabolite produced by P. aeruginosa. At blood pH it can 
easily penetrate biological membranes and gives P. aeruginosa its associated green 
pigmentation.  It has a variety of effects upon human cells such as inhibition of cell 
respiration, disruption of cilia function, inhibition of epidermal cell growth, disruption of 
calcium homeostasis, induction of apoptosis in neutrophils and inactivation of α1 pro ease 
inhibitor (Lau et al., 2004a; Lau et al,. 2004b).  Flagella and pili enable motilility of the cell 
but can also initiate an inflammatory response, in their own right, during an infection. 
(Gellatly and Hancock, 2013).  
The production of the extracellular polysaccharide, alginate – produced   by mucoid strains of 
P. aeruginosa – contributes to the formation of biofilms although it is not essential for 
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biofilm formation in vitro (Stapper et al., 2004).    It does however play a role in the biofilm 
structure and may be required for the formation of thicker three dimensional biofilms in vivo 
(Nivens et al., 2001).   Patients with CF tend to be colonised with mucoid strains of P. 
aeruginosa and therefore in these patients the production of alginate is likely to be an 
important virulence factor (Stapper et al., 2004).   
 
1.3.2   Biofilm formation and Quorum Sensing 
 
Biofilm formation is a feature of P. aeruginosa which forms an impenetrable barrier 
protecting the bacteria from the immune system defence.  Irreversible attachment of the 
bacteria to a surface initially takes place, followed by rapid multiplication of the bacteria and 
formation of microcolonies which produce an extracellular polymeric substance (EPS) which 
forms a matrix and holds these colonies together.  As the biofilm matures it appears as 
mushroom like structures from which cells can detach and bind irreversibly to another 
surface for the process to begin again (Donlan and Costerton, 2002; Whitters and Stockley, 
2012; Gellatly and Hancock, 2013).  (Fig 1.4).   The phenotype of the colonising strain of P. 
aeruginosa may also have an influence on biofilm formation.  Strains isolated from patients 
with CF and chronic colonisation are frequently of the mucoid phenotype (Schelstraete et al., 
2013). It is thought that the change of non mucoid to mucoid strains which is seen in CF 
takes place in response to environmental factors encountered during chronic infection.  In 
vitro this takes place under adverse growth conditions (Govan and Deretik, 1996; Pujana et 
al., 1999).  These mucoid strains can influence biofilm formation by overexpression of 
alginate which lends a tendency to form lumpy uneven biofilms rather than smoother flatter 
biofilms seen with strains unable to produce alginate (Flemming and Wingender, 2010). 
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P. aeruginosa also utilise quorum sensing – a highly regulated cell to cell communication 
system.  It is defined as the capacity to detect extracellular, small molecule signals and to 
alter gene expression in response to bacterial population densities that reach a threshold 
concentration (Asad et al., 2008).  Two quorum sensing systems termed LasR  and rhlR have 
been identified in P. aeruginosa. (Bjarnsholt and Givskov, 2006; Popat, Crusz and Diggle 
2008).  In addition to a role in modulating expression of virulence factors of P. aeruginosa  
(Smith et al., 2002 Asad and Opal, 2008), this complex signalling system has been shown to 
have a role in biofilm production with manipulation of quorum sensing pathways and the 
creation of mutant strains seen to alter the shape of biofilm formed (Davies et al., 1998).   
 
Burr et al have recently demonstrated some success in inhibiting quorum sensing of P. 
aeruginosa using low dose macrolide in patients with non cystic fibrosis suggesting therapies 
which impede this signalling pathway may have a role in future management of these patients 
and that quorum sensing is a factor influencing colonisation in bronchiectasis patients (Burr 
et al., 2016). 
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Figure 1.4  Biofilm lifecycle shows bacteria initially attaching to a surface (1).  Next there is 
irreversible attachement (2) followed by the formation of microcolonies (3) which become 
engulfed in a mushroom shaped EPS structure (4).  Finally bacteria are able to disperse from 
this and recolonize a new surface (5), and the cycle begins again.  
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1.3.3   Pseudomonas aeruginosa Lipopolysaccharide Structure 
P. aeruginosa lipopolysaccharide has an essential role in the structure and function of the 
outer membrane of P. aeruginosa and is crucial in mediating bacterial virulence and host 
response.  Lipopolysaccharide is an integral component of the P. aeruginosa cell envelope 
consisting of three structural domains.  Lipid A, core oligosaccharides consisting of an inner 
and outer core and the distal O- antigen (Fig 1.5).   
Lipid A attaches the LPS chain to the outer membrane of P. aeruginosa.  Lipid A 
modifications demonstrated in CF P. aeruginosa strains have been shown to be unique to CF 
and result in resistance to antimicrobial peptides suggesting a potential role for lipid A 
modifications in colonisation in CF (Ernst et al., 2003; Ernst et al., 2007). The core 
oligosaccharide is a short chain of sugar residues which is relatively well preserved between 
strains with little variation in its structure (Lam et al., 2011).  
 
O-antigen is the component of LPS which varies in length due to the number of repeating 
units of sugar in its composition.  Most strains of P. aeruginosa express two distinct forms of 
O-antigen which can exist simultaneously.  One termed the common polysaccharide elicits a 
weak antibody response whilst the O specific polysaccharide varies in chain length between 
strains and it is this which is highly immunogenic.  This variation in chain length confers 
serogroup specificity and is the basis of serotyping (Lam et al., 2011; Gellatly and Hancock, 
2013).  The gene sequences for the proteins involved in O-antigen synthesis and assembly 
have been identified and the major enzymes responsible are encoded in a cluster of genes that 
occupy a common genetic locus (Raymond et al., 2002).  A wzz gene has been identified 
within every locus and this Wzz protein is responsible for regulating the long O-antigen chain 
lengths (12 to 16 and 22 to 30 subunits) but not very long chain lengths (40-50 subunits) in 
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the wild type strain PAO1 (Burrows, Chow and Lam, 1997).  Two wzz genes have been 
identified (wzz1 and wzz2).  The Wzz protein has been shown to be important for the 
expression of long chain O-antigen length whilst the Wzz2 protein is important in production 
of very long chain O-antigen (Kintz et al, 2008). 
 
The terminology of rough or smooth strains is used to describe LPS with or without O-
antigen.   Rough refers to those without, and smooth to those expressing O-antigen  (King et 
al., 2009). The common polysaccharide antigen appears to become the major LPS antigen 
over time in cystic fibrosis with rough strain being the dominant one found (Hancock et al., 
1983; Penketh et al., 1983).  It has been hypothesised that this may be due to selective 
pressures for loss of the high molecular mass O-antigen, or indeed it may be the unique CF 
lung environment that contributes to this finding.  Longitudinal data is not available to 
suggest whether or not this occurs in non CF bronchiectasis.  Multiple studies do seem to 
suggest that the expression of O-antigen or smooth form, is required for P. aeruginosa to 
cause systemic infection (Pier and Thomas, 1982; Cryz et al., 1984; Goldberg et al., 1995; 
Ohno et al., 1995).  Animal studies have supported this with failure of rough LPS to spread in 
mice following introduction into the respiratory tract.  However at a significantly high dose it 
could cause pneumonia and death without significant evidence of systemic spread. This may 
be indicative of the ability of rough strains at a sufficiently high dose being able to 
overwhelm the local immune response (Priebe et al., 2004). This would indicate that although 
O-antigen is a requirement for systemic spread of P. aeruginosa it is not required to cause 
infection localised to the lung and that with a high bacterial load can overwhelm the innate 
immune system.   As O-antigen expression appears pivotal in the ability of P. aeruginosa to 
spread systemically, the ability of serum and the adaptive immune system to deal with this 
then becomes crucial. 
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Figure 1.5 P. aeruginosa LPS structure.  The three components of P. aeruginosa LPS with 
lipid A which attaches to the outer membrane of P. aeruginosa, the core oligosaccharides 
forming the inner and outer core and O- antigen which forms the distal component of LPS 
and varies in length.  This is the highly immunogenic component of LPS. 
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1.3.4   Serum killing of P. aeruginosa 
P. aeruginosa strains isolated from patients with cystic fibrosis are generally sensitive in 
normal healthy serum whilst the presence of O-antigen is a feature of strains which are 
resistant to killing by normal healthy serum (Hancock et al., 1983; Knirel et al 2006). Lab 
studies of mutant strains of P. aeruginosa have also shown serum sensitivity in those strains 
lacking O-antigen as well as those expressing only the common polysaccharide, suggesting 
that this confers no protection against serum mediated killing (Dasgupta et al., 1994). .  
Serum resistance of clinial and lab strains is not due to an inability to activate complement 
(Borowski and Schiller, 1983; Pier and Ames, 1984; Schiller and Joiner, 1986; Schiller, 
1988). However there have been no studies specifically examining the serum sensitivity of 
strains isolated from patients with non CF bronchiectasis. 
 
Both rough and smooth strains are able to activate complement although interestingly it has 
been shown that although the serum resistant strain consumed more C3, C5 and C9, there was 
significantly less C3 and C9 bound to the outer membrane of the serum resistant strain in 
comparison to a serum sensitive strain (Schiller and Joiner,1986).  This led to the hypothesis 
that perhaps the presence of long chain O-antigen was protective in inhibiting stable insertion 
of the membrane attack complex at the cell membrane by forming a barrier.  The same study 
also noted that a much greater proportion of activated C3 was able to bind to the cell surface 
in serum sensitive strains than in those that were resistant to killing again raising the 
possibility that long chain O-antigen formed a physical barrier to binding or there was an 
poor availability of binding sites for C3 (Schiller and Joiner 1986).   A similar mechanism of 
serum resistance has been shown with strains of other gram negative organisms including 
Salmonella minnesota and Eschericia coli suggesting that there is possibly a common 
mechanism of serum resistance in gram negative organisms, with O-antigen protecting from 
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insertion for the terminal products of the complement cascade to the cell membrane (Joiner et 
al., 1982; Goldman, Joiner and Lieve, 1984; Joiner et al., 1984; Taylor and Kroll, 1984).  
Although studies have generally indicated O-antigen expression is required for serum 
resistance its expression does not necessarily mean that the strain will be resistant to serum.  
For example  Dasgupta and colleagues observed that one of two lab strains expressing O-
antigen was sensitive to serum killing (Dasgupta et al., 1994). An ultrastructural analysis of 
these strains by the same group noted that the distribution of long O-antigen side chains may 
influence serum sensitivity as the strain noted to be sensitive to killing by healthy control 
serum had a patchy distribution of LPS over its surface whilst the resistant strain had an 
extensive coat on the outer leaflet of the outer membrane suggesting that it may not be the 
presence of long chain O-antigen alone which confers resistance, but the pattern of 
distribution (Lam et al., 1992).  
As a consequence of its immunogenic properties P. aeruginosa LPS has provided a potential 
target for vaccination therapy.  The surface accessibility makes it an ideal vaccine target 
although to date no effective vaccine has been developed despite three vaccine trials targeting 
LPS in CF (see below). 
 
1.3.5   LPS Based Vaccination for P. aeruginosa. 
 
Pseudogen was a heptavalent lipopolysaccharide Pseudomonas vaccine evaluated in twelve 
patients with cystic fibrosis already infected with P. aeruginosa and twenty  two patients with 
acute leukaemia.  This was associated with significant side effects including fever, pain, and 
headache – without any evidence of tolerance with progressive injections.  There was no 
evidence of clearance of P. aeruginosa from the airway secretions, or improvements in lung 
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function. The toxic effects of this vaccine were attributed to lipid A which is recognised for 
its ability as an endotoxin and ability to stimulate the production of pro inflammatory 
cytokines.  It was also considered that it may have increased immune complex formation in 
infected CF patients causing an inflammatory reaction via recruited neutrophils (Pennington 
et al., 1975; Doring and Pier, 2008). 
 
PEV-1 was an improved LPS based polyvalent vaccine (16 serotypes) to investigate the 
prophylactic benefit prior to the onset of P. aeruginosa infection in CF.  It was tested in 17 
patients with CF who were investigated prospectively to determine whether this would 
prevent initial colonisation with P. aeruginosa.  The acquisition of P. aeruginosa was 
unchanged compared to a matched control group at 3 year follow up.  The vaccination group 
also demonstrated a larger fall in peak flow measurement of lung function and decreased 
clinical status based on activity, physical examination, nutrition and x-ray findings.  This trial 
was therefore discontinued (Langford and Hiller, 1984).  
 
Auregen is a octavalent O- polysaccharide conjugate vaccine (conjugated with exotoxin A).  
Initially efficacy of this vaccine in patients not colonised with P. aeruginosa were promising 
compared to a retrospective control group with 35% of the vaccine group acquiring P. 
aeruginosa compared with 75% of subjects expected to become colonised 6 years after 
immunisation.  High levels of IgG antibodies were induced against all nine antigens which 
began to decrease rapidly after immunisation but were restored by annual boosters.  This 
regimen ensured a significant mean polysaccharide specific serum IgG level was maintained 
over a ten year period in the vaccinated uninfected group.  A decade after immunisation there 
were significant reductions in P. aeruginosa infection and improved health status in the 
vaccination group (Zuercher et al., 2006).  
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The success of this unblinded study led to a double blind, randomised placebo controlled 
large group phase III study which failed to find a benefit and further development was 
suspended.  The full results have not been published and thus the reasons for failure remain 
unknown (Sharma, Krause and Worgall, 2011).  
 
LPS and O-antigen would seem to be optimal targets for a vaccine in P. aeruginosa yet to 
date human trials have been unsuccessful and in some cases appear to be detrimental.  
Vaccines to target P. aeruginosa antigens of flagellae and outer membrane proteins have 
shown some promise but are still in early stages of development (Sharma, Krause and 
Worgall, 2011) and are not discussed here. 
 
1.4  Pseudomonas aeruginosa Colonisation in Non Cystic Fibrosis Bronchiectasis. 
 
Bronchiectasis is characterised by the clinical symptoms indicative of an ongoing 
inflammatory response in the host lungs.  The vicious cycle hypothesis of bronchiectasis 
describes the ongoing interaction of ineffective host defences, neutrophilic inflammation and 
persistent bacterial colonisation.  P. aeruginosa is a colonising organism of particular interest 
in this condition in part due to its association with worsening clinical parameters, but also 
because its inherent behaviours, adaptability and ability to protect itself from, and interact, 
with host defences. These data suggest a greater understanding of the interaction with host 
defences may provide pivotal data to develop targeted therapies for this pathogen which is 
largely resistant to common antibiotics.  Its complexity also suggests that there is an 
opportunity to explore other features of P. aeruginosa that may enhance its ability to colonise 
the host and perpetuate inflammation. 
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1.5   Hypothesis 
 
The publication of evidence of dysregulated adaptive immunity in the serum of HIV infected 
individuals with Salmonella Typhimurium (S. Typhimurium)  suggested a specific interaction 
of the host immune system with pathogens.  Here, there was inhibition of serum killing due to 
production of excess inhibitory IgG antibodies directed against S. Typhimurium LPS.  When 
IgG was removed and added to HIV uninfected serum, normally able to kill S. Typhimurium, 
inhibition of bacterial killing was confirming anti LPS IgG as an inhibitor of S. Typhimurium 
serum killing (MacLennan et al.,2010).  
 
A review of the literature, revealed that the concept of inhibitory or blocking antibodies in 
association with Gram-negative infections and specifically P. aeruginosa had been raised in 
the past without identification of the specificity of the bacterial / host interaction/s.  Initially 
an inhibitory factor in the serum of patients with chronic Gram-negative infections, 
preventing normal serum killing of these organisms was noted without identification of its 
nature (Waisbren and Brown, 1966). Blocking IgG was then identified in the serum of a 
patient with chronic P. aeruginosa infection (Guttman and Waisbren, 1975), with inhibition 
of serum killing by autologous serum also noted in patients with P.  aeruginosa and CF, 
compared to healthy serum (HØlby and Olling, 1977).  
 
Hornick and Fick described IgG2 containing immune complexes in the serum of CF patients 
chronically colonised by P. aeruginosa which inhibited phagocytosis and serum killing of P. 
aeruginosa with an associated elevated level of IgG2 in the serum (Hornick and Fick 1990). 
Finally, an association between CF patients and poorer clinical status was reported with 
inhibitory sera to their own strains which were sensitive to killing in normal healthy serum, 
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and therefore indicative of an inhibitory factor in patient serum, (Thomassen and Demko, 
1981).  
 
These observations led to the hypothesis that a similar phenomenon may be present in the 
serum of patients with bronchiectasis and chronic P. aeruginosa colonization, providing an 
explanation to the failure of host defenses to sterilize the airway 
 
1.6   Aims of my MD thesis 
The aims of my thesis were to collect serum and sputum samples in a well characterised 
group of patients with bronchiectasis. 
Where P. aeruginosa was identified as a colonising organism, experiments would be 
focussed on the presence of serum sensitivity of these strains using both patient and healthy 
control serum.   
If, in keeping, with previous studies of P. aeruginosa in CF, a discrepancy was found 
between strains sensitive in healthy serum but resistant to killing in autologous serum, further 
experiments would be undertaken to identify the mechanism. 
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CHAPTER 2 THESIS METHODS 
 
 
2.1 Patient Selection and Diagnosis 
Patients were recruited from the National Health Service bronchiectasis clinic at the Queen 
Elizabeth Hospital, Birmingham.  Patients were referred both from primary care physicians 
and from secondary health care providers, mainly respiratory physicians, for specialist 
management of bronchiectasis.    Patients with cystic fibrosis were also recruited for research 
purposes from the specialist cystic fibrosis clinic at New Cross Hospital, Wolverhampton.   
Approval for this study was given by South Birmingham Research Ethics Committee and by 
University Hospital Birmingham NHS Foundation Trust Research and Development 
Committee (07/H1207/231). Informed and written consent was obtained from each subject 
(Study Code:RRK3404).  Unselected patients routinely attending this clinic were invited to 
take part in this study to identify particular groups of patients with non-CF bronchiectasis by 
proving sputum and blood samples for research purposes at their out patient appointments 
with no need for extra outpatient visits.   
 
Each patient recruited had a diagnosis of bronchiectasis confirmed by High Resolution 
Computed Tomography scan (HRCT).  A full medical history was obtained from each 
patient, usually at the time of their initial referral and clinical assessment, to establish, where 
possible, any underlying cause of their bronchiectasis.  This was undertaken as part of their 
routine NHS care.  
 
Each patient had pulmonary function testing as part of their usual care.  Pulmonary function 
tests were performed by trained respiratory physiologists in the department of lung function 
  51 
and sleep at the Queen Elizabeth Hospital.  All tests were performed according to national 
guidelines. (British Thoracic Society and Association of Respiratory Technicians and 
Physiologists).  Pre-bronchodilator values of Forced Expiratory Volume exhaled at the end of 
the first second of forced expiration (FEV1) and Forced Vital Capacity (FVC) were recorded 
for each patient. 
 
Medical Research Council (MRC) dyspnoea scores were recorded for each patient.  This 
scale is a measurement of the disability experienced as a result of dyspnoea.  It is shown in 
table 2.1.  Information regarding MRC dyspnoea scores, was collected using information 
taken as part of the patients assessment at their routine clinic attendances.   
 
The St Georges Respiratory Questionnaire (SGRQ) was used to assess health related quality 
of life.    This was collected on one occasion at the time of recruitment to the study. The  
SGRQ (Jones, Quirk and Baveystock, 1991) is a self-administrated, health related quality of 
life questionnaire designed to measure impact on overall health, daily life and perceived well- 
being in patients with obstructive airways disease.  It consists of 50 items.  Each 
questionnaire response has a unique empirically derived weight.  Three component scores are 
calculated (symptoms, activity and impacts) in addition to a total score which summarises the 
impact of the disease on overall health status.  Scores range from 0 – 100 with higher scores 
indicating more impairment.  Each component score is calculated by dividing the summed 
weight by the adjusted maximum possible weight for the component and expressed as a 
percentage. The total score is calculated in the same manner. Although initially designed as a 
tool for assessing the impact of COPD on quality of life it has also been validated for use in 
non cystic fibrosis bronchiectasis (Wilson et al., 1997). 
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Grade Degree of Breathlessness 
1 Not troubled by breathlessness except on strenuous exercise. 
2 Short of breath when hurrying on a level or when walking up a slight hill. 
3 Walks slower than most people on the level, stops after a mile or so, or has 
to stop for breath walking at own pace. 
4 Stops for breath after walking 100yds, or after a few minutes on level 
ground. 
5 Too breathless to leave the house, or breathless when dressing/undressing. 
Table 2.1 MRC dyspnoa scores.  (Bestall et al., 1999) 
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Patients were also routinely asked about the number of exacerbations they had experienced 
between each clinic appointments. Most patients attended clinic regularly every 4-6 months 
and therefore the period of recollection for exacerbation history was short and many recorded 
this data in a daily symptom diary.  Information regarding all hospital attendances related to 
bronchiectasis was available on electronic hospital records.  Where patients had been 
admitted to hospital other than the Queen Elizabeth University Hospital Birmingham, the 
information was recorded at their next clinic attendance.   Patients recruited to the study had a 
number of different organisms isolated from sputum.  The focus of the work on this thesis is 
with regards to P. aeruginosa and thus much of the discussion focuses on those identified as 
being colonised with P. aeruginosa.   
 
2.1.1 Blood Sample Collection  
 
Each patient had blood samples collected for serum (collected in Z serum clot activator tube), 
plasma (collected in EDTA tube) and DNA (collected in EDTA tube and stored as whole 
sample).  Venous blood was taken peripherally using the vacutainer® system (Becton 
Dickson Ltd Oxford UK). The serum and plasma samples were harvested by centrifuging the 
blood samples at 1500g for 10 minutes at room temperature.  Blood was processed within 2 
hours of collection and serum and plasma were stored in aliquots at -80ºC until required.  
Blood was processed in the same manner from healthy control subjects. 
 
2.1.2 Sputum Sample Collection and Processing 
 
Sputum was usually processed by grading and recording purulence using the Bronkotest 
colour chart, and storage of sol phase and quantitative bacterial culture established within 2 
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ho rs of  olle  ion a   he  ime of pa ien ’s  lini  a  endan e.  Where this was not possible 
arrangements were made for the patient to attend the research unit at a convenient time, to 
bring a sample of sputum produced on that day.  Matched serum/plasma samples were taken 
at the same time.  Repeated samples were taken when the opportunity arose as the patient 
attended for a usual NHS follow up. 
 
Sputum colour was assessed using a 5 point grading system.  This ranges from 1-2 (clear to 
white) which is classified as mucoid.  3-5 (yellow to green), which is classified as 
mucopurulent to purulent.  This is utilised clinically where patients are encouraged to monitor 
the colour of their sputum with increasing purulence from their baseline being indicative of 
an exacerbation.  This visual grading of sputum correlates to the degree of activity of the 
underlying markers of airway inflammation.  
 
Sputum sol phase was obtained by ultracentrifugation of a minimum of 1g of sputum 
(29,000xg for 90 mins at 4q).  The supernatant was removed and stored at -80qC until use.  
Quantitative bacterial culture to determine the number of viable organisms was performed as 
follows.  A minimum of 1 gram of sputum was removed from the fresh sample and added to 
an equal volume of dithiothreitol (Sputasol, Oxoid, UK).  1000PL of the homogenised 
sputum sample was then serially diluted with distilled water creating dilutions from 10-1 to 
10-5.  One chocolate agar + PolyVite X (chocolate) plate was inoculated with 5Pl of the initial 
homogenised sputum sample to create a primary inoculum plate using the 4 streak method to 
ensure viable numbers of bacteria.  Then 10Pl of dilutions 10-3, 10-4, 10-5 were taken and used 
to inoculate a Chocolate agar and PolyViteX plate and a Columbia Agar +5% Horse blood 
(blood) plate (BioMerieux) – in the case of 10-4 dilution only and spread across the whole of 
the surface of the plate using a hockey stick.  These plates were incubated for 24-48 hours 
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(37qC, 5% CO2) and the number of colonies counted from the appropriate plate.  The number 
of colony forming units per ml (cfu/ml) was then calculated based on the dilution.   
 
2.2 Identification of Bacterial Species 
 
Bacterial species were preliminarily identified using the morphological appearance of 
bacterial growth on the culture plates according to local laboratory guidelines shown in tables 
2.2 and 2.3. Further tests including Gram staining, and functional testing were performed to 
confirm bacterial species.  Specific functional tests utilised for species identification are 
discussed. 
 
2.2.1 Oxidase Reaction 
 
The oxidase test is a biochemical reaction that assays for the presence of cytochrome oxidase 
(indophenol oxidase).  Oxidase positive bacteria contain the enzymes cytochrome oxidase 
and therefore the oxidase test can be used to differentiate between organisms which possess 
this enzyme and those which do not.  Cytochrome oxidase catalyses the transport of electrons 
from donor compounds to electron acceptors.    The test reagent N,N,N’,N’- tetra – methyl – p 
– phenylenediamine dihydrochloride (1% solution) acts as an electron acceptor for the 
enzyme oxidase.  The reagent turns blue, forming indophenol blue, in response to being 
oxidised (Gov.uk, 2017).    Reagent was added to colonies either by touching colonies on a 
growth plate with filter paper or swab soaked in reagent or scraping colonies from the growth 
plate on to an impregnated oxidase test strip.  
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 Table 2.3  G
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portant respiratory pathogens.  G
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B-haemolytic streptococci 
Staphylococcus 
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2.2.2 Catalase Test 
 
The catalase test detects this enzyme in bacteria and thereby differentiates between those 
which are catalase positive and those which are negative.  The catalase enzyme serves to 
neutralise the bactericidal effects of hydrogen peroxide by facilitating the breakdown of 
hydrogen peroxide (H2O2) into water and oxygen.  The reaction is identified by the formation 
of bubbles (UK Standard for Microbiological Investigations. Gov.uk, 2017). 
 Bacterial colonies were added to 3% H2O2 (Sigma-Aldrich) either in a test tube or on a 
microscope slide and observed for the rapid bubble formation. 
 
2.2.3 Optochin Susceptibility Test 
 
The optochin susceptibility test is used to differentiate S. pneumoniae from other haemolytic 
Streptococci.  Colonies were streaked onto blood agar medium and a filter paper disc 
impregnated with ethylhydrocupreine hydrochloride - optochin (Oxoid UK) was placed in 
this area and the plate incubated for 24 hours.  As pneumococci are lysed by optochin an 
inhibition zone is created around the disc if the colonies are pneumococci. A zone of 
inhibition >5mm is indicative of S.pneumoniae . Less than 5mm requires further investigation 
wi h Slidex pne mo ki  (Bio erie x).  Here  several  olonies of s spe  ed α- haemolytic 
species are emulsified in sterile saline before 2 drops are placed on a slide.  A drop of reagent 
R1 (latex S. pneumonia) and R2 (latex negative control) are added to each smear and mixed.  
A positive reaction shows distinct agglutination within 2 minutes whilst a negative reaction 
remains as a homogenous suspension or with only slight agglutination which does not 
intensify. (UK Standard for Microbiological Investigations. Gov.uk, 2017). 
 
  59 
2.2.4 Tributyrin Hydrolysis Test 
 
The tributyrin hydrolysis test is a chromographic test used to differentiate between Moraxella 
catarrhalis and Neisseria sp and relies on the production of the enzyme butyrate esterase by 
M. catarrhalis.  (Perez et al., 1990)   2-3 similar colonies were emulsified in sterile saline 
before the addition of a tributyrin tablet (Rosco).  This suspension was incubated at room 
temperature for 2- 4 hours.  A positive test was indicated by a yellow/yellow orange colour 
change indicating the presence of butyrate esterase.  Negative tests were red. 
 
2.2.5 Physiological Tests of Haemophilus influenzae and Haemophilus species 
 
It may not be possible to differentiate between H. influenzae and other Haemophilus sp. such 
as H. parainfluenzae, H. haemolyticus. H. parahaemolyticus based on morphological 
appearances on growth media alone.  Instead, the fastidious growth requirements of these 
strains was used to differentiate between the species.    
H. influenzae requires supplementation with both hemin (X factor) and Nicotinamide 
Adenine Dinucleotide - NAD (V factor) for growth, while Haemophilus parainfluenzae 
requires only NAD (V) supplementation.   Both factors are normally present in blood.  
Therefore testing was performed by placing discs containing either factor V or both factor V 
and X (Thermo Scientific) onto nutrient agar (BioMerieux 33606) with the colony to be 
tested.  As both factors are present in blood it was crucial that blood containing agar is not 
transferred from the original plate when the colony to be tested was picked.   
Inoculated plates were incubated at 37ºC for 18-48 hours in 5% CO2 and observed for growth 
around each disc margin.  If X and V factors were both required, as in the case of H. 
influenzae, growth was only observed around that disc margin.   
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Where H. influenzae was iden ified i  was s ored in 800μl s pplemen ed Brain Hear  inf sion 
bro h +200 μl gly erol a  -80°C until required. 
 
 
2.2.6 Pseudomonas aeruginosa Isolation 
 
The presence of P. aeruginosa was further confirmed following functional testing by 
inoculating Pseudomonas Selective Agar (BioMerieux) with a colony of Pseudomonas taken 
from the original chocolate agar plate.   Where confirmed, each species identified was then 
stored in glycerol stock (800µl culture in Luria Bertani Broth (LBB) + 200µl glycerol at -
80ºC until required. 
 
2.2.7 Analytical Profile Index (API) Identification of Pseudomonas Species 
 
The Analytical Profile Index (API) is a miniaturized panel of biochemical tests compiled for 
identification of groups of closely related bacteria. (BioMerieux) 
 
The API-20NE test kit was used to identify the precise strain of Pseudomonas where it was 
isolated from sputum using the methods described previously.   This standardised system uses 
an API 20 NE strip with 20 microtubules containing dehydrated substrates which, when 
inoculated with a distilled water bacterial suspension (3-4 colonies emulsified in 4mls of 
distilled water), reconstitutes the media during 24-48 hours incubation (according to the 
manufacturers instructions) if the bacteria are capable of growth by utilising the respective 
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substrate.  These changes are evidenced by colour changes either spontaneously or by the 
addition of reagents.   
The reactions were converted to a seven digit code.  This numerical profile was then entered 
in o  he man fa   rer’s da abase (h  ps://apiweb.biomerie x. om) or  orrela ed wi h  odes in 
the database book, to identify the precise genus and species of Pseudomonas.  
2.3 Bacterial Cultures in Liquid Media 
 
P. aeruginosa was grown in LB (Lysogeny) broth (LBB) by placing a colony in 5-10mls of 
media and incubating overnight with shaking at 37ºC. 
H. influenzae was grown in supplemented brain heart infusion broth (BHI) by placing a 
 olony in 5mls BHI + 5µl β-ni o inamide adenine din  leo ide (β NAD) (Sigma) + 100µl 
haemin (Sigma).  This was incubated at 37qC for 4 hours. 
 
2.3.1. Growth Curves (Pseudomonas) 
 
Growth curves for individual strains of P. aeruginosa were performed at 37ºC. Growth 
curves were performed by placing a colony of each strain into LBB and incubating at 37ºC.  
After 2 hours of incubation the optical density at an OD:600 of each strain was measured at 
regular 30 minute intervals until stationary phase was reached.  Figure 2.1 shows the normal 
phases of growth of bacteria.  This is not specific for P. aeruginosa and is a visual 
representation of the growth phases of bacteria generally. 
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Figure 2.1 shows an example of the phases of a bacterial growth curve.  During lag phase 
bacterial cells are maturing and are not yet able to divide.  During Log phase the number of 
cells doubles at a constant rate.  During stationary phase the population levels off as cell 
death equals cell doubling and death phase sees the death of bacterial populations due to lack 
of nutrients, or an adverse environment or temperature for continued growth.  
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2.4 Bactericidal Assays 
2.4.1 Pseudomonas aeruginosa Bactericidal Assays 
 
This protocol was adapted from that used by MacLennan et al (MacLennan et al., 2010), 
Briefly, stationary phase bacterial cultures were prepared by adding a colony of P. 
aeruginosa to 5 mls of LBB.  These were vortexed and incubated overnight at 37ºC.   
The following day optical density (OD) at 600nm (OD600) was measured for each strain and 
the volume of culture media to be used standardised to 1.5mls OD600= 0.6.   This was 
optimised to ensure a standard number (108) bacteria were present in the inoculum cultures.  
Pseudomonas isolates were washed by spinning at 10,000 rcf for 5 minutes.  The supernatant 
was removed and bacterial pellets resuspended in 1ml of PBS.  This was repeated and 
bacterial pellets resuspended in 900 µl PBS.  One hundred µl of this stock inoculum was then 
added to 900 µl PBS making a 10-1 dilution.  Ten µl of dilution 1 was added to 90 µl serum , 
and incubated at 37ºC on a rocker set at 180 rpm for 180 minutes with samples taken at T1 
(45 minutes), T2 (90 minutes) and T3 (180 minutes).   
To determine inoculum concentration 10µl of the stock inoculum was serially diluted using a 
multichannel pipette along 8 wells of a 96-wellplate filled with 90 µl PBS in each well.  A 
Miles and Misra plate (Fig 2.2) was prepared for the inoculum and incubated overnight at 
37ºC.  At each time point (45, 90 and 180 minutes) 10 µl of serum was taken from each 
sample and added to 90 µl PBS in a 96-wellplate and serially diluted along 4 wells of the 
plate.  For each sample in a row of wells, a Miles and Misra plate was prepared which was 
also incubated overnight as above.    Three x 10 µl spots of each dilution were pipetted on to 
the corresponding wedge on the Miles and Misra plate. The following day the colonies that 
grew in a wedge (where the average number was equal to ten or greater) were counted and 
the colony counts plotted on excel to observe the serum killing trend. 
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Figure 2.2 depicts the method used for performing bactericidal assays of P. aeruginosa.  
Following incubation of stationary phase cultures with both patient and healthy control sera, a 
Miles and Misra plate was prepared at each time point (45, 90 and 180 minutes).  The 
following day colonies were counted following overnight incubation.  
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2.5 Preparation of Serum 
2.5.1 Size Fractionation 
Fractionation of serum was performed using size exclusion columns (Vivaspin – GE 
Healthcare) with either 30, 100 or 300 kDa size-exclusion membranes enabling broad 
separation based on molecular weight.  Initially 1ml of serum (from either healthy control 
samples or patient serum) was run through the 300kDa exclusion column via centrifugation 
which retained ~200ul of the serum fraction with weight over 300kDa.   The flow through 
fraction containing proteins with molecular weight <300kDa was then standardised back to 
1ml with PBS and the procedure repeated consecutively with 100kDa and 30kDa size 
exclusion columns.    All fractions (>300kDa, 100-300kDa, 30-100kDa and <30kDa) were 
standardised to 1ml by the addition of PBS. Bactericidal assays were then performed with 
these preparations of differing molecular weight.   
 
 
2.5.2 IgG Isolation and Extraction  
IgG was removed from serum using Protein A-sepharose 4B (Sigma P9424) and Protein G-
sepharose (GE Healthcare).  Protein A and protein G are both isolated from the bacterial cell 
wall of Staphylococcus aureus and group G Streptococci (Bjorck et al., 1984).  Both have a 
high affinity for the Fc regions of IgG molecules but have different affinity for the subtypes. 
Immobilisation of protein A creates an affinity resin that can be used to isolate IgG fractions 
from serum whilst Protein G-sepharose, though similar, does not bind IgG3.  The respective 
binding capacity of protein A and protein G to all immunoglobulin classes in human serum 
are shown in table 2.4. 
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Immunoglobulin Binding Protein A Binding Protein G 
IgG1 High High 
IgG2 High High 
IgG3 No affinity High 
IgG4 High High 
IgA Moderate/slight affinity No affinity---- 
IgM Moderate/slight affinity No affinity. 
Table 2.4  Binding affinities to Human IgG subclasses of Protein A and Protein G.  
(Abcam.com, 2017) 
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The human serum used in the following experiments had total immunoglobulin levels and 
subclass levels measured by the routine immunology laboratory at the Queen Elizabeth 
hospital.  (IgG 6.00-16.00g/L, IgA 0.80-4.00g/L, IgM 0.50-2.00g/L).   
 
2.5.3   IgG isolation Using Protein A-sepharose 4B 
 
The binding capacity of protein A- sepharose was approximately 35mg/ml human IgG 
according to manufacturers guidelines.  Antibody was isolated following manufacturers 
(Sigma) guidelines. Briefly, 1.2 ml of resin was added to 1 ml of buffer A (0.02M NaH2PO4 
+ 0.15M NaCl).  This was poured into the column and washed with 20 mls of Buffer A.  1 ml 
of serum was then added with aliquots of flow through collected in 250 µl aliquots.  The resin 
was further washed with 10 ml of buffer A.  Elution was then carried out by adding 3 ml of 
buffer B (0.2 M Na2HPO4 + 0.1M C6H8O7) pH 3.  The eluted IgG was then neutralised with 
1M Tris (tris(hydroxymethyl)aminomethane HOCH2)3CNH2).  Bactericidal assays were then 
performed using the collected aliquots of serum and eluted IgG. 
 
2.5.4 IgG isolation Using Protein G-sepharose  
 
The binding capacity of protein G- sepharose 4B was > 20mg/ml human IgG according to 
manufacturers guidelines.  The resin was prepared as per manufacturers instructions.  Briefly, 
1 ml of serum sample was loaded on to the column lined with the resin.  This was washed 
with 3 mls of starting buffer and the flow through recovered in 500 µl aliquots.  The column 
was then washed with a further 8 mls of starting buffer.  IgG was eluted with 4 mls of 100 
mM glycine as specified and brought to a neutral pH with 1M tris.  Bactericidal assays were 
performed with the recovered serum aliquots and the eluted IgG. 
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2.5.5 LPS Specific Antibody Extraction 
 
Anti-LPS antibodies were removed from serum by first binding patient bacterial 
lipopolysaccharide (LPS) to polymyxin-B agarose (Sigma, P1411) overnight.   Polymyxin B 
has an affinity for bacterial cell membranes and, when immobilised on agarose, is used to 
remove endotoxins from solutions.   The polymyxin B agarose has a binding capacity of 500 
µg/ml so should be saturated with Pseudomonas LPS. This resin lined the column similarly to 
that described above and was extensively washed with 10ml of 0.1M ammonium bicarbonate 
buffer (pH8.0).   One ml serum was then passed over the column and aliquots collected.  The 
column was washed with 10 column volumes of wash buffer.  Bound antibody was eluted 
with a pH gradient using a citric acid buffer and the eluted protein was then buffer exchanged 
into PBS.   
 
2.5.6 Buffer Exchange 
 
Where necessary column fractions were buffer exchanged into PBS using 30kDa MW viva-
spin columns. Samples were added to the top of the column and spun. Flow through was 
discarded and the retained fraction washed/ diluted in 10x the original elution volume of 
PBS. The sample was re-spun and the retained fraction resuspended in PBS to the original 
elution volume.   
 
Protein concentration of serum/ flow through fractions was determined with the Bio-Rad 
Pro ein Assay ki  following man fa   rer’s ins r   ions.   The varying  olo r  hange in 
response to differing protein concentrations when measured at 595 nm with a microplate 
reader, provides a relative measurement of protein concentration in comparison to a standard 
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curve.  The standard used for determining approximate protein concentrations was Bovine 
Serum Albumin (BSA). (Bio-rad.com) 
 
2.5.7 Positive Selection of IgG2 Fraction of Serum. 
  
IgG was first purified from serum using Protein A –agarose (IgGBindTM resin) as previously 
described.  This serum fraction was buffer exchanged into PBS using ultrafiltration columns 
(Vivascience).  Following this, the purified IgG antibody in PBS was run through an anti-
human IgG2 monoclonal HP6200-sepharose column with the aim of isolating the IgG2 
subgroup of IgG by binding to the specific antibody.  The retained IgG2 was then eluted with 
0.1M citrate to a pH of 2.8 and then 2.3.  It was equilibrated in PBS before finally being 
neutralised with TRIS (pH 9.1) (Jefferis et al, 1992).   Flow through was collected and both 
the flow through fractions and elute were retained for use in bactericidal assays.   
 
2.5.8 Complement Inactivation 
 
Inactivation of serum complement was achieved by heating serum to 56ºC in a waterbath. 
This was then immediately used in for bactericidal assays with the protocol described above. 
 
2.6 Antibody – Binding Assay (Pseudomonas) 
2.6.1 Preparation of Stock Inoculum 
 
Initially stock inoculum was prepared using stationary phase cultures prepared as previously 
described.  Log phase inoculums were then generated by transferring 100µl of overnight 
culture to 10ml of LB broth and incubating at 37ºC to an OD600 :0.6 on a rocker plate.  One 
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point five mls of bacteria was then pelleted by spinning for five mins at 10,000rcf.  
Supernatant was aspirated and the pellet resuspended in 1ml of PBS.   This was then spun in 
a 1.5ml microcentrifuge tube at 6000rpm for 5 minutes to pellet the bacteria and the 
supernatant was removed before adding 1ml of PBS and repeating x1.  A final volume of 1ml 
PBS was added and vortexed to resuspend (stock inoculum) giving a final concentration of 
>2x109/ml bacteria. 
This phase was later adapted to use stationary phase cultures. 
Stationary phase cultures were prepared as described.  The volume of culture to be processed 
was determined by measuring the optical density (OD600) of each strain to standardise the 
concentration of bacteria used with all strains as before and resuspended in 1ml PBS.  The 
volume used was calculated as 1000/OD600 for each strain. 
At this stage a Miles Misra plate was prepared as previously described using serial dilutions 
of 10µl stock innoculum.  This was incubated overnight and the stock inoculum 
concentration determined by counting colonies the following day. 
Paraformaldehyde (PFA 300µl 4%) was then added to the stock inoculum to fix the bacteria. 
 
2.6.2  Determining Levels of Antibody-Binding Through Fluorescent-Activated Cell 
Sorting 
 
A 1:10 dilution of thawed serum was prepared in 1xPBS and 5 µl of 4% PFA fixed stock was 
added to 45µl of serum in a microcentrifuge tube.  Forty-five µL of PBS was used as the 
negative control. 
These tubes with serum and PBS were then vortexed and incubated for 20 minutes before 
adding 1ml PBS to each tube and then centrifuging at 6000 rcf, pouring off supernatant, 
racking the tubes and then adding 750 µl PBS and mixing by inversion.  This was repeated 
  71 
once more without the 750 µl of PBS and 50µl of supernatant remained in the 
microcentrifuge tube. 
Two µl anti-Human IgG1/IgG2/IgG3/IgG4/IgA/IgM – FITC (Fluorescein isothiocyanate) 
antibody was then added to each tube as appropriate and mixed by pipetting. 
This preparation was incubated in the dark for 20 minutes and then   1 ml of PBS was added 
and the bacteria pelleted at 6000rpm for 5 minutes.  Supernatant was poured off and the tubes 
were racked before adding 1ml of PBS and mixing by inversion.  This was repeated and 
200µl 4% PFA was added to each tube.  These were then vortexed and transferred to FACS 
tubes before running samples on the flow cytometer.    
 
2.6.3 Fluorescent-Activated Cell Sorting (FACS) Protocol 
 
Bacterial cells labelled as above, were resuspended in 0.5 ml PBS and analysed by flow 
cytometry using FACSAria II (BD Biosciences) equipped with 13 mW 488 nm solid state 
laser. The flow rate was usually adjusted to analyse 1000-2000 events/sec and 104 events per 
sample were recorded. The ND filter used was 1.0 and typically, the voltages used were: 
FITC (green fluorescence) – 450, FSC (forward scatter) and SSC (side scatter) – 280-300. A 
discriminator of 1000 was used on FSC to reduce electronic and small particle noise. Green 
fluorescence from FITC-labelled secondary antibody was collected using standard FITC filter 
set (502LB, 530/30BP). Data acquisition and analysis were undertaken using FACSDiva 
software (BD Biosciences). The labelled negative control sample was used to establish the 
baseline FITC fluorescence level. In the test samples the fluorescing and non-fluorescing cell 
populations were gated, quantified (percentage of parent population) and relevant parameters 
(FITC mean and median) were calculated using FASCDiva software.  
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2.6.4 Complement Deposition Assay 
 
Preparation of stock inoculum was as documented for measuring antibody deposition. 
Two µl anti-Human C1q/C3-FITC/anti-Human C5b-9 antibody (DAKO) was added to the 
microcentrifuge tubes containing a mixture of stock inoculum and dilute serum as 
appropriate.  These were processed as previously described in section 2.6.2. 
C1q/C3 samples – supernatant was poured off before racking the tubes and adding 200µl 
PBS with 1% formaldehyde to each tube. 
C5b-9 samples – Supernatant was aspirated leaving 50µl which was then resuspended by 
pipetting up and down. 
Two µl rabbit-anti-mouse-FITC antibody (DAKO) was added to each tube and mixed by 
pipetting. Samples were incubated in the dark for 20 minutes and then treated as previously 
described for measuring antibody deposition. 
Monoclonal Mouse Anti-Human C5b-9 (M0777) was used to label the C9 component in the 
C5b-9 complex – Membrane Attack Complex (MAC), one of the terminal products of the 
complement cascade. 
Anti- Human C3 antibody (F0201) reacts with isolated human C3c complement and the C3c 
part of C3 and C3b.  The cleavage of C3 to C3a and C3b is a crucial step in the complement 
cascade where all three pathways merge. 
Anti Human C1q Complement (F0254) was used to bind to C1q , the first component of the 
classical pathway and part of the C1 complex which links the adaptive humoral immune 
response to the complement system by binding to antibodies complexed with antigens. In 
addition C1q can also bind directly to the surface of certain pathogens and therefore initiate 
the complement response in he absence of antibody 
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2.7 Enzyme-Linked Immunosorbent Assay (ELISA) 
 
Figure 2.3 illustrates the principle of ELISA.  The principles of preparation of ELISA using 
LPS antigen specific to Pseudomonas aeruginosa strain P1A are shown below.  
 
2.7.1 Coating of ELISA Plates with Lipopolysaccharide Antigen 
 
LPS Antigen from B4 Pseudomonas strain was prepared in coating buffer (Na2CO3 ( 0.015M) 
+ NaHCO3 (0.035M) pH 9.6) to roughly a concentration of 100ug/ml and 100µl was added to 
each well of a 96 well microtitre plate as previously described.    The plate was placed in a 
humid chamber and incubated overnight at 4ºC (overnight coat) or alternatively for 1 hour at 
37ºC. 
 
2.7.2 Blocking of ELISA Plates with Bovine Serum Antigen (BSA) 
 
The overnight coat was shaken off and plates washed three times with wash buffer (0.1M 
PBS, pH 6.8 + 0.05%Tween 20) by immersing the plates in buffer and dry knocking on the 
bench onto a paper towel. 
Blocking buffer (0.1M PBS,pH6.8 +1% BSA) was added (200µl/well) and  plates were 
placed in a humid chamber and incubated for 60-90minutes at 37ºC.   
 
2.7.3 Binding of Test Serum Antibodies to LPS 
 
The microtitre plate was washed with wash buffer (x3) and the required volume of dilution 
buffer (0.1M PBS pH6.8+0.05% Tween 20+1% BSA) was added to each plate and the 
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required volume of test serum was added to rows 1-7 of the 96 wells.  A dilution series was 
performed down 6 rows of the microtitre plate ensuring mixing by pipetting up and down, 
with 50µl discarded from the final well leaving a total volume of 100µl per well. The plate 
outlay is shown below (Fig 2.4).  Plates were then placed in a humid chamber and incubated 
for one hour at 37ºC. 
 
2.7.4 Secondary Antibody Binding to Test Serum Antibodies 
 
Secondary antibodies were prepared in a 1:2000 dilution with dilution buffer (Southern 
biotech Goat Anti-human IgG (2047-04)/IgA(2050-04)/IgM(2020-04-AP as appropriate.  The 
microtitre plate was washed with wash buffer (x3) before adding 100µl of 1:2000 secondary 
antibody/well to the appropriate plate and then placed in a humid chamber for incubation for 
1 hour.   
 
2.7.5 Determination of Test Serum Antibody Concentration Through Measurement of 
Signal 
 
The microtitre plate was washed in three times in wash buffer  before antibody concentrations 
were determined by measurement of signal using SIGMAFAST p-Nitrophenyl phosphate 
substrate (1x TRIS buffer and 1xPNPP tablet/20ml d H2O) substrate. 
One hundred µl substrate was added per well and the OD was measured at 5 minute intervals 
using the ELISA reader. 
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Figure 2.3 depicts ELISA using bacterial LPS bound to a 96 well plate and utilising test 
serum (patient or healthy control sera) as primary antibody with secondary antibodies anti 
human IgA, IgG or IgM bound to test serum antibodies.  The level of binding of test serum 
antibody to LPS was determined by colour change observed in ELISA reader.   
 
 
 
 
 
 
 
 
1.  Bacterial LPS bound 
to 96 well plate.
2.  Binding of serum 
antibodies to bacterial 
LPS.
3.  Secondary 
antibody binding to 
serum antibodies.
4.  Addition of 
substrate.
Serum 
antibodies
Secondary 
antibody
Substrate
5.  Colour change 
observed and 
quantified in elisa
reader.
1
2
3
4
5
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Sample 1 2 3 4 5 6 7 8 
1                                 7.5µl                         Serum 
1:20                         142.5µl                     PBS/BSA/Tween                           ↓ 50µl  
Control 
1:20 
2                  
1:60                         100µl                        PBS/BSA/Tween                           ↓ 50µl 
Control 
1:60 
3                  
1:180                       100µl                        PBS/BSA/Tween                           ↓ 50µl 
Control 
1:180 
4                  
1:540                       100µl                        PBS/BSA/Tween                           ↓ 50µl 
Control 
1:540 
5                   
1:1620                     100µl                        PBS/BSA/Tween                           ↓ 50µl 
Control 
1:1620 
6                  
1:4860                     100µl                        PBS/BSA/Tween                           → 50µl 
Control 
1:4860 
Sample 8 999 10 11 12 13 14  
7                                 7.5µl                         Serum 
1:20                         142.5µl                     PBS/BSA/Tween                           ↓ 50µl  
Control 
1:20 
8                 
1:60                         100µl                        PBS/BSA/Tween                           ↓ 50µl 
Control 
1:60 
9                   
1:180                       100µl                        PBS/BSA/Tween                           ↓ 50µl 
Control 
1:180 
10                  
1:540                       100µl                        PBS/BSA/Tween                           ↓ 50µl 
Control 
1:540 
11                 
1:1620                     100µl                        PBS/BSA/Tween                           ↓ 50µl 
Control 
1:1620 
12                   
1:4860                     100µl                        PBS/BSA/Tween                           → 50µl 
Control 
1:4860 
 
Figure 2.4 shows the serial dilution of test serum binding to LPS bound to a 96 well plate. 
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2.8 LPS and Outer Membrane Preparations 
2.8.1 Isolation of LPS from Pseudomonas strains. 
 
A 5ml overnight culture of bacteria was grown in LB broth at 37ºC.  The OD600 was 
measured for each strain to ensure a standard number of viable bacteria were used and the 
volume spun at 18000rcf for 10 minutes was determined by 1000/OD600.    The supernatant 
was discarded and the remaining pellet resuspended in 100µl of SDS cracking buffer.  (0.1 M 
Tris (pH 5.8), 0.2 M E-mercaptoethanol, 20% glycerol and 2% SDS).  The suspension was 
boiled for four minutes on a heat block before immediately freezing at -80ºC for 5 minutes 
and then boiling again for a further 4 minutes.  These three steps were to ensure full cracking 
of the bacterial cells.    The boiled suspension was spun in a microcentrifuge at 140000g for 2 
minutes before removing 80µl of the supernatant and adding 5µl 5mg/ml Proteinase K 
(Qiagen). Proteinase K cleaves peptide bonds adjacent to the carboxylic group of aliphatic 
and aromatic amino acids and is used for general digestion of protein in biological samples.   
This ensured that LPS containing samples alone were generated.  This 85µl sample was then 
heated at 60ºC for one hour before heating at 95ºC for a further 5 minutes.    Larger amounts 
of LPS were prepared in a similar manner simply by proportionally scaling up volumes of 
bacterial culture used. 
 
2.8.2 Outer Membrane Protein Isolation 
 
Overnight bacterial cultures were prepared as above and cells harvested in the same way.  
The recovered bacterial pellet was resuspended in 20ml of 10mM Tris buffer ph7.4 and 
centrifuged at 10000g, 4ºC for 10 minutes before resuspending in 20ml 10mM Tris Buffer 
pH7.4 containing 2mM PMSF. 
  78 
This was sonicated 5x30 seconds before centrifuging to remove unbroken cells (6000G, 4ºC 
10mins) followed by centrifugation (30000G, 4ºC 90min) to separate the envelope and 
cytoplasmic fractions. 
The pelleted envelopes were resuspended in 10ml 10mM Tris buffer ph 7.4-2% (v/v) 
TritonX-100 and incubated at 25ºC for 15 min to allow solubilisation of the inner membrane. 
The TritonX-100 extracted envelopes were harvested by centrifugation (30000g, 4ºC, 90 
min), before washing in 1ml 10mM Tris x 3 and finally resuspending in 1ml 10mM Tris 
buffer pH 7.4.  This pelleted material contained predominantly outer membrane protein.  This 
was aliquoted into 250µl lots and frozen at -80ºC before use.  
 
2.9 Silver staining 
 
LPS samples were prepared from individual bacterial strains as described.   
Samples were resolved by SDS-PAGE and visualised using a SilverQuest Silver Staining Kit 
(Invitrogen) which provides a rapid and sensitive method for detection of protein and 
polysaccharide products.  
SDS-PAGE relies on a discontinuous buffer system.  Two ions differing in electrophoretic 
mobility form a moving boundary when voltage is applied.  The intermediate mobility of 
proteins causes them to concentrate, into a narrow zone at the beginning of electrophoresis.  
As that zone moves through the gel, the sieving effect of the polyacrylamide gel matrix 
causes proteins of different molecular weights to move at different rates.   The moving 
boundary concentrates the proteins into sharp bands prior to separation (www.bio-rad.com). 
Ten µl of LPS prepared from individual bacterial strains (as described above) were loaded 
onto a precast gel. (Bis-tris precast NuPAGE gel).  Once resolved the gel was fixed to 
eliminate interfering substances and restrict the movement of protein out of the gel matrix.  It 
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was then sensitised with sensitising solution (Ethanol 30ml, Sensitizer 10ml, Ultrapure water 
60ml) to increase the sensitivity and the contrast before being washed with ultrapure water.  
The silver staining agent (Stainer 1ml Ultrapure water 99ml) was then added and binds silver 
ions to the protein before further washing to remove excess stainer.  The image was 
developed with a dilute formaldehyde solution (Developer 10ml, Developer enhancer 1 drop, 
Ultrapure water 90ml) which reduces silver ions to metallic silver on the protein bands 
resulting in visualisation.  The reaction was stopped with stopping solution to prevent 
overdevelopment before washing the gel in ultrapure water.  All solutions were prepared as 
per SilverQuestTM silver staining fast staining protocol version F (Invitrogen). (Rabilloud et 
al., 1994)    
 
2.10 Western Blot 
Silver staining gels of bacterial LPS and outer membrane proteins were prepared as 
previously described.   
 
2.10.1 Western Transfer 
 
Western transfer was performed using the iBlot® Dry Blotting Transfer System (Invitrogen).  
This is a self contained blotting unit used for fast, dry blotting of proteins allowing protein 
transfer in 7 minutes with high detection sensitivity and evenness to a PVDF membrane.   
The ready availability of ions in the gel matrix enable rapid protein transfers.   
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2.10.2 Western Blotting 
 
Western blotting was performed using a 1:200 dilution of patient serum and a 1:5000 dilution 
of either anti-human IgG, IgM, IgA conjugated to alkaline phosphatase (Sigma) before 
detection with NBP-BCIP (nitroblue tetrazolium chloride–5-bromo-4-chloro-3′-
indolylphosphate) as the substrate.    
The membranes produced were incubated in Blotto (5% skim milk powder in 1xTBS buffer) 
for 30 minutes with shaking.  Membranes were then incubated in primary antibody (serum) 
for one hour and then extensively washed with TBST buffer (0.1% Tween 20 in 1x TBS 
buffer) before incubating in secondary antibody (anti-human IgG, IgM, IgA –AP) for one 
hour with shaking.  Membranes were developed in the dark with NBP-BCIP. 
 
2.11 Immunofluorescence Microscopy 
 
Overnight cultures of Pseudomonas aeruginosa strains were prepared as previously 
described.  One ml of solution was spun at 5000g for 4 minutes and then 750µl of supernatant 
was removed before the pellet was washed with 750µl of 1x PBS and centrifuged once more 
at 5000g for 4 minutes.  Seven hundred and fifty µl of supernatant was again removed before 
the addition of 750µl fixative (4% PFA).  This was vortexed briefly and placed on ice for 20 
minutes before washing extensively and then resuspending the pellet in 1x PBS. 
Slides were washed in cleaning solution (73ml 96% EtOH + 27ml H2O + 1ml 37% HCl), 
H2O and coating solution (0.01 poly-L-lysin) consecutively for 5-10 minutes each.  Slides 
were then dried at 60ºC for 1 hour. 
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2.12 Fluorescein Labelling of Cells 
 
Twenty µl fixed cells were placed on the poly-L-lysin coated slides and warmed at 42ºC on a 
heating block for 10 minutes.  Slides were washed (3x10minutes) with PBS + 0.5% Tween 
20 in a Coplin jar and then 16µl 1:200 dilution of serum (PBS + 0.5% Tween20), primary 
antibody, was placed on the slide and incubated for 1 hr in a moisture chamber.  The slide 
was then washed extensively (6X10 minutes) as before and then 16 µl secondary antibody 
(anti-human IgG, IgA, IgM, C1, C3 or C5b-9 conjugated to FITC) diluted 1:1000 was 
pipetted onto the slide and incubated for one hour in darkness in a moisture chamber.  The 
slides were again washed extensively before air drying in darkness. Fluorescence was 
detected for all samples with identical gain and exposure time (0.84 sec). Visualisation was 
undertaken with a Leica DMRE fluorescence microscope-DC200 digital camera system and 
captured images were selected randomly from fields of view. 
 
2.13 Statistical Methods 
 
All experiments were performed a minimum of 3 times unless stated otherwise.  Statistical 
signifi an e be ween pa ien  gro ps was de ermined by S  den ’s    es .  Error bars represen  
the mean +/- SD for all bacterial assays.  For aanlysis of patient demographic data statistical 
analysis was performed using SPSS Version 18 IBM New York.  S  den ’s t test was used 
with p value <0.05 considered significant. 
 
 
 
  82 
CHAPTER 3:  ASSESSMENT OF BACTERICIDAL ACTIVITY OF PATIENT’S 
SERUM  
 
3.1. Sputum Bacterial Strains 
 
P. aeruginosa ‘strains’ were isola ed from pa ien ’s sp   m as des ribed in me hods 2.1.2.     
Quantitative cultures of sputum were prepared as describe in methods 2.1.2.  In all patients 
more than one morphologically different strain of P. aeruginosa were visually identified.  
Other organisms in addition to P. aeruginosa were identified from the sputum of P2 and P7.  
H. influenza and Corynebacterium were grown on a horse blood agar plate prepared at the 
same time as quantitative culture of P. aeruginosa.  Where morphologically different P. 
aeruginosa colonies were identified, a colony was picked of each, and inoculated on 
Pseudomonas Selective Agar (BioMerieux), confirming growth of P. aeruginosa and further 
confirming the different morphology.  Each of these strains was then stored in glycerol stock 
as described in methods 2.2.6.  No genotyping was undertaken to confirm genotypically 
different strains corresponding to differing morphological appearances.  Each individual 
strain isolated was allocated a number (1-11) corresponding to the patient from whom the 
sputum was isolated and a letter (A-D) corresponding to the morphologically different strain.  
The quantitative culture (cfu/ml) from each sample was recorded.   The total bacterial load 
isolated from each patient is as listed in table 3.1. 
 
To determine the serum resistance profile, each isolate was exposed individually to 
autologous serum and healthy control serum (HCS) in triplicate.  Bacteria were resuspended 
in PBS to a final concentration of 107 CFU/ml; 10 µl was then mixed with 90 µl of undiluted 
human serum at 37°C with shaking (180rpm) and viable counts determined by evaluating the 
number of colony forming units/ml following bactericidal assays as described in methods 
section 2.4 
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Patient Number Pseudomonas 
aeruginosa total 
bacterial load. 
Number of 
morphologically 
different strains isolated. 
Other Bacterial Strains. 
P1 9.63x108 3 (A-C)  
P2 2x105 2 (A-B) H. influenzae 1x107 
P3 2.29x108 4 (A-D)  
P4 9.1x107 3 (A-C)  
P5 2x105 2 (A-B)  
P6 1.995x108 3 (A-C)  
P7 1.016x107 2 (A-B) Corynebacterium 1x107 
P8 2.765x108 4 (A-D)  
P9 1.315x109 4 (A-D)  
P10 1.11x107 3 (A-C)  
P11 1.244x107 4 (A-D)  
 
Table 3.1 shows the total bacterial load of the sputum samples from the patients included in 
this study with the number of different morphological strains of P. aeruginosa isolated from 
the sputum sample also documented.  Morphologically different strains are labelled A, B, C 
and D.  Any other significant pathogens isolated are also shown. 
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The results were plotted on Microsoft excel with an average bacterial count calculated at each 
time point.  Graphs were plotted using the numbers of colony forming units present at each 
time point.  For each strain these were standardised to log10 change in colony forming units. 
Each strain is represented numerically.  P1A represents bacterial strain A from Patient 1, P1B 
bacterial strain B from patient 1 and S1 represents serum from patient 1, S2 from patient 2 
etc.   The demographics of P1-P11 are shown in table 3.2.  Significant comorbidities were 
considered to be any coexisting cardiorespiratory disease, autoimmune disease or disease 
requiring the use of regular immunosuppressant therapy.  Long term antibiotics where taken 
are shown.  From the total of eleven patients two were male with nine female patients.  The 
average age was 64.3 years with the age range between 48 and 87 years of age.  Nine patients 
were receiving long term prophylactic antibiotic at the time of sample collection.  One patient 
was on long term oral steroid therapy for rheumatoid arthritis. 
 
3.2   P. aeruginosa Bactericidal Assay Results 
 
 
The results of bactericidal assays for each bacterial strain isolated from P1-P11 are 
represented in figure 3.1 1-33.  The vast majority of the strains were sensitive both to patient 
and healthy control serum killing. Three of the 33 strains (P6A, P6B and P7A) were resistant 
in all serum tested indicating these strains are innately serum resistant. Interestingly, P1, P2 
and P3 all had strains that, although sensitive in healthy control serum, were not killed by 
their own serum (Table 3.3).  
 
 
 
 
  
85 
 Patient 
G
ender 
A
ge 
Long term
 antibiotic 
Inhaled corticosteroid 
Im
m
unosuppressant therapy. 
Significant 
C
om
orbidities. 
P1 
M
ale 
48 
N
ebulised colom
ycin 
Y
es 
N
o 
N
o 
P2 
Fem
ale 
59 
N
ebulised colom
ycin 
N
o 
N
o 
N
o 
P3 
M
ale 
68 
N
ebulised colom
ycin 
Y
es 
N
o 
C
O
PD
 
P4 
Fem
ale 
60 
N
ebulised colom
ycin 
N
o 
N
o 
N
o 
P5 
Fem
ale 
63 
N
ebulised cefuroxim
e 
Y
es 
N
o 
C
O
PD
 
P6 
Fem
ale 
55 
N
ebulised colom
ycin 
N
o 
N
o 
N
o 
P7 
Fem
ale 
68 
N
il 
N
o 
N
o 
N
o 
P8 
Fem
ale 
60 
O
ral azithrom
ycin  
(3x w
eekly) 
N
o 
N
o 
N
o 
P9 
Fem
ale 
64 
N
il 
N
o 
Y
es (O
ral corticosteroid) 
R
heum
atoid arthritis 
P10 
Fem
ale 
87 
N
il 
Y
es 
N
o 
Ischaem
ic heart disease 
P11 
Fem
ale 
76 
N
ebulised colom
ycin 
N
o 
N
o 
Ischaem
ic heart disease. 
 Table 3.2 Patient dem
ographics.  The characteristics of the patients w
hose serum
 and sputum
 w
as utilised in this study are show
n, including 
details of those w
ho w
ere treated w
ith long term
 oral or inhaled antibiotic in addition to other relevant illness or treatm
ents they w
ere receiving.  
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Figure 3.1 (1-33) Killing curves of 33 morphologically different strains from 11 patients with 
bronchiectasis were subject to bactericidal killing assays with autologous serum and healthy 
control serum.  Counts of P. aeruginosa colony forming units (cfu) were taken at 45, 90 and 
180 minutes. Negative values correspond with a decrease in viable P. aeruginosa compared 
with initial concentration. Strains isolated from 3 patients (P1, P2, and P3) were resistant to 
serum killing by the patients own serum but fully sensitive to killing by healthy control sera.  
P6 and P7 both isolated strains which were resistant to serum killing both with autologous 
and healthy control sera (P6A, P6C and P7A). All other strains were sensitive to killing by 
both autologous and healthy control sera.  For all data, assays were performed in triplicate 
and an average colony count taken at each time point. Error bars represent the mean +/- SD 
for each assay.  
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Patient Total number 
of 
morphologically 
different strains 
Serum 
resistant 
strains in 
HCS and 
patient sera. 
Serum 
sensitive 
strains in 
both HCS 
and patient 
sera 
Strains 
sensitive in 
HCS.  
Resistant in 
patient 
serum. 
P1 3 0 0 3 
P2 2 0 0 2 
P3 4 0 0 4 
P4 3 0 3 0 
P5 2 0 2 0 
P6 3 2 1 0 
P7 2 1 1 0 
P8 4 0 4 0 
P9 4 0 4 0 
P10 3 0 3 0 
P11 3 0 3 0 
 
Table 3.3.  Summary of serum resistant strains from all 11 patients showing that P1-P3 had 
strains resistant to killing by autologous sera whilst sensitive in HCS. 
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Three patients (P1-P3) were shown to grow strains of P. aeruginosa which were sensitive to 
killing in healthy control sera, indicating that they were serum sensitive strains, but not 
sensitive to killing in autologous serum.  To confirm that these strains were sensitive to serum 
killing these strains P1A, P2A and P3A were exposed to the sera of twenty separate healthy 
control subjects with the same results.  Bactericidal assays were carried out as described in 
methods section 2.1.1. The results are shown in figure 3.2.  All three strains were shown to be 
serum sensitive after 45 minutes of incubation whilst again confirming resistance to killing 
by autologous serum.  After 180 minutes of incubation there was a significant difference in 
cfu/ml for all three strains in autologuous serum when compared to HCS (p<0.005). 
 
The finding that strains P1A, P2A and P3A were fully sensitive to killing in healthy control 
sera but not in autologous sera indicated that these were not serum resistant strains and that 
the lack of serum killing was an inherent feature of the serum from these patients. 
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Figure 3.2:  Killing curves of P.aeruginosa strains identified from patients P1, P2 and P3 in 
autologous serum and sera from 20 healthy control volunteers.  Negative values correspond 
with a decrease in viable P. aeruginosa compared with initial concentration.  P. aeruginosa 
strains P1A, P2A and P3A were shown to be resistant to killing in autologous serum and fully 
sensitive to killing in serum from 20 healthy control subjects.  All strains were killed in all 
HCS after 45 minutes incubation. There was a clear difference in cfu/ml for all HCS vs 
autologous serum at 180 minutes incubation (p<0.005 by Students t test) for all three strains. 
The curves depicting bacterial killing by healthy control sera and autologous sera are overlaid 
for simplicity.  For all data, assays were performed in triplicate and an average colony count 
taken at each time point. Error bars represent the mean +/- SD for each assay.  
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3.3 Serum Total Immunoglobulins 
 
Serum total immunoglobulins were checked as part of routine clinical care in these patients.  
Total antibody deficiency was not the reason for the lack of serum killing (table 3.4).  All 
patients had normal total levels of immunoglobulins,  Immunoglobulin G subclasses were 
also in the normal range for all three patients with serum unable to kill autologous strains 
indicating that hypogammaglobulinaemia or IgG subclass deficiency was not the reason.  IgG 
subclasses were mainly collected at a different time point from that of total IgG, which 
explains why the combined total of IgG subclass does not always equal the total IgG level.  
The identification of 3 patients who had strains of P. aeruginosa, sensitive to killing by HCS 
but resistant to killing by autologous serum, with normal immunoglobulin levels suggested 
either the absence of another serum component essential for bacterial killing or the presence 
of an extra factor in the serum that blocks bacterial killing. The following experiments were 
designed to establish whether the absence of bactericidal activity in the serum of these 
patients was due to the absence of a serum component essential for bactericidal activity or the 
presence of an inhibitory factor. 
 
3.4 Identification of Serum Factors Inhibiting Bacterial Killing 
 
First, the bactericidal ability of serum from patients P4-11 against strain P1A was 
investigated with the aim of establishing whether or not this strain, shown to be resistant to 
killing in autologous serum, was also resistant to killing in the serum from other patients 
similarly colonised with P. aeruginosa.  The ability of serum from patients 1-3 to kill strains 
from patients P4-11 was also investigated with the aim of establishing whether the serum 
from these patients was capable of killing other P. aeruginosa strains.  The results of these  
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Antibody subclasses 
and normal ranges. 
(g/L) 
P1 P2 P3 
IgA       (0.80-4.00) 2.09 2.17 4.94 
IgM      (0.50-2.00) 0.85 0.82 1.05 
IgG       (6.00-16.00) 10.66 12.66 10.69 
IgG1     (3.20-10.20) 4.34 5.56 4.13 
IgG2     (1.20-6.60) 4.34 7.29 3,31 
IgG3     (0.20-1.90) 2.09 1.15 1.67 
IgG4     (0.00-1.30) <0.01 0.77 0.13 
 
Table 3.4 shows the total immunoglobulin levels present in the sera of patients P1-P3.  None 
were found to be deficient in IgA, IgG or IgM.  IgG subgroups were also within the normal 
range as measured by the immunology laboratory for all patients. 
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assays was indicative of the factors mediating resistance to serum killing being common to 
strains P1–3 and sera S1–3 but absent from the other strains and sera of patients similarly 
colonised with P. aeruginosa.  The serum of all 11 patients was tested and serum S4-S11 
were all able to kill P1A (Fig 3.3) whereas S1,S2 and S3 were unable to effect killing with a 
significant difference in cfu/ml at 180 minutes between S1-3 and S4-11 (p<0.005). The serum 
sensitive strain P4A was also tested against the serum of patients 4-11 (Fig 3.4) all of which 
were able to effect killing against this strain.  Although S1 was unable to kill its own strain it 
could kill the P. aeruginosa isolates from P4-P11 suggesting that it did not lack the necessary 
factors to kill P. aeruginosa strains.  Interestingly S1 was also unable to kill P2A and P3A 
(Fig 3.5) and S1-S3 were all able to effect killing of P4A but none could kill P1A (Fig 3.6).  
These results suggest that the inability of sera S1-S3 to kill strain P1A –P3A is both serum 
and strain specific.  To assess the immune factors mediating bacterial killing, the role of 
complement in killing P. aeruginosa and measurement of specific anti P. aeruginosa 
antibody levels in the sera of P1-P3 was assessed. 
3.5 Complement Inactivation of Serum 
 
 
To demonstrate that complement mediated killing is crucial in the ability of serum to kill P. 
aeruginosa, assays were performed assessing the ability of healthy control serum and S4 to 
kill strains P1A and P4A with following complement inactivation.  P1A and P4A were both 
sensitive to killing in HCS and S4 at 37°C.  Vials with 90 µL of serum were heated on a 
heating block to 56ºC for 20 min prior to mixing with bacterial strains.  Bactericidal assays 
were performed as previously described in methods 2.4.   
This results of these assays demonstrates that sera, including HCS, that can kill strains of P. 
aeruginosa at physiological temperatures can no longer kill these strains when complement is 
inactivated confirming the crucial role of complement in bacterial killing (p<0.005). 
  103 
 
Figure 3.3 shows killing curves of strain P1A vs S1-S11. Negative values correspond with a 
decrease in viable P. aeruginosa as compared with initial concentration. P1A was resistant in 
autologous serum as previously demonstrated but also in S2 and S3 whilst P1A was fully 
sensitive to killing in S4-S11 (p< 0.005 by S  den ’s   es  for  olony  o n s of P1A in  S1, S2 
and S3, compared with S4 – S11 and HCS after 180 minutes incubation). Curves of HCS and 
S4-S11 overlaid for simplicity . Assays performed in triplicate.  Error bars represent the mean 
+/- SD for each assay.   
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Figure 3.4 shows killing curves of strain P4A (a strain sensitive to killing by autologous 
serum) vs S4-S11. Sera from those patients colonised with P. aeruginosa sensitive to killing 
by autologous sera were previously shown to be able to kill P1A as shown in Figure 3.3.  
This sera was also able to kill P4A, a strain shown to be sensitive to killing by autologous 
sera.  Strains of P4A were dead after 45 minutes incubation with serum from patients 4-11.  
Curves overlaid for simplicity. 
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Figure 3.5. Killing curves of strains P1-P11 vs S1.  Strains P1-3 are resistant to killing in S1 
whilst all other strains are serum sensitive after 180 minutes incubation.. Strains P6A, P7A, 
P8A, P10A and P11A were all dead at 45 minutes incubation time and therefore the curves 
are overlaid for simplicity.  There was a significant difference in cfu/ml between P1A, P2A 
and P3A compared with P4A-P11A in S1 af er 180 min  es in  ba ion (p<0.005 by S  den ’s 
t test) This is representative of 3 independent assays. Error bars represent the mean +/- SD for 
each assay.   
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Figure 3.6 Killing curves of strains P1A and P4A vs S1, S2 and S3.  P4A was serum sensitive 
in S1-S3 (curves overlaid for simplicity) but S1-3 could not kill P1A at 180 minutes 
incubation. This is representative of 3 independent assays.  Error bars represent the mean +/- 
SD for each assay.   
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Figure 3.7 Killing curves of strains P1A and P4A by HCS and S4 and HCS and S4 heated to 
56°C to inactivate complement.  Complement inactivation is depicted as CI. Complement 
inactivation of HCS and S4 inhibited killing of both strains which were fully sensitive to 
unheated serum killing at 45 minutes in HCS and S4 (curves overlaid for simplicity) 
indicating that complement mediated killing is crucial in serum bacterial killing of P. 
aeruginosa.  P1A was shown, as before, to be sensitive to killing by HCS.  However when 
complement was inactivated in HCS there was a significant change in cfu/ml at 180 minutes 
incubation (p<0.00001 by S  den ’s    es ).  For all data, assays were performed in triplicate 
and an average colony count taken at each time point. Error bars represent the mean +/- SD 
for each assay.   
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3.6 Measurement of Specific Anti P. aeruginosa Antibodies 
 
Having demonstrated that the serum from P1-P3 had normal levels of total antibody (IgA, 
IgG and IgM), and that complement was crucial in bacterial killing, we next sought to 
determine if antibody and complement proteins were binding to the bacterial surface. The 
levels of binding of serum IgG, IgA, IgM, C1, C3 and C5b-9  o pa ien ’s isola ed s rains was 
measured using flow cytometric analysis.  Samples were prepared as described in methods 
2.6.2.  Data acquisition and analysis were done using FACSDiva software (BD Biosciences). 
The labelled negative control sample (PBS) was used to establish the baseline FITC 
fluorescence level. In the test samples the fluorescing and non-fluorescing cell populations 
were gated, quantified (percentage of parent population) and relevant statistical parameters 
(FITC mean and median) were calculated using FASCDiva software.  The geometric mean 
was then used to plot level of FITC binding on bar charts as shown.  Histograms 
representative of immunoglobulin deposition are shown in appendix 1.     
 
It was shown that patient sera had specific binding of all proteins tested in levels similar to, or 
greater than that in HCS which was able to kill strains P1-P3 (Fig 3.8) Furthermore, IgG and 
complement components C1q, C3, and the C5b-9 membrane attack complex (MAC) were 
shown to be deposited on all strains (Fig 3.9) 
Impaired bacterial killing of strains P1A –P3A in autologous serum was therefore concluded 
not to be due a lack of complement or antibody binding as complement components were 
deposited on all strains.  Therefore, I assessed the possibility that the lack of bacterial killing 
was due to an inhibitory factor present in the serum of patients 1-3.  
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Figure 3.8.  Binding of specific IgG, IgM, IgA antibodies and C1q and C3 complement 
factors from indicated patient serum and HCS to P1A, P2A, and P3A. Each strain was tested 
with autologous serum and at least three separate healthy controls. Data are representative of 
three independent experiments. P1A was also tested with S2 and S3 serum.  Anti P. 
aeruginosa IgG adherence was noted to be higher than that in HCS in S1-S3.   
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Figure 3.9 Serum titres of P. aeruginosa specific IgG compared with C5b-9 MAC deposition 
on autologous strains.  MAC deposition was demonstrated on each of the strains resistant to 
killing in autologous serum.  The trend was towards increased MAC deposition with 
increasing total anti P. aeruginosa IgG titre for the strains sensitive to killing in autologous 
serum with P2A and P3A demonstrating the highest levels of MAC deposition with moderate 
IgG titres. 
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3.7 Mixing of Patient Serum and Healthy Control Serum 
 
As it was shown that patient serum was not lacking a factor to effect killing of P. aeruginosa  
next explored was whether this serum had an extra factor that was blocking complement 
killing. Each strain P1A –P3A was exposed to autologous serum mixed with healthy control 
serum in differing concentrations to establish whether this would restore bacterial killing of 
autologous serum.  Bactericidal assays were performed with these serum mixes as described 
in chapter 2.  First HCS was added to S1, S2 or S3 (50:50 ratio).  HCS similarly diluted with 
PBS readily killed P. aeruginosa.  In contrast, HCS mixed with patient sera instigated little to 
no killing of bacterial isolates supporting the presence of a blocking factor (Fig 3.10).  
As bacterial killing could be inhibited in HCS with the addition of patient serum in a 50:50 
mixture, HCS was added to patient serum in steadily increasing amounts and assays carried 
out at each increment, to establish the ratio at which the action of HCS could overcome the 
inhibition.  HCS was unable to effect killing of P1A even when it constituted 90% of the 
serum mix (Fig 3.11). A killing curve equivalent to HCS alone could only be achieved when 
HCS constituted 97% of the serum mix (Fig 3.12). This is shown for strains P1A (Figs 3.11 
and 3.12).  This demonstrated the presence of a potent factor inhibiting bacterial killing 
present in the serum of P1. The same assays were carried out with the other strains which had 
demonstrated resistance to killing by autologous serum with similar results.  P2A in S2 (Fig 
3.13 and P3A in S3 (Fig 3.14) 
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Figure 3.10.  Bactericidal assays with mixes of HCS and phosphate buffered saline mixed in 
a 50%50% ratio showed that HCS retained the ability to kill strains P1A-P3A (curves 
overlaid for simplicity).  When patient serum was mixed 50%/50% with HCS these mixtures 
were unable to kill autologous strains P1A-P3A.  There was a significant change in cfu/ml at 
180 minutes incubation for all three strains when HCS mixed with PBS is compared with 
HCS and autologous strain (p<0.005 by Students t test) for all three strains.  For all 
data,assays were performed in triplicate and an average colony count taken at each time 
point. Error bars represent the mean +/- SD for each assay.   
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Figure 3.11 demonstrates that with increased concentrations of HCS of up to 90% mixed with 
autologous serum, serum mediated killing of P1A was still inhibited.  Killing was greatest at 
180 minutes incubation where the mixture contained 70% HCS but even this constituted only 
-1 log 10 change from inoculum.   For all data, assays were performed in triplicate with 
average colony count taken at each time point.  Error bars represent the mean +/- SD for each 
assay.  
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Figure 3.12 demonstrates that killing of P1A in mixes of S1 and HCS (90-100%) showed a 
steady reduction in cfu/ml at 180 minutes incubation with increasing concentrations of HCS 
but that complete killing of bacteria at 90 minutes incubation was not restored until the 
mixture contained 93% HCS and 7% S1.  For all data, assays were performed in triplicate 
with average colony count taken at each time point.  Error bars represent the mean +/- SD for 
each assay.  
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Figure 3.13 S2 in mixes with healthy control sera was able to inhibit serum mediated 
bacterial killing of P2A until the sera contained 70% HCS at which concentration complete 
bacterial killing was observed at 180 minutes.  For all data assays were performed in 
triplicate with an average colony count calculated at each time point.  Assays were performed 
in triplicate.  Error bars represent the mean +/- SD for each assay.  
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Figure 3.14 S3 in mixes with HCS was able to inhibit serum mediated bacterial killing of 
P3A until the serum contained 80% HCS at which level complete bacterial killing was 
observed at 90 minutes.  For all data assays were performed in triplicate with an average 
colony count calculated at each time point.  Assays were performed in triplicate.  Error bars 
represent the mean +/- SD for each assay.  
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The results of bactericidal assays with serum mixes of HCS and patient serum confirmed the 
presence of an inhibitory factor in the serum of patients P1-P3 which inhibited killing of 
autologous bacterial strains.  Complete killing by S1–3 was only restored when HCS 
represented 93, 70, and 80%, respectively, of the mixed sera indicating a potent capacity to 
inhibit bacterial killing.    
3.8 Conclusion 
Analysis of the serum and sputum samples from a well characterised group of patients with 
non CF bronchiectasis demonstrated the presence of a potent inhibitory factor in the serum of 
3 of these patients from a cohort of 11 patients chronically colonised with P. aeruginosa.  
Detailed analysis of the serum and sputum from these patients demonstrated that this factor 
modulating serum killing is common to S1-3 and P1-3 but absent from the other sera and P. 
aeruginosa strains isolated from the remaining 8 patients.  The patients all had normal serum 
immunoglobulin levels but specific anti P. aeruginosa IgG levels were higher than seen in 
HCS.  High levels of MAC deposition were also demonstrated for autologous serum on these 
strains again suggesting that immune deficiency was not the underlying reason for the 
inability of S1-S3 to kill autologous strains.  Strains P1-P3 were also shown to be serum 
sensitive strains both in HCS and in the sera of other patients colonized with P. aeruginosa 
confirming the capacity for bacterial killing was present but the defe   resided in  he pa ien ’s 
plasma but was only relevant to their autologous strains. 
The next step was to identify the nature of the factor inhibiting serum bacterial killing. 
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CHAPTER 4 IDENTIFICATION OF SERUM INHIBITORY FACTOR 
 
 
The aim of the experiments described in this chapter were to isolate and identify the 
inhibitory factor/s present in patient serum responsible for the blocking of bactericidal 
activity.  Unless stated otherwise serum from patient P1 and strain P1A were used in the 
following experiments.  This serum had previously shown potent ability to block bacterial 
killing in healthy control serum. 
 
4.1 Fractionation of P1 Serum 
 
To determine the molecular weight of the inhibitory factor, S1 was fractionated as previously 
described in chapter 2.5.1 together with HCS. The serum was fractionated into ranges of 
molecular weights >300kDa, 100-300kDa, 30-100kDa and <30kDa and standardised to 1ml 
with the addition of PBS, as previously described.   
Bactericidal assays were then performed as previously described using each recovered 
fraction of S1 and HCS with P1A as the target organism to determine which fraction 
contained the blocking factor.  45 µL of each fraction recovered from S1 and HCS was mixed 
50:50 with a further whole sample of HCS and   ilised in  his assay  and 45 μL of PBS was 
added to 45 μL of HCS as a  on rol. 
HCS was able to kill P1A bacteria when mixed with all fractions except for 100-300 kDa of 
S1 (p=0.000) (Fig 4.1). This demonstrated that the inhibitory factor found in S1 has a 
molecular weight between 100 kDa and 300 kDa.    
IgG has a molecular weight of 160kDa (2 light chains weigh 23-25kDa each and 2 heavy 
chains weigh 53kDa each). IgA similarly has a molecular weight of approximately 160kDa, 
whilst IgM weighs approximately 970kDa (Janeway et al., 2001).  It was therefore 
hypothesised that the blocking activity in S1 serum was IgG mediated.  Previously, it was 
demonstrated that there were high titres of IgG expressed by S1, S2 and S3 against 
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autologous bacterial strains suggesting a potential role of IgG in serum blocking activity.  
Therefore, we aimed to determine if patient IgG could inhibit HCS bactericidal killing.  
 
4.2 Purification of Immunoglobulin G (IgG) From Serum 
 
To determine if IgG was responsible for the inhibition of serum killing of P. aeruginosa we 
extracted the antibody from patient serum to determine if IgG-depleted sera could also inhibit 
HCS killing.   Furthermore, the purified patient-IgG could be added to HCS to determine if it 
was sufficient alone to inhibit bacterial killing.  IgG purification was first carried out using 
Protein A Sepharose 4B column as described in Methods 2.5.3.  IgG was also purified by 
affinity chromatography using protein G immobilised on agarose as described in methods 
2.5.4. 
 
Bactericidal assays were carried out as previously described.   Recovered fractions of S1 
ser m deple e of Ig  was added in remen ally  o HCS  o a  o al vol me of 90μL.   An ibody 
depleted S1 from the protein A column mixed with HCS did not inhibit the bactericidal 
activity of HCS supporting the role of IgG in inhibiting killing of P1A in autologous serum. 
However 90 μL of S1 deple ed of Ig  alone s ill inhibi ed killing of P1A s gges ing 
incomplete removal of IgG by the protein A column. (Fig 4.2) IgG depletion was therefore 
also performed using a protein G column with Protein G having a high affinity for all 
subclasses of human IgG. (Table 2.4). Assays using recovered flow through of S1 depleted of 
Ig   sing pro ein   ex ra  ion showed  ha  90 μL S1 deple ed of Ig  was able  o kill P1A a  
180 minutes incubation. (Fig 4.3)    
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Figure 4.1 Serum assays of fractionated S1 and HCS.  Each fraction (45μL) was added  o 
45μL of HCS for ea h assay.  Killing of s rain P1A was inhibi ed in S1 as previo sly shown.  
It was also inhibited by S1 fractions containing serum components with weight 100-300KDa. 
Bacterial killing after 180 minutes incubation was significantly different in serum containing 
this S1 fraction when compared to all fractions of HCS (p=0.0009 by S  den ’s    es ).  
Removal of these fractions from S1 serum restored killing of P1A after 45 minutes incubation 
in assays containing S1 fractions with molecular weight < 100kDa.  P1A was sensitive to 
serum killing with assays containing all fractions of HCS.  Curves overlaid for simplicity. 
Assays were performed in triplicate.  Error bars represent the mean +/- SD for each assay.  
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Figure 4.2 Serum assays of IgG deplete serum from protein A column vs P1A.  Bacterial 
killing was inhibited when S1 was mixed with HCS confirming the presence of the inhibitory 
factor prior to IgG depletion.  Where HCS was added to IgG deplete S1 serum bacterial 
killing was present at 45 minutes incubation. (Lines representing 60µL HCS + 30µL S1(-
IgG), 70µL HCS+20µL S1(-IgG) and 90µL HCS (-IgG) overlap with all strains dead at 
45minutes incubation).  Inhibition of killing was seen where 90µL S1 (-IgG) was utilised.  
This is thought to be due to incomplete removal of IgG by protein A and possibly depletion 
of other serum factors needed to effect killing.  There was a significant difference in bacterial 
killing be ween 45μL HCS mixed wi h 45μL of S1 wi h and wi ho   Ig  at 180 minutes 
incubation (p= 0.0001 meas red by S  den ’s    es ).  Similarly wi h mixes of 60 μLof HCS 
and S1 with and without IgG there was a significant difference in bacterial killing at 180 
min  es in  ba ion (p= 0.0009 meas red by S  den ’s    es ).  This is represen a ive of 3 
independent assays.  Error bars represent the mean +/- SD for each assay.  
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4.3 Bactericidal Assays Using IgG Depletion with Protein G 
 
Bactericidal assays were repeated using 4 recovered fractions of S1 following IgG extraction 
with protein G and then mixed with HCS.  When HCS was added to IgG deplete fractions of 
S1 following protein G depletion, bacterial killing was restored at 45 minutes incubation for 
fra  ions 2 3 and 4 and 90 min  es for fra  ion 1.  Where 90μL of S1 deple e of IgG was 
utilised killing was restored at 180 minutes (Fig 4.3). The next step was to establish whether 
addition of the S1 eluate to HCS would inhibit bactericidal activity. 
 
4.4 Addition of S1 Eluate to HCS 
 
Ba  eri idal assays were performed as des ribed previo sly. Using 45μL of Ig  el a e added 
 o 45μL of HCS wi h a HCS/PBS  on rol.   This mix  re was able  o inhibi  killing of P1A 
compared to HCS/PBS control, killing P1A after 45 minutes incubation demonstrating that 
the addition of IgG directly to HCS was sufficient to inhibit bacterial killing (Fig 4.4).  To 
establish the potency of IgG required to introduce inhibition of bacterial killing to HCS, 
purified S1 IgG (eluted from protein G column) was added to HCS in varying amounts and 
bactericidal assays were carried out as before. It was established that only 4% of S1 IgG was 
needed to inhibit all killing of bacteria up to 180 mins incubation.  Bacterial killing was 
restored in HCS when the concentration of IgG eluate was 1/64 after 90 minutes incubation.  
This data demonstrated that bactericidal killing was inhibited at IgG proportion of 6.25% and 
only restored at 90 minutes incubation with a proportion of IgG equating to 3.125%. (Fig 4.5) 
This confirmed previous findings that the potent inhibitory factor present in S1 is IgG.  The 
aim of the following experiments was to establish which subclass of IgG was responsible for 
this inhibitory behaviour. 
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Figure 4.3 Bactericidal assays of recovered fractions of IgG depleted S1 using protein G 
column against P1A.  Inhibition of bacterial killing of P1A was found with S1 added to HCS.  
When HCS was added to IgG deplete fractions of S1 bactericidal killing was restored at 45 
minutes incubation (fractions 2, 3 and 4 – curves overlaid for simplicity). There was a 
significant log 10 difference in cfu/ml between 50%S1 and fractions 2,3, an 4 mixed with 
HCS at 45 minutes incubation (p=0.006 by S  den ’s    es ).  Bactericidal killing was restored 
at 90 minutes for fraction 1.  Where the assay was performed using larger amounts of IgG 
depleted S1 (75% and 100%) killing was restored at 180 minutes incubation (curves overlaid 
for simplicity). This is representative of 3 independent assays.  Error bars represent the mean 
+/- SD for each assay.  
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Figure 4.4 depicts bactericidal assays with S1 IgG eluate added to HCS vs P1A.  The addition 
of IgG eluate to HCS inhibited the bactericidal activity of HCS to P1A. HCS retained 
bactericidal activity with the addition of PBS.  The inhibitory activity of S1 serum was 
maintained with the addition of PBS to S1. There was a significant difference in bacterial 
killing after 180 minutes incubation when HCS was mixed with 50% PBS or mixed with 50% 
Ig  el a e (p=0.0003 by S  den ’s    es ).  This is representative of 3 independent assays. 
Error bars represent the mean +/- SD for each assay. 
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Figure 4.5.  Bactericidal assays with serial dilutions of S1 IgG eluate vs P1A.    Bacterial 
killing was inhibited in HCS with dilutions of 1/2 to 1/32 IgG eluate.  Bactericidal killing was 
restored in HCS at 90 minutes incubation with concentrations of 1/64 IgG eluate.  Higher 
numbers of colony forming units were present with increased concentrations of IgG eluate in 
HCS.  Data are representative of 3 individual assays.  Error bars represent the mean +/- SD 
for each assay. 
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4.5. Identification of IgG Subclass Responsible for Inhibition of Bacterial Killing 
 
If it was a specific IgG subtype leading to the inhibition of serum killing, it should bind to the 
relevant patient strains more than patients without inhibition. To determine the levels of 
IgG1,2,3 and 4 binding to each patient isolate we used flow cytometry as described in 
methods. Patients 1-3 did not have statistically different levels of IgG1, 3 or 4 binding to their 
cognate strains compared to patients 4-11. In contrast, these three patients had much higher 
IgG2 binding to their cognate strains than any of the other patients. HCS also did not have 
significant IgG2 binding to these three strains.  (Fig 4.6)   
 
The high titres of IgG2 seen in the blocking sera suggested that IgG2 was the responsible 
specific inhibitory factor in the serum of patients S1-S3.   This experiment was also replicated 
measuring IgG3 and IgG4 titres against autologuous strains where no significant differences 
were seen in IgG3 and IgG4 subtype titres between blocking and non blocking sera..  (Fig 
4.7)   
 
This finding was not unexpected as both IgG3 and IgG4 contribute only 11% of total IgG in 
human serum.  IgG3 provides the immune response against protein and polypeptide antigen 
but the role of IgG4 is not fully established.  The results of both figure 4.6 and 4.7 suggested 
that IgG2 was likely to be the factor inhibiting killing of bacterial strains in patients P1-P3.   
 
To determine the role of IgG2 further, immunofluorescent labeling of P1A was performed 
using first IgG depleted S1 serum (S1-IgG) as the primary antibody.  Immunofluorescence 
labelling of P1A cells with either FITC labelled anti- human-IgG1 or anti human-IgG2 
specific secondary antibodies was also performed.  S1 serum and HCS were used as primary 
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antibodies (methods 2.11).  The aim was to visualise antibody subgroup binding to bacteria 
and determine any differences between blocking sera and HCS.   
 
Immunofluorescence labelling of P1A cells showed that there were marked differences in 
visualised IgG2 binding between samples when HCS and S1 serum were used as primary 
antibodies showing a major increase with S1.  This adds further support to the findings of 
flow cytometry. Immunofluorescence also confirmed that S1 serum with IgG removed by the 
protein A column had little detectable IgG1 or IgG2. (Fig 4.8)   
 
Flow cytometry and immunofluorescence therefore suggested that IgG2 was likely to play a 
role in inhibiting bacterial killing.  To determine further if IgG2 was responsible for the 
serum-inhibition, the effect of removing IgG2 from serum was examined. IgG2 was removed 
and purified from S1 by passing the serum over an affinity column coated with a monoclonal 
antibody against human IgG2 (Jefferis et al, 1992) followed by elution as described in 
methods 2.5.7. Bactericidal assays were performed as previously described in methods.  HCS 
was mixed with IgG2 deplete S1 and purified IgG2 in a 50/50 ratio.  Killing was inhibited in 
in HCS when mixed with purified IgG2 whilst P1A was killed after 180 minutes incubation 
when mixed with S1 serum depleted of IgG2.  This demonstrated the central role of IgG2 in 
inhibiting bacterial killing.  IgG2 deplete flow- through lost its inhibitory ability whilst IgG2 
subsequently eluted from the column blocked the serum bactericidal activity of HCS.    
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Figure 4.6 Anti P. aeruginosa titres of IgG1 and IgG2 isotypes in HCS and patient sera 
specific to autologous strains as determined by FACS.  IgG1 titres were not statistically 
different between the blocking sera (S1-S3) and those without blocking activity (S4-S11). S1 
– S3 demonstrated statistically higher (p<0.001) IgG2 titres compared with S4-S11.   
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Figure 4.7 Titres of IgG3 and IgG4 isotypes in patient sera specific to autologous strains.  No 
significant differences were found between the blocking sera (S1-S3) and non blocking sera 
(S4-S11).   
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Figure 4.8 Immunofluorescence microscopy of P1A in S1 and HCS labeled with antihuman 
IgG1 and IgG2 shows a clear difference in observable IgG2 binding with S1 compared to 
HCS.    Immunofluorescence of S1 which had been passed through a protein A column to 
deplete IgG has little detectable IgG1 or 2 binding suggesting that these had been 
successfully removed from serum.  
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Figure 4.9  depicts bactericidal assays against P1A using 1gG2 purified from S1 mixed with 
HCS, and S1 depleted of IgG2 mixed with HCS in a 50/50 ratio.  Purified IgG2 inhibited 
bacterial killing when added to HCS whereas the addition of IgG2 depleted S1 to HCS 
restored bacterial killing of P1A at 180 minutes incubation with a significant difference in 
cfu/ml after 180 minutes incubation (p=0.003 by S  den ’s    es ).  As before P1A was 
resistant to killing by S1 and fully sensitive in HCS.  Bacterial killing was also inhibited in 
HCS mixed 50% with S1.  Data are representative of 3 individual assays.  Error bars 
represent the mean +/- SD for each assay. 
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4.6  Conclusion 
 
IgG2 was demonstrated to be the inhibitory factor present in inhibitory serum.  Initially it was 
shown that removal of total IgG from inhibitory serum restored bactericidal activity.  This 
was shown to be a potent inhibitor of bacterial killing with eluted IgG from inhibitory serum 
able to inhibit killing by HCS even when present in small quantities.   FACS and 
immuofluorescence microscopy demonstrated that the IgG subgroup likely to be responsible 
for the inhibitory actions of S1 serum was IgG2 as it demonstrated avid binding to P1A 
visualised by immunofluorescence and was present in significantly higher titres in blocking 
sera compared to non blocking sera.  Removal of IgG2 restored the ability of S1 serum to kill 
autologous strains of P.aeruginosa, whilst addition of the recovered IgG2 eluate to HCS 
inhibited the ability of HCS to kill these strains. 
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CHAPTER 5 IDENTIFYING BACTERIAL TARGET FOR INHIBITORY IgG2 
5.1 Analysis of Bacterial Strains 
Having established that an inappropriate IgG2 response in the serum of patients P1-P3 was 
responsible for inhibition of bacterial killing of P. aeruginosa strains isolated from these 
patients, the next step was to characterise the bacterial strains isolated from these patients.  
IgG2 forms the prevalent immune response to polysaccharide antigens in humans, therefore 
the following experiments were specifically targeted to examining the properties of the 
lipopolysaccharide (LPS) component of P. aeruginosa.  In particular, the O-antigen side 
chain was studied given its immunogenic properties (Joiner et al., 1984; Knirel et al., 2006; 
Doring and Pier, 2008; King et al., 2009). 
The initial aim was to determine whether or not there were any features of the P. aeruginosa 
strains isolated from the sputum of patients P1-P3 which were different from the strains 
isolated from other patients P4-P11.  LPS preparations were made from P1A, as described in 
methods section 2.8.1. 
 
5.2 Silver Stained Lipopolysaccharide Gels 
Bacterial LPS was purified from all strains separated on a SDS-Page gel and visualised using 
SilverQuest Kit (Invitrogen), as described in methods chapter 2.9.  Silver staining of LPS 
preparations revealed that the strains P1A, P2A, and P3A produced significant 
amounts of long-chain O-antigen in contrast to the isolates from other patients, which 
had no detectable O-antigen.  The best representation of silver stained LPS gel is 
shown in Figure 5.1.   
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Figure 5.1 A pattern of banding was seen on analysis of P1A, P2A and P3A strains visualised 
by silver stain of polysaccharide preparations of P. aeruginosa, between 35 -55 kDa.  This 
banding was not seen in the other strains analysed.  This corresponds to the long chain O-
antigen of LPS and was expressed by the 3 strains, which were resistant to killing in 
autologous sera..  Silver staining gels were repeated 4 times in total with consistent results.  
The images shown indicate the results for several patient strains and the LPS bands are 
indicated by arrows.   
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Having identified this feature that was common to the P. aeruginosa strains P1A, P2A and 
P3A, Western immunoblotting was performed to assess whether inhibitory IgG2 targeted a 
specific component of bacterial structure.  Western blotting of outer membrane protein 
(OMP) preparations, (Fig 5.2) and LPS preparations were performed with patient serum and 
subsequent anti-human IgG labelling as described in methods 2.10. S1 was shown to 
recognise the outer membrane proteins of each strain with no clear difference between the 
response to P1A-P3A compared to the response to P4A-P11A (Fig 5.2). S1 was also shown 
to recognise the O-antigen chains of LPS from P1A, P2A and P3A with no detectable 
response to the LPS preparations from the remaining eight strains P4A-P11 (Fig 5.3).  S2 and 
S3 similarly recognised O-antigen of P1A, P2A and P3A.   In contrast HCS had no detectable 
IgG response to the O-antigen from P1A, P2A or P3A (Fig 5.4 and 5.5).  This indicated that 
the target of inhibitory IgG was LPS and more specifically O-antigen expressed by strains 
P1A, P2A and P3A.   
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Figure 5.2 Western immunoblotting of outer membrane proteins preparations of all P. 
aeruginosa strains with S1 as the primary antibody source and anti human IgG as the 
secondary antibody. The gel demonstrated that S1 bound to several outer membrane proteins 
from all 11 patient strains with not visible difference between strains resistant to killing by 
S1. 
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Figure 5.3.  Western immunoblotting of LPS preparations of all P. aeruginosa strains with S1 
as antibody source and anti human IgG as secondary antibody showed that S1 bound to the 
O-antigen of P1A, P2A and P3A with no or minimal binding to the other strains (P4-11A). 
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Figure 5.4 shows a comparison of Western Immunoblotting with S1 and HCS as the primary 
antibody source.  LPS preparations of P1A were separated on SDS-Page and the presence of 
O antigen was detected using S1 sera (image on the Left), or HCS (image on the Right) as the 
primary antibody, and anti-human IgG as the secondary antibody.  No anti LPS IgG was 
detected in HCS in contrast to S1.   
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Figure 5.5 shows Western immunoblotting of LPS preparations of P1A, P2A and P3A.  In 
each case S2, S3 or HCS were the primary antibody source, with anti-human IgG as 
secondary antibody..  There was a high LPS specific IgG binding detected from both S2 and 
S3 to all three strains whereas no such binding was found with HCS.   
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5.3 The Role of anti LPS Antibodies in Inhibiting Killing of P. aeruginosa 
 
We next sought to investigate whether inhibitory IgG2, found in the serum of patients P1, P2 
and P3 bound long chain O-antigen of LPS from strains of P. aeruginosa found in the sputum 
of these patients to block bacterial killing.   
 
To determine this link, LPS specific antibodies were removed from S1 serum by 
immobilising LPS purified from P1A on a polymyxin-B agarose column and passing S1 
through the column to remove any specific LPS antibody (Methods 2.5.5).  The recovered 
flow through fractions were then utilised in bactericidal assays to determine whether the 
removal of specific antibody bound to LPS would restore the ability of S1 serum to kill P1A. 
Similarly, the eluate was examined in bactericidal assays to assess whether the addition of 
this purified anti LPS antibody to HCS would inhibit bacterial killing.   Bactericidal assays 
were performed as previously described in methods 2.4. 
 
Ninety microlitres of four fractions of S1 deplete of LPS antibody were collected as flow 
through from the column.  Bactericidal assays using these fractions showed that although 
viable numbers of P1A were still detected after 180 minutes incubation, the number of colony 
forming units was fewer than in buffer control or S1, suggesting that removal of anti LPS 
antibody did restore some capacity for killing by S1 serum (p<0.0001) (Fig 5.6). As the 
column extraction may have deactivated much of the complement, eluate containing anti LPS 
antibody was added to HCS in a ratio of 50% and was able to reduce killing of P1A by HCS 
after 45 minutes incubation.  Again, this assay demonstrated a significant log10 change in cfu 
where S1 minus anti LPS antibody was used compared with S1 mixed with HCS (p<0.0001) 
(Fig 5.7). 
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Figure 5.6 shows that P1A was fully sensitive to killing by HCS while killing was inhibited 
by S1.  Killing was improved by the recovered fractions of S1 from the LPS column though 
still less and slower than for HCS. Inhibition of killing of S1 was significantly different to 
that of fraction 2 S1 deplete of LPS antibodies at 180 minutes incubation (p<0.0001 by 
S  den ’s    es .)  Each assay was performed in triplicate with an average count of colony 
forming units calculated at each time point.  This is representative of 3 independent assays. 
Error bars represent the mean +/- SD for each assay. 
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Figure 5.7 depicts serum killing of P1A by HCS mixed with S1 deplete of anti LPS antibody.  
S1 depleted of anti LPS antibody added to HCS in a 50%/50% mixture in bactericidal assay 
vs P1A.  This was able to kill P1A after 45 minutes incubation.  S1 depleted of LPS antibody 
alone also demonstrated a significant log change in bacterial numbers after 180 minutes 
incubation compared to the killing curves for undepleted S1 sera or mixes of undepleted S1 
sera and HCS (50%/50%) after 180 minutes incubation. (p<0.0001 by S  den ’s  -test).   Each 
assay was performed in triplicate with an average count of colony forming units calculated at 
each time point.  Error bars represent the mean +/- SD for each assay. 
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Having demonstrated that the addition of purified anti LPS antibody to HCS could inhibit 
bacterial killing of P1A, a dose response with HCS was undertaken.  The aim was to establish 
whether the titre of anti LPS antibody was critical in inhibiting bacterial killing rather than its 
presence alone.  Bacterial assays were carried out as previously described in methods chapter 
2.  Increasing proportion of purified anti LPS antibody mixed with HCS showed delayed and  
reduced bacterial killing after 180 minutes incubation when mixed in a ratio of 33% HCS to 
67% anti LPS antibody  but was less reduced at a 67%/33% ratio (p=0.1) (Fig 5.8). These 
data confirmed both potency and a proportion dependant effect. 
 
5.4 Immunofluorescence Microscopy of S1 Depleted of anti LPS Antibody 
 
Having established the role for the patient derived anti-LPS antibody to inhibit killing of 
P1A, immunofluorescence microscopy was performed as described in methods chapter 2 on 
flow through fractions of S1 following extraction of anti LPS antibody via the polymyxin –B 
agarose column. Briefly, as before, FITC anti human IgG1 and IgG2 was used to detect IgG 1 
and IgG2 subclasses.  For comparison, immunofluorescence microscopy of P1A with S1 and 
HCS and FITC anti human IGg1 and IgG2 is shown in addition to immunofluorescence of 
recovered fractions of S1 serum from protein G column run through to remove all IgG in the 
sample.   
 
Immunofluorescence microscopy showed that the flow through fractions of S1, depleted of 
anti LPS antibody, did have detectable P. aeruginosa IgG1 binding, but not IgG2.    When 
compared to the images of P1A with S1 and FITC anti human IgG2 there was a marked 
difference in visualised IgG2 binding.  When compared to images of P1A with S1 depleted of 
IgG following protein G column extraction there was a similar absence of detectable IgG2 
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binding.  However, there was detectable IgG1 activity suggesting that the anti LPS antibody 
is of the IgG2 subtype.  This was removed by binding to a purified P1A LPS column 
confirming that this was the target of inhibitory IgG2 (Fig 5.9.). 
 
Previously I had shown that the addition of purified anti LPS antibody from S1 to HCS 
inhibited killing of P1A in a dose-dependent manner indicating that the potency and 
amount of anti-LPS antibody is critical for inhibition (Fig 5.7).   This was further evaluated 
as a titre with Enzyme-linked immunosorbent assay (ELISA) described in methods chapter 2.  
Briefly, P1A LPS was attached to a 96 well plate.  Dilutions of serum from patients 1-11 
were added in addition to dilutions of HCS from 2 controls. Anti-human IgG conjugated to 
alkaline phosphatase followed this, with results derived 30 minutes after the addition of 
developer.  The patients with impaired serum killing of P1A were shown to have much higher 
titres of anti LPS IgG compared to the serum of patients not only able to kill autologous 
P.aeruginosa strains but also able to kill the strain P1A.  This added further support that the 
presence of anti LPS IgG was pivotal in inhibition of P. aeruginosa killing in these patients 
but that the titre was significantly higher in patients 1, 2 and 3 (whose colonising strains were 
also high LPS producing) indicating that the strain driven antibody response and titre of the 
subsequent anti LPS IgG was also critical (Fig 5.10). 
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Figure 5.8 depicts results of a bactericidal assay with the addition of purified anti LPS 
antibody from S1 to HCS in increasing proportions directed against P1A.  The addition of 
anti LPS antibody even in a ratio of 33% to HCS was shown to inhibit bacterial killing of 
P1A.  This effect was greater at 50/50 a  180 min  es in  ba ion  (p=0.1 by S  den ’s  -test) 
but no further inhibition was seen at a mixture of 67% anti LPS antibody and 33% HCS..Each 
assay was performed in triplicate with an average count of colony forming units calculated at 
each time point. Error bars represent the mean +/- SD of 3 assays.   
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Figure 5.9 Immunofluorescence microscopy of sputum smear P1A in S1 deplete of anti LPS 
antibody, in neat S1 and following IgG extraction from S1.  In all cases FITC labelled anti 
human IgG1 and IgG2 were utilised to detect IgG1 and IgG2 binding to bacteria. 
Immunofluorescence of P1A with S1 following anti LPS antibody removal demonstrated 
detectable anti-P. aeruginosa IgG1 but not anti P. aeruginosa  IgG2.    
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Figure 5.10 Using ELISA S1, S2 and S3 demonstrated high antibody titres to P1A LPS in 
comparison to HCS and patient sera able kill P1A.  Results were derived 30 minutes after 
addition of developer on plate reader (OD405).  
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5.5   Confirmation of Role of Anti LPS IgG Titre. 
 
To confirm that this inhibition was not only due to the presence of anti LPS IgG but rather the 
titre, anti LPS antibodies were purified from S4 – a serum with normal bactericidal killing 
and shown to be able to kill P1A. This was achieved by running S4 through a column lined 
with purified P1A LPS as previously described.  The eluted anti LPS antibodies were 
concentrated 10 fold and utilised in bactericidal assays with P1A.  The addition of this 
purified S4 anti LPS antibody to HCS was once more shown to inhibit killing of P1A in a 
dose dependent manner (Fig 5.11) as previously shown using autologous serum anti LPS 
antibody (Fig 5.8), but now demonstrated using purified, concentrated anti LPS antibody 
from a serum previously shown to be able to kill P1A.   
 
The strains P1A, P2A and P3A were all shown to express high amounts of O-antigen, the 
immunogenic portion of LPS.  This common feature indicated that this component of LPS 
was therefore likely to be the specific target for inhibitory antibody.  To test this further, S1 
was depleted of antibody to lipid A and core oligosaccharide constituents of LPS by passing 
it over a polymyxin B column with immobilised purified LPS from P4A which is a strain 
lacking O-antigen expression and therefore it was considered that the flow through would 
still contain anti LPS antibodies recognising O-antigen whilst the antibody eluted from the 
column would recognise lipid A and core oligosaccharide.  Simultaneously, S1 was passed 
over a polymyxin B column on which LPS isolated from P1A was immobilised.  As this 
strain expresses O-antigen the flow through would be depleted of S1 anti LPS antibody whilst 
the eluate would contain high levels.   
 
ELISA was performed as previously described by binding LPS isolated from P1A to a 96 
well plate with the flow through and eluate fractions from each column utilised as primary 
  149 
antibody and anti human IgG-AP as secondary antibody, to establish comparative titres of 
anti LPS IgG (Fig 5.12). Bactericidal assays were performed with mixes of HCS and eluate 
and the flow through fractions from the column lined with purified P4A LPS (Fig 5.13). 
ELISA showed that titres of anti LPS IgG in the eluate from S1 in the column lined with P1A 
LPS and the flow through from S1 run through the column lined with P4A LPS were 
comparable with S1 alone.  The titres were approximately 100 times greater than that from 
the flow through of S1 from a column lined with P1A LPS and approximately 10 times 
greater than that from the eluate of S1 from the P4A LPS column (Fig 5.12). 
 
Bactericidal assays were performed using the S1 eluate from the P4A column (S1 anti lipid 
A/core antibody) and the flow through from the same column (S1 deplete of anti-lipid A/ 
core antibody).  Both were mixed in ratios of 50% with HCS and bactericidal assays 
performed as previously described in methods.  The addition of S1 deplete of lipid A/core 
antibody to HCS was able to inhibit killing by HCS.  Conversely there was a 3 log10  cfu/ml 
difference at 90 minutes incubation when the eluate containing anti lipid A/core antibody was 
added to HCS indicative of significant bacterial killing (Fig 5.13) (P=0.0001).  The absence 
of complete killing of P1A at ninety minutes can be explained by the presence of some anti 
LPS IgG present in this eluate albeit in a lower titre compared with native S1 (Fig 5.12) and 
its recognised potency.  Nevertheless, this indicated that even following removal of antibody 
specific only to lipid A and other constituents of LPS from S1 serum, the inhibitory antibody 
was retained in S1 serum.  Table 5.1 summarises the findings of assays following extraction 
of IgG, specific IgG2, O- antigen and lipid A/ core specific antibodies. 
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Figure 5.11 depicts bactericidal assay with purified anti LPS antibody from S4 mixed with 
HCS against P1A.  HCS was mixed with buffer as control.  Killing of P1A was inhibited in a 
ratio dependent manner.  Full killing of P1A was established after 180 minutes incubation 
with 33% anti LPS antibody from S4 mixed with HCS.  This established that killing of P1A 
could be inhibited using purified, concentrated anti LPS antibody from serum previously 
shown to kill both its autologous strain and P1A. There was a log10 cfu/ml increase in 
bacterial killing when comparing serum mixes containing 67% anti P1A LPS antibody vs 
50% (p=0.1 by S  den ’s    es ).  This is representative of 3 independent assays.  Error bars 
represent the mean +/- SE for these assays. 
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Figure 5.12 shows comparative titres of anti LPS IgG following specific antibody removal as 
measured by ELISA.  Titres of anti-LPS antibodies purified from S1 after passage through a 
column containing purified LPS with a long chain O-antigen (P1A) or a column containing 
LPS lacking long chain O-antigen (P4A) were measured using ELISA.  Titres of anti LPS 
IgG in the eluate from S1 following extraction of antibody specific to P1A LPS, and the flow 
through from S1 run through the column lined with P4A LPS, were similar to the titres from 
S1.  The titres were approximately 100 times greater than that from the flow through of S1 
from a column lined with P1A LPS and approximately 10 times greater than that from the 
eluate of S1 from the P4A LPS column.  It is noted that there is still anti LPS antibody 
present in this eluate therefore suggesting there is some binding of anti LPS antibody to the 
P4A LPS preparation.  Error bars represent the mean +/- SD of three ELISAs.   
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Figure 5.13 Bacterial assays of S1 depleted of antibody specific to LPS constituents including 
lipid A/ core antibody and S1 anti lipid A/core antibody mixed with HCS vs P1A.  Complete 
inhibition of killing was seen with S1 and S1 deplete of lipid A and core abs.  There was a 
significant decrease in P.aeruginosa cfu/ml seen when anti lipid A/core abs eluate was added 
to HCS suggesting that this was not the factor contributing to the inhibition of bacterial 
killing by S1.  When this was compared to HCS mixed with S1 deplete of lipid A and core 
abs there was a significant difference in bacterial killing (p=0.0001 by S  den ’s    es ) at 180 
minutes. Assays performed in triplicate.  Error bars represent the mean +/- SD of each assay. 
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5.6 Patient Demographics 
 
Patients had demographic data recorded as described in methods chapter 2.  Having 
identified three patients from this cohort with high titres of anti LPS IgG2 in their 
serum and an inability of serum to kill strains of P. aeruginosa isolated from their 
sputum an analysis was made to identify any significant differences between the two 
groups of patients.  The demographic data is recorded in table 5.2. 
 Statistical analysis was performed using SPSS Version 18 IBM New York.  S  den ’s 
t test was used with p value <0.05 considered significant.   In the cohort of patients 
studied, total average SGRQ score was 50.18 (+/- 15 SD), for patients who did not 
demonstrate any inhibitory activity in their serum, compared to 60.99 (+/- 13.7 SD) 
for those with inhibitory activity although this did not reach statistical significance 
which likely reflects the small sample size.    In the individual domains (symptoms, 
activity and impacts), there were no differences between the two groups.  
The FEV1 was lower on average in the patients with inhibitory serum compared to 
those without (P=0.026).  The average FEV 1 in the group with inhibitory serum was 
38% predicted (+/- 20 SD) whilst in the group with normal killing the average FEV1 
was 74.6% predicted (+/- 17.5 SD).  The data is   summarised in table 5.2.   
Furthermore, the group with inhibitory serum had significantly more hospital 
admissions in the year preceding sample collection than those without inhibitory 
activity. (p = 0.034.)  3 hospital admissions were recorded in total in the blocking 
group and only one in the group with normal serum killing. No significant difference 
was observed in MRC dyspnoea scores between the 2 groups 
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 Table 5.2 Sum
m
ary of the clinical data of patients w
ith inhibitory serum
 antibody vs those w
ithout. 
Patient 
A
ge 
M
R
C
 
score 
A
nnual 
exacerbation rate 
H
ospital adm
issions 
SG
R
Q
 
total 
Sym
ptom
s A
ctivity Im
pacts FEV
1  (%
 
predicted) 
P1 
48 
4 
3 
2 
67.0 
68.8 
85.7 
55.7 
21 
P2 
59 
2 
1 
0 
42.0 
45.9 
47.0 
37.8 
67 
P3 
68 
3 
4 
1 
74.0 
88.2 
77.8 
67.5 
26 
P4 
60 
2 
6 
0 
43.4 
82.5 
49.2 
27.8 
105 
P5 
63 
2 
0 
0 
72.7 
88.9 
93.3 
55.8 
78 
P6 
55 
2 
3 
0 
39.1 
74.8 
35.3 
30.1 
80 
P7 
68 
3 
4 
0 
68.9 
85.9 
85.9 
54.0 
48 
P8 
60 
2 
2 
0 
31.9 
66.4 
29.3 
22.7 
59 
P9 
64 
3 
2 
1 
64.3 
71.9 
79.1 
53.4 
61 
P10 
87 
3 
1 
0 
45.9 
67.0 
66.3 
27.7 
93 
P11 
76 
2 
4 
0 
35.2 
56.1 
60.2 
14.4 
73 
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5.7   Conclusion 
 
IgG2 has been shown to be the factor in serum of patients P1, P2 and P3 which 
inhibits the killing of autologous strains of P.aeruginosa isolated from sputum, which 
are otherwise fully sensitive in HCS. 
 
Analysis of these P. aeruginosa strains has shown the common feature is expression 
of long chain O antigen which is not seen with strains that are fully sensitive in 
autologous serum, HCS as well as S1, S2 and S3.  This indicated that O-antigen may 
be the target of these inhibitory antibodies.  Further analysis demonstrated that IgG2 
is specific to LPS, binding to bacteria with the inhibitory serum from patients 1,2 and 
3.  Removal of LPS specific antibodies restores patient serum killing whilst addition 
of O-antigen specific antibody eluate to HCS inhibits killing of that serum.   
 
Bactericidal assays using purified anti LPS from S1 and S4 has demonstrated that not 
only is the presence of anti LPS antibody required to inhibit killing of these strains but 
that the titre of anti LPS IgG is also crucial.  ELISA has demonstrated a high titre of 
anti LPS IgG in the serum of patients with impaired serum killing compared to those 
with normal serum killing of P. aeruginosa.  Bactericidal assays analysing 
constituents of LPS where lipid A and core specific antibodies are removed from S1 
have shown that the inhibition of bacterial killing is retained whilst the addition of 
anti lipid A and core antibodies to HCS does not inhibit killing. Where preparations of 
LPS with long chain O -antigen are purified and used to bind serum antibodies, 
bactericidal assays using this bound antibody retain the ability to inhibit serum killing.  
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This, in combination with the expression of long chain O-antigen by strains P1A, P2A 
and P3A confirms that immunogenic O-antigen is the target of inhibitory IgG2. 
There is furthermore the suggestion   that this finding is associated with poorer health 
status as assessed by lung function and hospital admissions in the group of patients.   
The average FEV1 predicted was lower in the group with inhibitory antibody in 
comparison to those with normal killing, with more hospital admissions in this group 
too.  As discussed previously the isolation of P. aeruginosa in patients with 
bronchiectasis is associated with poorer quality of life.  Whether P. aeruginosa 
worsens lung function and quality of life, or indeed those with poorer health status 
and lung function have an increased tendency to colonisation with P. aeruginosa, is 
unclear.  Nonetheless this association is well established.  The finding that markers of 
health status are more adversely affected in the group with inhibitory antibodies 
suggests that this may be a further, independent risk factor in patients with 
bronchiectasis and P. aeruginosa colonisation.  Similar to the association of 
worsening health status and P. aeruginosa colonisation, it is unclear whether the 
presence of inhibitory antibodies is a causative factor in poorer health status, or 
indeed whether those with poorer health status have a predisposition or tendency to 
develop inhibitory antibodies to P. aeruginosa. 
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CHAPTER 6 DISCUSSION 
 
 
Non cystic fibrosis bronchiectasis is a condition characterised by cough and chronic 
sputum production, with a heightened propensity to recurrent lower respiratory tract 
infections culminating for many patients in an ongoing sequence of chronic infection 
and inflammation leading to ongoing lung damage.   The theory of the vicious cycle 
of bronchiectasis (Cole and Wilson, 1989) elegantly illustrates this ongoing interplay 
beginning with an initial insult to the lung and subsequent failure of host defences 
leading, in some cases, to ongoing damage, failure of mucociliary clearance, ongoing 
inflammation and bacterial colonisation. 
 
P. aeruginosa is a  ommon  olonising organism isola ed in  he “s able  lini al s a e” 
in patients with bronchiectasis (Angrill et al., 2002; Pasteur et al., 2010). Its 
association with greater impairment of lung function (Wilson et al,. 1997; Martinez-
Garcia., 2007; Goeminne et al., 2012; Rogers et al., 2013; Guan et al., 2014; 
McDonnell et al., 2015) increased frequency of exacerbations (Rogers et al., 2014) 
and worsened quality of life (Wilson et al., 1997), render it one of the most critical 
pathogens in the sputum of these patients.  In addition, the antibiotic resistance 
patterns of P. aeruginosa strains often limit the choice of antibiotic therapies for these 
patients in clinical practice making management increasingly difficult.    
 
 The patients in the current study were well characterised with radiologically 
confirmed bronchiectasis and persistent growth of P. aeruginosa in repeated sputum 
samples in the absence of an acute episode of deterioration to suggest an 
exacerbation.  All patients had at least 3 sputum samples positive for growth of P. 
aeruginosa in the year preceding entry to the study (including the sample taken at the 
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time of consent). 
 
Inhibition of bactericidal activity in the serum of patients with chronic Gram- 
negative infection was first described in the 1960s with the suggestion of the presence 
of an inhibitory factor which rather than promoting serum killing did the opposite 
(Waisbren et al., 1966). La er s  dies in  he 19 0s des ribed  he presen e of “ 
blo king “ an ibodies in  he ser m of pa ien s wi h P. aeruginosa (Guttman et al., 
1975). Subsequent studies in cystic fibrosis with P. aeruginosa colonisation suggested 
that IgG2 inhibited bacterial killing by formation of IgG2 containing immune 
complexes in the serum (Hornick et al., 1990).  In addition, patients with cystic 
fibrosis and P. aeruginosa who had strains resistant to killing by autologous serum 
had poorer clinical health.  However, this concept of an inhibitory factor in the serum, 
although appearing clinically important, was not explored further (Thomassen et al., 
1981) 
 More recently, similar inhibitory activity of serum against killing of S. Typhimurium 
has been described in serum of  HIV infected individuals due to anti LPS IgG ( 
MacLennan et al., 2010).  This publication led to the hypothesis that a similar process 
may be present in patients with non cystic fibrosis bronchiectasis and P. aeruginosa 
colonisation and formed the basis of the experiments described in this thesis.  
 
6.1   Anti LPS IgG2 is the Inhibitor of P. aeruginosa Killing by Serum. 
 
Initial analysis of the serum and sputum isolated from eleven patients with P. 
aeruginosa colonisation was undertaken using a bactericidal assay modified from that 
described by MacLennan et al to demonstrate serum resistance of S. Typhimurium 
  160 
(MacLennan et al., 2010). It was consistently demonstrated that 3 of the 11 patients 
had P. aeruginosa strains in sputum, which although sensitive to serum killing in 
healthy control serum were resistant when mixed with autologous serum.  
Interestingly however the serum from these 3 patients could effect killing of P. 
aeruginosa from the other patients in the cohort suggesting that the effect was strain 
specific. Each of the 3 patients had normal serum levels of immunoglobulin and had 
no recognised immune deficiency to explain the lack of serum killing.  The sensitivity 
of the P. aeruginosa strains from these 3 patients to killing by healthy control serum 
confirmed that they were not inherently serum resistant.   
 
Having concluded that the results likely reflected a patient and strain specific 
inhibitory factor was present in the serum of the 3 patients, further work was carried 
out, with careful analysis of serum establishing that the inhibitory factor was IgG and 
of the IgG2 subclass.  This was confirmed following removal of IgG and the addition 
of purified IgG2 from inhibitory serum to HCS and repeating the bactericidal assays. 
Patient serum depleted of IgG became able to kill P. aeruginosa strains previously 
resistant to killing by this serum and addition of the IgG2 from the blocking serum to 
HCS rendered i  no longer able  o kill  he “resis an ” s rain even a  very low 
 on en ra ions.  Analysis of “blo king” ser m from  he 3 pa ien s showed markedly 
higher levels of anti P. aeruginosa IgG2 than in healthy control serum and serum 
from other patients within the cohort.  Immunofluorescence microscopy of P. 
aeruginosa cultures adds additional support to the role of IgG2 by showing excessive 
binding of IgG2 to the bacteria present.   
 
In view of these supporting data, further bacterial assays were undertaken with serum 
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depleted of IgG2 which became able  o effe   killing of  he “resis an ” P. aeruginosa 
strains.  The addition of IgG2 purified from the defective serum to HCS inhibited 
previously effective P. aeruginosa killing. 
 
Having concluded that both serum and bacterial factors specific to these 3 patients 
were central to prevention of P. aeruginosa killing, and that IgG2 was pivotal, 
analysis of the P. aeruginosa strains by silver staining gels demonstrated that these 
autologous strains expressed large quantities of the long chain O-antigen, suggesting 
this feature of LPS might explain the results.  It would be consistent with the blocking 
by autologous serum but the effective killing of the same strain by serum from other 
patients colonised with strains not expressing the O-antigen and hence not developing 
a specific immune response.  
Western immunoblotting, ELISA and immunofluorescence microscopy all provided 
further supporting evidence that specific anti LPS antibodies were responsible for the 
inhibition of killing of P. aeruginosa.  Removal of the antibodies and specifically 
IgG2 from blocking serum restored the ability to kill autologous strains, whilst the 
addition of purified anti LPS antibody to effective HCS caused blocking of P. 
aeruginosa killing.  Not only was the presence of anti LPS antibody shown to be 
crucial in the inhibition of serum killing, but the titre was also shown to have an 
influence.  Anti LPS antibodies from serum normally able to effect killing of the 
“resis an ” s rains  was also able  o inhibi  killing when  on en ra ed and added to 
HCS.   
Removal of antibodies specific to the O-antigen and antibodies specific to the other 
core constituents of LPS enabled the specific antigen target of the LPS molecule to be 
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confirmed.  Antibodies that bound to lipid A and core constituents of LPS had no 
effect on the ability of HCS to kill P. aeruginosa.  On the other hand addition of 
antibodies to O- antigen to HCS inhibited killing.  The results confirmed that high 
IgG2 titres, targeted against the O- antigen constituent of P. aeruginosa LPS was able 
to block serum killing of P. aeruginosa strains expressing the long chain O-antigen.   
 
6.2   Proposed Mechanism of Inhibition of Serum Killing. 
 
Antibodies are a physiological response to foreign material and especially associated 
with protection against invasive infection.  Normally, the specific recognition of 
antigen by antibody leads to its binding and, in the case of bacteria, destruction 
through the complement cascade as described in chapter 1 ultimately ending in MAC 
insertion into the bacterial cell membrane leading to cell lysis.  Human IgG1 forms 
the main response to protein antigens and IgG2 is the main antibody subgroup 
response to polysaccharide antigen (Siber et al., 1980). P. aeruginosa and other 
bacteria express both protein antigens on the cell surface and varying degrees of 
polysaccharide as part of the LPS complex. Thus, both a specific IgG1 and IgG2 
response would be expected. 
The proposed mechanism responsible for the blocking of complement activated P. 
aeruginosa killing seen here is that high titres of anti O-antigen IgG2 inhibits killing 
of P. aeruginosa by binding to the LPS long chain O-antigen, and hence depositing 
complement distal to the cell surface membrane and sterically impeding MAC 
insertion at the cell membrane where it would ordinarily compromise the integrity of 
the cell membrane leading to lysis.  This mechanism may also block access of cell 
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membrane protein IgG1 to the cell membrane where it should activate complement 
and MAC insertion (MacLennan et al., 2010; Brown, Joiner and Frank, 1983; Moffitt 
and Frank, 1984; Wells et al., 2014).  (Fig 6.1)  
The mechanism described also accounts for the fact that inhibitory serum was still 
able to effectively kill other strains of P. aeruginosa where O- antigen was not highly 
expressed, as both the inhibiting antibody and the specific LPS antigen on the bacteria 
need to be present to block the process. 
P. aeruginosa strains resistant to complement mediated killing were previously noted 
to activate complement normally and in a similar fashion to serum sensitive strains, 
but were thought to be resistant to serum killing due to an inability of MAC to insert 
stably into the cell membrane of a P. aeruginosa strain expressing long chain O-
antigen. (Schiller and Joiner, 1986).  It was noted that this apparent bacterial self 
protective mechanism was common among gram-negative organisms with long LPS 
O side chains however, no pathway leading to instability of MAC insertion was 
defined (Joiner et al., 1982; Schiller and Joiner, 1986), but it may likely be that 
proposed in the current thesis. Similarly, I have shown that the P. aeruginosa strains 
P1A, P2A and P3A could activate complement and therefore did not account for the 
ineffective killing nature of some serum to these strains.
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Figure 6.1 Proposed mechanisms for inhibition of serum-mediated killing. High titres 
of O-antigen-specific IgG2 bind P. aeruginosa O-antigen and impede access of 
complement or protective IgG1 antibody to the P. aeruginosa surface. Low levels of 
LPS-specific IgG2 cannot completely block access of complement-depositing 
antibodies to the bacterial membrane. P. aeruginosa strains with no O-antigen do not 
bind specific anti-LPS IgG2 distal from the surface and thus complement is able to 
reach bacterial membrane and effect killing. (Figure 6.1 reproduced with the kind 
permission of Dr Timothy Wells.  Unpublished data.) 
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6.3 Implications for Patients 
 
Patients who suffer from bronchiectasis experience daily symptoms as previously described 
causing significant morbidity.  P. aeruginosa isolation is associated with poorer quality of 
life and worse lung function with more frequent exacerbations in this patient group. (Wilson 
et al., 1997; Martinez-Garcia., 2007; Goeminne et al., 2012; Rogers et al., 2013; Guan et al., 
2014; Rogers et al., 2014; McDonnell et al., 2015). This means that it is an organism of 
particular impact in bronchiectasis.  Antibiotic therapies are typically limited to ciprofloxacin 
as the only effective oral antibiotic available, or intravenous therapies with meropenem, 
piperacillin and tazobactam, ceftazadime, aztreonam, tobramycin, colistin, and gentamicin.   
For patients this often requires admission to hospital for lengthy courses of intravenous 
antibiotic when they exacerbate, or home administration of long-term nebulised antibiotics in 
some cases.  Therefore, not only does infection with P. aeruginosa have an effect on patients 
health but also has wider cost implications with hospital admissions, time absent from work 
and long term therapy.    
 
Demographic data was collected on this cohort of patients as described in methods chapter 
and presented in chapter 5. The lung function as measured by FEV1 predicted was 
significantly worse in the group with inhibitory serum with more hospital admissions.  There 
was a trend towards poorer quality of life as measured by the SGRQ but because of the low 
numbers it was not possible to undertake multivariate analysis to determine whether the 
increased hospital admissions were as a consequence of the reduction in bacterial killing 
alone.  It is however, worthy of note that within a group of patients already known to suffer 
poor quality of life and poor lung function that there may be a further immunological factor 
affecting some patients that is associated with poorer lung function, increased hospital 
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admission and hence may be a target for alternative therapies. Indeed, a recent report by 
Wells et al suggesting that plasmaphoresis in patients with IgG2 blocking antibodies has a 
significant (though temporary) effect on exacerbations and hospital admissions (Wells et al., 
2017).  This report is later discussed in more detail. 
Work published since the completion of the thesis, has studied a second well characterised 
cohort of patients with bronchiectasis and identified that a similar proportion of patients 
colonised with P. aeruginosa have IgG2 mediated inhibition of serum killing (Newcastle 
UK).  From a total of 41 patients with bronchiectasis (including the 11 included in this 
thesis), 28 were found to be colonised with P. aeruginosa.  Of this 28, 6 demonstrated IgG2 
mediated inhibition of serum killing.  These 6 patients had poorer lung function (as measured 
by FEV1 % predicted) compared to those without inhibition (p<0.002) and the 13 who were 
not colonised with P. aeruginosa (p<0.05).   The average FEV1 of the group with inhibited 
serum killing was 34% predicted compared with 67% for those with P. aeruginosa and 
normal killing and 52% for those colonised with other organisms (Wells et al., 2014)  The 
results from this larger cohort of patients continues to suggest poorer lung function in those 
with inhibitory IgG2 compared to those with normal killing and supports the clinical impact 
for such patients.  As discussed previously it is unclear whether poorer lung function 
predisposes to, or is in part caused by, development of inhibitory IgG2.  It is also not known 
why only a proportion of patients with P. aeruginosa have inhibitory IgG2.  This may relate 
to the length of time that a patient has been colonised for, or indeed whether they are 
colonised with mucoid or non-mucoid strains.  In the cohort of patients studied here it is not 
possible to accurately determine the time point at which they first isolated P. aeruginosa in 
sputum to establish whether the length of time they have been colonised for is relevant, and 
this is often difficult to determine in patients with non CF bronchiectasis.  It may be practical 
to determine this in a cohort of patients with cystic fibrosis where normal clinical care 
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encompasses regular and frequent sputum sampling, where there is emphasis on the first 
isolation of P. aeruginosa due to the need to attempt eradication when first isolated.   
 
6.4 Implications for Potential P. aeruginosa Vaccine Therapies. 
 
Vaccination against P. aeruginosa infection is considered to be an aim in the management of 
colonised patients but to date this strategy has failed.  Theoretically a vaccination would be 
considered to have a role in attempting to prevent initial P. aeruginosa infection in those 
deemed most at risk of pulmonary infection/colonisation, such as  patients with cystic 
fibrosis, bronchiectasis and other chronic lung disease where infective exacerbations with this 
organism are common, but also those considered at risk of hospital acquired infections 
including patients in intensive care units and burns patients (Church et al., 2006). Multi drug 
resistant P. aeruginosa infection is associated with a high mortality in cases of ventilator 
associated pneumonia (Rello et al., 1997; Sievert et al., 2013) and thus vaccination may also 
be considered useful in this group of patients.  More recently P. aeruginosa has been 
identified as a major source of combat related wound infections (Peterson et al., 2007; 
Murray et al., 2011) suggesting that a vaccine against this pathogen would potentially have a 
role in protecting at risk individuals, hence having a broad range of indications.  No trials 
have taken place in patients in non-CF bronchiectasis.  
 
Most studies of potential vaccine targets for P. aeruginosa have focused on LPS as the 
immunogenic target due to its accessibility on the bacterial cell surface.  However, to date 
studies have either demonstrated no benefit, some detrimental effects or have been suspended 
(Doring and Pier, 2008; Sharma, Krause and Worgall, 2011). A full overview of these studies 
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is given in the introduction in chapter 1.  A recent Cochrane review concluded that 
vaccination for P. aeruginosa could not be recommended in light of the failure of these trials 
(Johansen and Gotzsche, 2015).  The failure to develop an effective vaccine against P. 
aeruginosa is thought, in part, to be due to the difficulties in enrolling patients susceptible to 
P. aeruginosa infection or colonisation in trials to generate sufficient statistically power to 
prove efficacy (Doring and Pier, 2008; Worgall., 2012).  The nature of colonisation of P. 
aeruginosa in the most widely studied group of patients with CF, has inherent difficulties in 
recruiting to clinical trials as ideally patients would be vaccinated before they have P. 
aeruginosa isolated in sputum but colonisation often takes place in childhood (Worgall., 
2012). This creates some problems to introduce long lasting immunity by vaccination in 
young children in addition to the difficulties in recruiting to clinical trials. 
 
 
When non-mucoid strains are identified in the sputum of patients with CF, aggressive 
eradication can be undertaken to prevent, or delay, colonisation with the mucoid phenotype 
with evidence to indicate eradication at this stage (Hansen, Pressler and Holby, 2008; 
Schelstraete et al., 2013).  Colonisation with the mucoid phenotype predicts shorter survival 
in CF and cannot readily be eradicated hence the logical need to identify and eradicate P. 
aeruginosa where possible (Henry, Mellis, and Petrovic, 1992; Govan and Deretik, 1996; 
Nixon et al., 2001). Although previously thought impossible to eradicate mucoid P. 
aeruginosa, there is evidence to suggest this is not impossible and attempts at eradication 
should be attempted (Douglas et al., 2009; Troxler et al., 2011) Conversion to the mucoid 
phenotype is associated not only with alginate production but these strains often lack O- 
antigen (Doring and Pier, 2008). 
Conversely the virulent non mucoid strains which initially infect the lungs of CF patients are 
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usually of the smooth type – expressing O-antigen, and these are the strains more commonly 
isolated from the sputum of patients with bronchiectasis with mucoid strains isolated much 
less commonly (Rivera and Nicotra, 1982; Hancock et al., 1983; Hatano, Goldberg and Pier, 
1995; Nicotra et al., 1995; Hart and Borowitz, 2004; Doring and Pier, 2008).   Interestingly 
these mucoid phenotypes often convert to non mucoid in lab cultures indicating that they are 
phenotypically flexible (Bergan and Holby, 1975; Cetin, Toreci and Ang, 1965). 
This pattern of colonisation with P. aeruginosa, although complex, does not fully explain the 
lack of an effective vaccine as although strains are able mutate from non mucoid to mucoid 
phenotypes in response to the CF airway, with variation in LPS O- antigen, altered lipid A 
(Ernst et al., 2006; Ernst et al., 2007), other antigens such as outer membrane proteins are 
highly conserved therefore possibly providing a suitable target for vaccine development 
(Doring and Pier, 2008).  In light of these findings, vaccine therapy targeting other antigens 
rather than LPS may be prudent.   Additionally, the significance of colonisation with P. 
aeruginosa, particularly in CF, emphasises the need for an effective vaccine. 
 
The findings of anti-LPS antibody inhibiting killing of P. aeruginosa presented in this thesis 
raises a caution and a possible mechanism for the failure of vaccine where P. aeruginosa LPS 
is the antigenic target.  The finding that strains of P. aeruginosa expressing long chain O-
antigen are associated with the production of antibody that inhibits killing by serum, suggests 
that there is potentially a risk that O-antigen polysaccharide based vaccines may induce a 
similar response with induction of an inappropriate IgG2 antibody response making 
vaccination ineffective especially for subsequent strains with high O-antigen expression.   
6.5 Future Therapies 
The identification of anti LPS IgG2 in the serum of patients with bronchiectasis has offered 
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an opportunity to explore other potential targets for treatment in patients colonised by P. 
aeruginosa other than antibiotic therapy which has formed the mainstay of treatment thus far.  
Increasing antimicrobial resistance has made the need for alternative therapies even greater 
with antibiotic resistance identified by the World Health Organisation as one of the biggest 
threats to global health. (World Health Organisation., 2015).   
Therapies targeting an inappropriate antigen or generating inappropriate immune reactions 
are already well established in other medical conditions.  In particular, autoimmune or 
neurological conditions such as myasthenia gravis and Guillain-Barré syndrome.  In 
Myasthenia Gravis circulating antibodies against the acetylcholine receptor (AChR) block or 
destroy receptors for acetylcholine at the neuromuscular junction and treatment with IV 
immunoglobulin replacement from healthy donors and plasmaphoresis have become 
established treatments.  Plasmaphoresis is utilised to remove harmful circulating antibodies 
directed against the acetylcholine receptor with recognized short term benefits (Dau, 1982).   
The potential for utilising a similar strategy in bronchiectasis patients identified as having 
blocking anti LPS antibody identified in their serum has been explored as mentioned above.  
Two such patients with severe symptoms, recurrent exacerbations and poor lung function 
were identified who were failing to respond to standard therapies and ethical approval was 
obtained for plasmaphoresis followed by administration of IV immunoglobulin.  The results 
suggested an overall improvement with a significant reduction in days in hospital and 
subjective improvements in quality of life.  There were statistically significant improvements 
in days spent in hospital, IV antibiotic use and inflammatory markers measured in sera.  One 
patient had an improvement in lung function in the months following therapy.  There was an 
initial reduction in anti LPS IgG titres as would be expected, which increased over the 
following 3 months to a level that inhibited bacterial and coincided with the re-emergence of 
  171 
P. aeruginosa colonisation (Wells et al., 2017).   
These preliminary results suggest symptomatic and clinical benefit in patients identified with 
anti LPS IgG2 in their serum but clearly larger and longer studies are required to determine 
the real cost / risk benefit.  The wider use of this treatment strategy for treating P. aeruginosa 
colonisation would also require a simple method to identify those with inhibitory antibodies 
such as the Ps IgG2 ELISA generated here.   
The results in this thesis and the further cohort of patients (Wells et al., 2014), would indicate 
that this inhibition of serum killing affects around 21% of patients with P. aeruginosa 
colonisation in bronchiectasis and specific identification of suitable patients is necessary.  
The preliminary results, however, show that removal of inhibitory anti LPS IgG2 both in 
vitro and in vivo by plasmaphoresis does restore bacterial killing and has identifiable 
therapeutic benefit. 
 
6.6   Relevance of Inhibitory Antibody in the Lung. 
Patients with bronchiectasis and P. aeruginosa suffer morbidity associated with their 
condition and as outlined previously there is a poorer quality of life in those with colonisation 
(Wilson et al,. 1997; Martinez-Garcia., 2007; Goeminne et al., 2012; Rogers et al., 2013; 
Guan et al., 2014; Rogers et al., 2014; McDonnell et al., 2015).  
The findings reported in this thesis indicate a worse lung function and quality of life in 
patients with inhibitory anti LPS IgG2.  This mechanism however describes a systemic serum 
antibody response to P. aeruginosa, yet bacteraemia and systemic infection with P. 
aeruginosa is rare in such patients and a literature search failed  to yield any results 
concerning prevalence.  P. aeruginosa bacteraemia is considered a problem in 
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immunocompromised patients with an increased prevalence associated with haematological 
malignancies (Fick., 1993). Retrospective studies of patients with identified P. aeruginosa 
bacteraemia demonstrated that 79% - 88% of these were attributed to hospital-acquired 
infection with the majority of patients being immunocompromised (Aliaga, Mediavilla and 
Cobo, 2002; Kang et al., 2003).   
High levels of antibody have been shown to be present in the lungs of patients with 
bronchiectasis both as a result of diffusion from plasma and that locally produced within the 
lung (Hill et al., 1998). Whether or not a similar inhibitory mechanism to that described in 
serum is present when antibody is isolated from lung is not known.  However, it would seem 
unlikely that local immune responses would not also be influenced by the presenting antigens 
and certainly in the presence of active lung inflammation the predominant source of airways 
antibody would be that derived from the serum.   
A study published after the completion of the work for this thesis demonstrated higher levels 
of IgG1 and IgG2 in the sol phase of sputum from one patient with impaired serum killing 
compared with a patient with normal serum killing of their P. aeruginosa strain and the P 
aeruginosa was shown to be bound to IgG2.  When this opsonised bacterium was mixed with 
HCS, the strains isolated from the patient with impaired serum killing and opsonised with sol 
phase from this same patient, demonstrated no bacterial killing after 180 minutes incubation.  
When a resistant P. aeruginosa strain from a different patient was opsonised with the same 
sol phase and exposed to HCS bacterial killing was also reduced.  However when opsonised 
with sol phase from a patient colonised with P. aeruginosa but with normal serum killing and 
exposed to HCS bacterial killing was complete after 45 minutes.  This indicated that 
inhibitory antibodies have a similar effect when isolated from sputum as from serum.  Strains 
from patients with normal serum killing and inhibitory serum killing opsonised with HCS 
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were both killed rapidly by washed peripheral blood cells.  However when the strain from the 
patient with impaired serum killing was opsonised with his/her own inhibitory sera and 
incubated with washed peripheral cells it was not killed (Wells et al., 2014).  This also 
suggests a role of inhibitory antibody in preventing killing of bacteria within the lung from 
immune cell mediated clearance.  
 Recognising that P. aeruginosa often exists within a biofilm in the lung it was also shown 
that incubating the biofilm of the strain from a patient with impaired serum killing with HCS 
or serum from a patient with normal serum killing reduced the amount of biofilm over a 2hr 
period, whilst incubation with autologous serum had no effect (Wells et al., 2014).  This 
indicated that in addition to preventing direct antibody mediated killing of bacteria, cellular 
mediated killing via opsonisation is also impaired.  
6.7   Future work 
Future work would benefit from a continued study of anti LPS IgG2 mediated inhibition of P. 
aeruginosa killing in a larger cohort of patients with colonisation.  I have identified trends 
towards poorer clinical status in the patients with inhibition of serum killing but analysis of a 
larger group of patients would increase the power to determine the clinical significance on 
progression of lung disease and the effect on quality of life and symptoms.  The presence of 
impaired serum killing described here should also be explored in other groups of patients 
susceptible to P. aeruginosa colonisation, specifically those with cystic fibrosis.  As 
described previously the strains of P. aeruginosa isolated from the CF lung tend to be of the 
mucoid phenotype compared to non-mucoid in bronchiectasis.  These strains are reported to 
produce less O-antigen compared with non mucoid strains (Hancock et al.,1983; Doring and 
Pier, 2008). Whether this would affect the prevalence of anti O-antigen IgG2 in serum 
remains to be determined.   
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There are other structural and immunological differences in the CF lung compared with non 
CF bronchiectasis.  The CFTR mutation results in a dehydrated and thickened airway surface 
liquid with impaired mucociliary clearance and impaired local immune response as a 
consequence (Gellatly and Hancock, 2013).  Additionally, lung damage tends to occur in a 
much more generalised pattern of distribution in CF where it can remain localised to a 
specific lung or lobe in bronchiectasis – the aetiology of bronchiectasis may have some 
influence.  Cystic fibrosis also affects a younger age group than non CF bronchiectasis.   CF 
patients with P. aeruginosa colonisation are also managed differently in clinical practice to 
those with non CF bronchiectasis regularly inhaling anti pseudomonal antibiotics, or 
attending hospital regularly for administration of prolonged courses of intravenous 
antibiotics.    Therefore, it is likely that any sputum or serum samples collected from patients 
with CF will be taken at a time when they are receiving antibiotic/s, either systemically or by 
the inhaled route in contrast to the non CF bronchiectasis patients who provide samples 
outside these constraints.  Non CF bronchiectasis patients more likely take oral or 
intravenous antibiotic only at the time of an exacerbation in contrast to patients with CF. 
Therefore it is important to recognise that these differences could potentially affect outcome 
studies and impact of anti O-antigen IgG2 in patients with CF.   
 
6.8.  Conclusion. 
A proportion of patients with bronchiectasis and P. aeruginosa colonisation, have anti LPS 
IgG2 in their serum that impairs killing of autologous bacterial strains.  These strains have 
been shown to express long chain O-antigen that is recognized by the inhibitory antibodies.  
This may partially explain the persistence of P. aeruginosa colonisation in these patients 
although it is recognised that a number of other factors can also affect the virulence of P. 
aeruginosa.  Here, I have described an antibody dependent mechanism capable of enhancing 
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bacterial colonisation.  There is an association with poorer lung function and increased 
hospital admissions in this small group of affected patients.   
Future therapeutic strategies could be influenced by these data and the recent report 
demonstrating some clinical success of removing the inhibitory antibody from serum.  The 
finding of ineffective anti-LPS IgG2 may also have implications for future vaccine design.  
Future work evaluating the presence and prevalence of this inhibition of bacterial killing by 
serum, and its presence and role in sputum as a direct factor in bacterial killing and the 
opsonophagocytic pathway in larger cohorts of patients both with non CF bronchiectasis and 
CF may allow further understanding of the impact and mechanisms of P. aeruginosa 
colonisation. 
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